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1. HISTORICAL DEVELOPMENT OF MEDICINAL COATING 
The first reports on pill coating date from Greek-Arabic civilization. Al Razil (AD 850-930) coated 
pills with mucilage from Plantago psyllium and Aricienna (AD 980-1037) reported the use of silver, 
which is the first reference to pigment coating. In medieval France, the art of coating with honey 
was developed and later with sugar to sweeten bitter pills. With the development of sugar cane 
and sugar beet cultivation in the 19th century, sugar became more easily accessible to Europeans 
and North Americans and greatly stimulated candy production [1]. Thus, the candy-making 
industry was the first to develop and enhance the art of coating [2]. 
Today sugar coating has been partially replaced by film coating, but is still in use and 
competitive, especially if modern equipment and effective atomization allow short processing 
times. The application of thin coating layers can be automatically controlled and optimized in 
modern equipment, which was developed from the conventional coating pan in the form of 
perforated cylindrical drums. The prototype was the Accela Cota introduced in the 1950s.  
The fluid bed spraying process for coating was introduced by Wurster and became important for 
coating smaller particles as pellets. The evolution of automatic spray coating operations started in 
the mid-1950s since it was found to give much better homogeneity and smoother surface and 
time- consuming procedures could be shortened [1].  
 
1.1. Sugar-Coating 
Despite the undoubted disadvantages of the sugar-coating process in terms of process length, 
intensive operator attention and so forth, it is important to be aware that sugar coating can have 
certain advantages: 
 it utilizes inexpensive and readily available raw materials; 
 constituent raw materials are widely accepted and no regulatory problems occurred; 
 modern, simplified techniques have greatly reduced coating times over traditional sugar-
coating methods; 
 no complex equipment or services are required; 
 the process is capable of being controlled and documented to meet modern GMP 
standards; 
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 simplicity of equipment and ready availability of raw materials make sugar coating an ideal 
coating method for developing countries; 
 the process is generally not as critical as film coating; recovering and reworking procedures 
are usually possible; 
 for high humidity climates, it generally offers a stability advantage over film-coated tablets;  
 results are aesthetically pleasing and have wide consumer acceptability; 
 tablet cores may generally be softer than those demanded by film coating, especially those 
for aqueous film coating. 
1.1.1. Stages in sugar coating 
Sugar coating requires several working steps: sealing, sub-coating, smoothing, coloring, polishing 
and eventually printing. 
 
Figure 1: Stages in sugar coating [3]. 
 
 
First of all, it is necessary to protect the tablet core from the aqueous nature of sucrose 
applications to follow. Sealing also prevents certain types of materials from migrating to the tablet 
surface and spoiling the appearance, e.g. oils, acids, etc. This is unfortunately an organic solvent-
dependent step in an otherwise aqueous process. A film of water-impervious polymer is built up 
using materials such as shellac, cellulose acetate phthalate (CAP), polyvinyl acetate phthalate 
(PVAP) and zein. Shellac has all the disadvantages of a natural material whereas the other 
polymers used tend to be those which have an additional use as enteric-coating materials, so that 
they should be applied only in sufficient quantity to form an efficient seal. A lamination process, 
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whereby an application of sealant is followed by an application of dusting power, e.g. talc, is 
nearly always used. 
During the sugar-coating process the increase in weight achieved can be 30–50% of the weight of 
the original tablet core. Much of the added weight is applied at the sub - coating stage. Sub - 
coating serves to confer on the tablet core a perfectly rounded aspect. 
The ideal shape for sugar coating is a deeply convex core with minimal edges. This condition will 
obviously require less coating material than where the tablet edge is comparatively thick. 
Basically, there are two methods. In the lamination process, a volume of binder solution is applied 
to the sealed cores in the coating pan. Once this has spread over the tablet bed, an application of 
powder is dusted into the pan and, when this has evenly distributed itself over the contents, 
drying air is applied. The drying air process needs to be carefully controlled to prevent too rapid 
evaporation of the water. The objective should be to create as smooth a coat as possible in order 
to reduce the time for smoothing the coat in the final stages of process. Excessively rapid drying 
results in a very uneven surface. Too low an evaporation rate gives rise to a lengthy process and 
the danger of cores adhering together. In recent years, automation in the sugar-coating process 
has required the use of a liquid sub - coat. These are generally suspensions of filler materials(i.e. 
calcium carbonate, talc or sucrose in the gum solutions.  
The system contains only approximately 23% water and consequently dries quickly.  
The product at the end of the sub - coating will be too rough to continue with colour coating. 
Smoothing is usually achieved by applications of plain 70% w/w syrup. However large degrees of 
unevenness will require some sub - coating solids in the initial smoothing coats. Typically, 
however, if sub - coating is carried out well, then approximately ten applications of 70% syrup will 
be required for tablets that are suitable for the next stage. 
Colour coating is one of the most important steps in the sugar-coating process as it has 
immediate visual impact. During this step the coating syrup contains the colour solids necessary to 
achieve the desire shade. Water-soluble dyes were used previously as colouring agents for sugar-
coated tablets. This has largely been superseded by the use of modern water-insoluble pigment 
forms including the aluminium lakes of the water-soluble colours. Here, the water-soluble dye is 
adsorbed onto a hydrated alumina surface, filtered, washed and dried. By careful processing, the 
optimum particle size profile is achieved. The smaller and more even the particle size, the greater 
the colouring power and hence the smaller the quantity that need be used to achieve the same 
result. These lake pigments are essentially insoluble in aqueous systems between pH 3.5 and 9.0 
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and find important uses in tablet coatings both using the sugar and film-coating processes. The 
advantages of lakes over soluble dyes, including the soluble natural colours, are multi-fold. A 
pigment system is superior to a water-soluble dye for colouring sugar-coated tablets due to: 
(i) maintenance of evenness of colour because:  
 the colour is not water soluble and thus is not prone to colour migration problems; 
 the colour is opaque, and thus is not affected by any minor unevenness in the sub - coat 
layer; 
(ii) maintenance of colour uniformity from batch to batch, which results from the fact that, 
again because the colorant is opaque, the final colour is not affected by small fluctuations in the 
quantity of colour solution applied; 
(iii) reduction in overall processing time; 
(iv) reduction in the thickness of the colour-coating layer. 
After the colour-coating process, the tablets have a somewhat dull, matt appearance which 
requires a separate polishing step to give them the high degree of gloss traditionally associated 
with sugar-coated tablets. Methods vary considerably, but it is generally important that the tablets 
are dry prior to polishing. Preferably they should be at least trayed overnight in a suitable 
atmosphere. Some examples of polishing methods which are currently in use include: 
 
 application of an organic solvent solution/suspension of waxes, (i.e. carnauba and 
beeswax). A recently available variant on this theme provides an emulsion of both waxes in an 
aqueous continuous phase stabilized by a food and pharmaceutically acceptable surfactant. The 
results obtained are equivalent to traditional methods utilizing organic solvent solutions but, of 
course, with the big bonus of aqueous processing; 
 use of wax-lined pan; 
 use of canvas-lined pan with wax solution/suspension; 
 finely powdered wax application; 
 mineral oil application. 
 
In addition, there are polishing techniques reliant upon the use of glazes containing shellac in 
alcohol with or without waxes. The use of these materials is rather more dependable, and is not so 
reliant on atmospheric conditions of temperature and humidity to obtain the optimum result. This 
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comment does not apply, however, to the aqueous material, which has a high degree of 
dependability in use. 
Some regulatory authorities demand that tablets, be they coated or uncoated, should possess 
some detailed identifying mark. Those authorities who do not actually require this actively 
encourage it as part of the overall GMP and product acceptability requirements. Unfortunately, 
unlike film-coated tablets, sugar-coated tablets cannot be monogrammed by engraving the punch 
tooling. Instead a printing process is used [3]. 
 
1.2. Film-Coating 
Film coatings are an integral part of the dosage form development process. The process of film 
coating involves the application of a thin polymeric film onto the surface of a solid substrate. The 
substrate can be tablets, capsules, granules or particles. Typically, the coating is approximately 25 
to 100 µm in thickness and is applied to improve the physical and chemical properties of the 
substrate. Though new uses of coatings are being continually developed, film coating are mainly 
applied to: 
 protect drugs from environmental factors such as light, moisture and air, in order to 
improve chemical and physical stability; 
 change product appearance to enhance marketability and product identity or high 
undesirable color changes of the substrate; 
 mask unpleasant taste, texture or odor; 
 facilitate the swallowing of the dosage form; 
 improve handling during packaging operations by reducing dust formation; 
 control or modify drug release; 
 prevent the interaction of incompatible ingredients [4; 5]. 
 
1.2.1.Equipments 
Typical core materials for film coating processes are tablets or pellets; in some cases the coating 
of small particles such as crystals is described. Pharmaceutical coating processes take place in 
coating pans or fluid bed apparatuses. Most tablets are coated in (perforated) pans or drums but 
also fluid bed equipment is in use. Pellet coating is typically performed in a fluid bed [6].  
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1.2.1.1. Coating Pan 
Conventionally coating pans are usually pear – shaped, but sometimes hexagonal or spherical. 
They are made from stainless steel or copper. To prevent abrasion, an insulating layer should be 
sprayed on before starting process [1].  
Film coating in pan involves spraying the coating composition through one or more spray guns 
onto a rotating bed of the cores to be coated, typically tablets. The spray gun is fixed and the cores 
pass through the application zone. Most of the time the tumbling cores are drying outside the 
application area. Thus, the coating process consist of a continuous application of liquid coating to 
a small portion of the product in pan. The applied coating must dry before it touches the coating 
pan or receives its next application. As the cores rotate in pan, a portion of the applied coating 
composition may be physically transferred from to the coated cores to the adjacent ones. To 
attain a continuous coating operation, the rate of liquid (organic solvent or water) evaporation 
from the coated product must be equal to the rate of liquid applied.  
At equilibrium, there is a balance between the input and the exhaust variables. The input 
variables include temperature and humidity of the drying air, spray rate and surface area of cores 
to be coated. The exhaust variables include exhaust air, rate of liquid (organic solvent or water) 
evaporation from the coated product and coated core surfaces from which the solvent or water 
should evaporate.  
The coating pan schematized in Figures 2 - 4 can provide adequate air flow and control over the 
coating process [5]. 
 
Figure 2: Simplified diagram of Accela Cota [7]. 
 
 
12 
 
The Accela Cota has a horizontal rotating cylindrical drum, the curved surface of which is 
uniformly perforated. The ends of the cylinder are conically dished, so that tablets in the drum are 
inverted and also mixed laterally during the coating operation. There are baffles to assist the 
mixing process. Drying air enters the drum through the perforations on the side remote from the 
tablet bed, and is drawn through the bed by the exhaust fan located in the exhaust duct 
connected to the plenum positioned under the tablet bed. This plenum has a mouth that fits 
closely to the outside of the perforated curved surface of the drum. The angles of the front and 
rear sides of the pan are 56° and 61° respectively, which was originally intended to ensure 
complete mixing of the tablets from the top of the bed to the bottom and from front to rear.  
However, it was found that this was insufficient to ensure homogeneous mixing and baffles were 
fitted. Generally, the baffles are of the same shape but of different size for each model and can be 
easily removed or replaced with those of a different design depending on the physical 
characteristics of the tablet to be coated, e.g. friability.  
The batch size for each particular model will depend upon the bulk density of the tablets. 
Maximum loading will be achieved with tablets made from a high-density material or from small 
tablets which will have a high packing density. Exceeding these maximum loadings can cause 
damage to the drive mechanism. Minimum loadings are found by experience and depend on size 
and shape of the tablets. If the units are used with batch sizes below these levels, then it is likely 
that problems will be encountered due to a large portion of the baffles being exposed above the 
tablet bed. In addition, the exhaust plenum will not be completely covered and this can result in 
the drying air bypassing the tablets before entering the exhaust duct.  
Shape can affect the coating process in a number of ways. Tablets shaped as squares can cause 
sticking problems and the formation of ‘twins’. Logos across the centre of bi-convex tablets result 
in damage to the intagliations. It is, therefore, an aspect of tablet design which should be 
appreciated by both marketing and formulation departments. Small tablets produce a very dense 
bed in the coating pan which tends to reduce the batch size and increase the coating time [7]. 
Other side-vented coating pans, which are very similar to the Accela Cota, are manufactured by 
Dumoulin in France and by Freund in Japan who manufactured the Hi-Coater. The Hi-Coater was 
originally designed to overcome the patents on the Accela Cota held by Eli Lilly, the inventors.  
It has four perforated panels linked to air ducts that are in constant contact with the exhaust 
ducts. 
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Figure 3: Simplified diagram of Hi- Coater [7]. 
 
Capacities range from 500 g load up to the HCF 200, claimed to hold 700 kg. Loading and 
unloading can be achieved through the front of the unit and by a flap in the pan which discharges 
into a mobile container under the machine or onto a conveyor [7]. 
 
Figure 4: Diagram of Driam [7]. 
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The Driam differs from the Accela Cota coaters in the shape of the coating pan and the way the 
air is utilized in the drying process. On the outside of the drum covering the perforated areas, 
there are the air flow channels with removable covers. At the rear of the pan the air channels are 
connected to the air distributor. This distributor guides the drying air through the air channels and 
the perforations into the product. The direction of air flow is reversible. 
Direct Air Flow: air is supplied through the perforated areas at the top of the pan and through the 
product bed, and the air exhausted through the perforated areas under the product. 
Reverse Air Flow: air is supplied through the perforated areas at the bottom of the pan and 
through the product bed. It is exhausted through the perforated areas at the top of the pan or 
through the hollow shaft at the rear. 
In contrast to the production machines, the laboratory unit is a complete and self-contained 
piece of equipment with built-in air supply and exhaust, steam heating, spray system, a completely 
contained cleaning system with pump, and all control and monitoring instruments. The unit is 
mobile, requiring little space, and is operational after connections have been made to electric 
power, steam and compressed air supply. The air volume and the differential pressure in the drum 
are adjusted by the air control dampers in the air supply and exhaust system. A built-in 
temperature control stabilizes the preset air supply temperature [7].  
GS Technology manufactures non-perforated pans with capacities from 10 to 1000 litres. 
Originally developed for sugar coating, they use baffles which give a very even distribution of the 
drying air through the tablet bed or pellets. An advantage of this type of pan is that it can be used 
for coating a large range of particulate sizes from less than a millimeter to tablets of all shapes and 
sizes. It is claimed to be the best statistical mixer for coating available A typical system is shown 
schematically in Figure 5. 
The GS control and coating systems can be fitted to any coating pan, be it Accela Cota, Driam and 
Hi-Coater. This control, it is claimed, results in dramatic decreases in coating times, particularly for 
sugar. For film coating, GS have a special reciprocating piston pump, the speed of which is 
automatically controlled from the bed temperature. For sugar coating, a modified GRACO pump is 
used. The type of spray-gun, nozzle configuration and position above the bed is critical in all 
coating processes. These are all either fully interchangeable or adjustable in the GS system. 
Drying is effected through perforated baffles immersed in the bed of cores, similar to the 
immersion- Sword technique, giving a very even distribution of drying of air and allowing a very 
low differential pressure to be employed which reduces attrition considerably  
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Figure 5: GS control system [7]. 
 
1.2.1.2. Fluid Bed Coaters 
Fluid bed top - spray, Würster bottom spray columns and rotating disk granulators are commonly 
employed to apply film coating to pharmaceutical powder, granules, pellets and mini – tablets. 
 
(a) Top - spray coating 
The top - spray coater has been used to apply aqueous and organic solvent based film coatings, 
controlled release coating and holt melts on granules and small particles. 
The top spray coating machinery exhibits a conically shaped lengthened expansion chamber to 
allow powders to remain fluidized longer and to move with higher velocity so that agglomeration 
is minimized, permitting a uniform deceleration of the air stream. Moreover, the nozzle is 
positioned low in the expansion chamber so that coating materials impinge on the fluidized 
particles a short distance from the nozzle: this reduces droplets spray drying and provides for 
longer subsequent drying of coated particles. The filler housing is larger and designed to shake the 
fine back into the bed without interrupting fluidization, thus, reducing agglomeration tendencies 
[7]. 
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(b) Bottom spray coating 
The Würster machine (Figure 6) employs a cylindrical product container with perforated plate. 
Inside the container is a second cylinder (coating partition), which is raised slightly above 
perforated plate. Centered in the plate below this partition, is a spray nozzle used to dispense the 
coating solution. The perforated plate is designed with large holes in the area under the coating 
partition and smaller holes in the remainder of the plate, except for one ring of large holes at the 
perimeter. This design allows the substrate particles to be pneumatically transported upward 
through the coating partition and downward outside this partition. Material passing through the 
coating partition receives a layer of coating material, dries in the expansion chamber and falls back 
in a semi fluidized state. Material circulates rapidly in this fashion and receives a layer of coating 
on each pass through the coating partition. The ring of large holes on the periphery of the 
perforate plate prevents the accumulation of the material at the container wall. The Würster 
process provides a highly organized particle flow and high quality reproducible films. For this 
reason the system is used extensively for sustained release coatings where product performance 
requirements are the most rigorous. The process is capable for handling solvents, aqueous 
solution, emulsions, suspensions and hot melts [8].  
 
(c) Rotating disk granulators and coaters 
This technique combines an expansion chamber to form the rotating disk granulator and a fluid 
bed coater device (Figure 6). It employs a rotating disk in the product container. The disk can be 
moved up or down to create a variable slit opening between the outer perimeter of the disk and 
the side wall of the container. This allow independent control of air velocity over air volume. This 
fluidized the material along the circumferential surface of the product container. At the same time 
disk rotates at varying speeds and move s the product by centrifugal force to the outer portions 
where it is lifted by the fluidizing air stream into the expansion chamber. As the material 
decelerates, it descends to the center of the disk and repeat the sequence. The motion of the 
fluidized material is, thus, controlled by the forces of fluidization, centrifugal force and gravity. 
This fluidization pattern is often described as a spiraling helix or rope – like pattern around the 
inside of the rotor chamber. Spray nozzle can be immersed in the bed of fluidized material and the 
spray applied in tangential fashion with respect to the particle flow. The particle can be coated 
with polymeric material. Additionally, dry powders can be fed into the wet bed, resulting in a build 
up of powder layers onto the particles substrate (layering technique). At the end of the coating 
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process the liquid spray is shut off and the material in the product chamber dried by increasing the 
fluidizing air volume and temperature [8].  
 
Figure 6: Bottom spray and rotating disk coaters [7]. 
 
 
 
2. COMPOSITION OF FILM COATING FORMULA 
Pharmaceutically acceptable film coating of solid dosage forms are primarily based on acrylic or 
cellulosic polymers. Many of these polymers have been formulated into aqueous colloidal 
dispersions (e.g., latexes or pseudolatexes) in order to overcome the high costs, potential toxicities 
and environmental concerns associated with the use of organic polymer solutions.  
Film coating has been successfully utilized to control the release of active ingredients, prevent 
interaction between ingredients, increase the strength of the dosage form to maintain product 
integrity during shipping and protect the dosage form from the environment.  
Most formulations contain plasticizers that impart flexibility to the films and reduce the 
incidence of crack formation. Coating formulations usually contain many additives, in addition to 
the polymer, that aid in processing, appearance and product performance. The amount and type 
of plasticizer in the film and the presence of other additives in the coating can significantly impact 
the film’s mechanical properties. Pigments may be added to alter the appearance of the final 
product and lubricants may be required to prevent agglomeration of the coated substrates. In 
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addition, factors such as storage conditions and processing temperature will influence coalescence 
and film formation and thus product performance [9]. 
 
2.1.Polymers 
The film former is the major ingredient in a coating formulation. For aqueous-based coating 
systems, the polymers can be divided into two essential classes: aqueous soluble polymer and 
water insoluble or pH dependent soluble polymers. 
The most commonly used aqueous soluble polymers consist primarily of polyethylene glycols, 
polyvinyl pyrrolidone (povidone) and cellulosic polymers (Carboxymethyl cellulose sodium, 
Hydroxypropyl cellulose, Hydroxypropyl methylcellulose and Methylcellulose) [5]. 
The water insoluble polymers are used when an enteric coating or a special controlled release 
delivery system is desired. Enteric coatings constitute the major portion of the pH dependent 
polymers. These polymers can be solubilized by adjusting the pH of the coating or they can be 
formulated to be suspended in aqueous media and applied as insoluble polymer particles.  
Some of the most common polymer with pH-dependent solubility are cellulose acetate phthalate 
(CAP), hydroxypropyl methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), 
(meth)acrylic acid copolymer (Eudragit® E, Eudragit® L, Eudragit® S). Among water insoluble 
coating polymers, Eudragit® RL, Eudragit® RS, polyvinyl acetate and ethylcellulose are included [5].  
Polymers used for different coating purpose are better elucidate in section 4. 
Table 1 shows a list of some ready-to-use coating formula. 
 
Table 1: Ready-to-use formulations with poly(meth)acrylates [10]. 
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2.2. Plasticizer 
Films prepared from pure polymers frequently are brittle and crack on drying. To correct this 
deficiency, the polymer can be chemically modified or other excipients can be added to make the 
film more pliable [5]. 
Plasticizers are added to polymeric solutions or dispersions to increase workability or flexibility of 
the polymer, reduce its brittleness, improve flowability, increase toughness and tear resistance of 
the films. These effects are the result of the plasticizer’s ability to weaken intermolecular 
attractions and allow the polymeric molecules to move more easily [9]. 
Thus, plasticizers can be classified into two general categories: internal and external plasticizers.  
Internal plasticizing involves the chemical modification of a basic polymer to alter the physical 
properties of the polymer. Changes both in degree and type of substitution or in polymer chain 
length could influence the physical characteristic of the polymeric film.  
Generally, the formulator must work with polymers that are available and the film properties are 
altered by the addition of external plasticizers. The external plasticizer can be another polymer, a 
nonvolatile liquid or even the aqueous solvent. The plasticizer alters the polymer – polymer 
interactions to improve the flexibility of the film by relieving molecular rigidity. As general rule, the 
film will become more flexible and more resistant to mechanical stress when a plasticizer is added 
to a coating composition [5]. Thus, several theories have been proposed to explain the mechanism 
by which the plasticizing agents impart flexibility to polymeric films.  
According to the lubricity theory, the plasticizer functions as an internal lubricant and facilitates 
movement of the polymer chains. The gel theory proposes that the un- plasticized polymer exists 
as a three-dimensional gel and that the plasticizer functions by cleaving the intermolecular bonds 
within the gel. Finally, the free volume theory states that plasticizers increase the free space 
around the polymer chains, providing a greater area for movement of the polymer molecules. In 
addition, enhancing the flexibility of the film, plasticizers influence permeability and drug release 
[5].  
Plasticizer acts by interposing itself between the polymer chains to decrease the degree of 
interaction between the polymer molecules thereby enhancing chain mobility and the dissipation 
of internal stresses that lead to bridging and cracking of film [4; 5]. 
Moreover, plasticizers alter the thermo- mechanical properties of film forming polymers 
lowering its softening temperature of the polymer (MST). Thus, the degree of lowering is 
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considered a common measure of plasticizer effectiveness: the more efficient the plasticizer, the 
more the softening temperature was lowered. The greater decreases in Tg is dependent both to a 
large extent on type and amount of plasticizer added to the coating formulation and to the extent 
of polymer–plasticizer interactions [4; 9].  
Typically, plasticizers facilitate the transformation of the discrete polymer particles on the 
sprayed surface into a continuous film and increase the ease of film deformation. This was 
manifested by a decrease in tensile strength, an increase in elongation at break and a reduction of 
the modulus of elasticity [4; 5]. Typical plasticizers are listed in table 2. 
To be effective, plasticizers must be compatible with the polymer: water insoluble polymer 
suspension formulations require high concentration of water insoluble plasticizers [5]. 
Plasticizers that are soluble in the solvent phase can be added directly to the mixture or may be 
dissolved first in the solvent prior to addition of the polymer. Water insoluble plasticizers should 
be first emulsified in water using latex- compatible emulsifiers and then appropriately agitated 
with the entire mixture until an equilibrium plasticizer distribution occurs between the water and 
polymer phases.  
 
Table 2: Plasticizers [5]. 
PLASTICIZERS 
Castor oil, USP 
Propylene glycol, USP 
Glycerin, USP 
Polyethylene glycols (PEG), NF, low molecular weights (200 – 400 series) 
Polysorbates NF (Tweens) 
Sorbitans NF (Spans) 
Polyoxyl derivatives NF 
Diethyl Phthalate 
Acetylated monoglycerides 
Triacetin 
Triethyl citrate (TEC) 
Dibutyl sebacate (DBS) 
 
The incorporation of a plasticizer into an aqueous polymeric dispersion is crucial and a sufficient 
time must be allowed for the plasticizer to partition into the polymer phase before starting the 
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coating process. The rate and extent of plasticizer partitioning for an aqueous dispersion is 
dependent on the solubility of the plasticizer in water and its affinity toward the polymer phase. 
Equilibration of plasticizer distribution in an aqueous polymeric dispersion for water-soluble 
plasticizers has been shown to occur rapidly, whereas the time required to achieve equilibrium 
distribution for water-insoluble agents requires substantially longer mixing times. If insufficient 
time is allowed, the unincorporated plasticizer droplets as well as the plasticized polymer particles 
will be sprayed onto the substrate during the coating process. Uneven plasticizer distribution 
within the film could result and, potentially, cause changes in the mechanical properties of the film 
during aging [9]. 
 
2.3. Dyes and Pigments 
Often a distinctive color is desired to give the product a unique identity. It is a GMP 
requirement that products must be differentiated at all stages during the manufacturing and 
distribution cycle [1]. The colorant can be either solubilized in the solvent system or suspended as 
insoluble particles. The addition of pigments into a coating formulation may improve the esthetic 
appearance of the final product, providing distinctive color and pharmaceutical elegance to the 
coated substrates [5]. 
 
Table 3: Colorants and Opaquants [5]. 
COLORANTS and OPAQUANTS 
Colorants Opaquants 
FD&C dyes Silicates 
FD&C lakes Talc 
Iron oxides Aluminium silicate 
Titanium dioxide Magnesium carbonate 
Natural colorants Calcium sulfate 
Anthocyanins Magnesium oxide 
Caramel Aluminium hydroxide 
Carotenoids  
Flavones  
Tumeric  
Carmine  
Annatto  
Amaranth  
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The most brilliant colorants are provided by certified Food, Drug and Cosmetic (FD&C) or Drug 
and Cosmetics (D&C) dyes and lakes. Lakes are prepared from dyes by precipitating the colorants 
with aluminium or talc carriers. These synthetics colorants are water insoluble and provide the 
most reproducible colors. Commercially available lakes generally contain 10 to 30% dye content, 
but some lakes may contain up to 50%. Although lakes are water insoluble, dye can be displaced 
from carrier through the use of solvent systems that dissolve the dye. Table 3 is a list of colorants 
and opaquants. 
Commercial color concentrates and film coating concentrates are available. They are promoted 
as providing less batch - to- batch color variation. To achieve reproducible colors, the insoluble 
colorants should be milled and matched with a color standard. The two commercial materials for 
aqueous film coating are Opaspry ® (an opaque color concentrate for film coating) and Opadry ® 
(a complete film coating concentrate) available from Colorcon [5]. 
The addition of pigments into a coating formulation may improve the esthetic appearance of the 
final product. Opaquants (such as titanium dioxide) may be used in coatings to protect 
photosensitive drugs from exposure to light, thus improving product stability. The addition of 
pigments in the coating will significantly influence the mechanical, adhesive and drug-release 
properties of the resulting film. As the concentration of an insoluble pigment is increased, the 
amount of polymer necessary to completely surround the particles increases. At a specific 
concentration, known as the critical pigment volume concentration (CPVC), the polymer present is 
insufficient to surround all of the insoluble particles and marked changes in the mechanical 
properties of the film will occur. The CPVC is a characteristic of specific polymer–filler 
combinations and theoretic determinations of this value are practically impossible [9]. 
 
2.4. Glossing and Polishing Agents 
At the end of the coating process, some gloss is developed directly from the polymers, especially 
with poly(meth)acrylates. Gloss could be improved by polyethylene glycols solutions sprayed on 
the film coating at the end of the process or by the application of an additional layer of wax 
dissolved in an organic solvent.  
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2.5. Antiadherents 
Fillers are mainly powder materials which are insoluble in coating solvents and reduce the 
sticking effects on the binder. If the binder is sugar, the fillers are mainly calcium carbonate, 
calcium phosphate, starch and titanium dioxide which, additionally, is a white pigment [1]. 
Nevertheless, stickiness and tackiness of polymeric films is a concern during both coating process 
and storage. The extent of product agglomeration may be influenced by processing temperature, 
curing temperature, plasticizer content and polymer type. To minimize product agglomeration, 
antiadherents may be incorporated into the coating formulation [9]. Substances that reduce 
sticking effect in film coating and improve smoothness of the surface are also called glidants. Talc 
and stearates (such as magnesium stearate alone or in combination with talc and glyceryl 
monostearate, GMS) are the most commonly employed antiadherents in film coating formulations 
[1]. These fillers, however, are not water soluble and they have been shown to influence the 
mechanical and drug-release properties[9]. Moreover, Carbosil (fumed silica) and micronized silica 
(Syloid) are acceptable glidants but, tend to increase the permeability by pore formation and give 
matt surfaces in high concentrations [1]. 
 
2.6. Surfactants 
As mentioned above, incorporating water-insoluble plasticizers into an aqueous polymeric 
dispersions requires that the plasticizer first be emulsified in water with an appropriate surfactant. 
The addition of these compounds to film coating formulations has been shown to influence the 
mechanical properties of the films. Sorbitan mono- oleate and polysorbate 80 are the most 
commonly employed surfactants in films coating based on Eudragit® L 30 D-55 plasticized with the 
hydrophobic tributyl citrate, while no significant benefits were noted when the polymeric 
dispersion was plasticized with the water-soluble triethyl citrate. Moreover, surfactants should be 
added to the film coating formulation in order to improve the spreadability of the coating material 
across the core surfaces and, thus, modulate drug release [9]. 
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3. FILM FORMATION 
In order to select the appropriate coating excipients, an understanding of the mechanisms 
behind film formation is necessary.  
There is a fundamental difference in film-formation between aqueous polymer dispersions, 
where the polymer and the liquid phase are in a heterogeneous system, and polymer solutions, 
where the polymer and the liquid phase are in a homogeneous system. Whereas film formation 
from a solution simply occurs upon solvent evaporation (sol to gel transition), dispersed polymer 
systems require polymer spheres to deform, coalesce and fuse together to form a continuous film 
[10; 11]. It should be mentioned that even if the polymer particles completely fuse together and 
form a continuous polymeric film without defects, the inner film structure can be very different 
from the structure of films of identical composition, but prepared from organic polymer solutions. 
For instance, if a blend of two miscible polymers is used, films prepared from organic solutions are 
likely to exhibit a very high degree of polymer–polymer chain entanglement throughout the 
network. The composition of the films is homogeneous, even in the nanometer size range. In 
contrast, films prepared from aqueous polymer dispersions are likely to contain nano-domains of 
the respective pure polymers, since polymer–polymer chain inter-diffusion is generally restricted 
to the surface near regions of the initially individual polymer particles. This difference in the 
nanostructure of the films of identical composition, but prepared from aqueous dispersions or 
organic solutions, can potentially strongly affect the resulting film properties and, thus, drug 
release kinetics [12; 13]. 
For aqueous polymer dispersion the minimum film-forming temperature (MFFT) and glass 
transition temperature (Tg) of the system are key parameters for efficient film formation.  
(a) Glass Transition Temperature 
The glass transition temperature (Tg) is the temperature at which the mechanical behavior of a 
film changes. Below this temperature, the polymer exists in a glassy state that is characterized by a 
substructure in which there is minimal polymer chain movement. Above the Tg, the polymer is in a 
rubbery state, which is characterized by increased polymer chain movement and polymer 
elasticity [9].  
(b) Minimum Film Forming Temperature (MFFT) 
The MFFT is the temperature above which a continuous film is formed under defined drying 
conditions. Upon drying, the particles come into direct contact with each other and form dense 
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sphere packaging, due to evaporation and the surface tension between water and polymer. During 
further evaporation, capillary forces lead to coalescence of the particles and the forming of a 
homogeneous film. Coalescence only occurs at temperatures above MFFT. To achieve fast film 
formation, the temperature should be 10–20°C above MFFT [10]. 
 
3.1. Film Formation from Solutions 
Film formation from polymeric solutions is a relatively straightforward process since the polymer 
is in the dissolved state. The sprayed droplets spread onto the substrate surface and, as the 
solvent evaporates, the polymer chains interpenetrate, going through a gel state then forming the 
film with further drying. Polymer chain interpenetration occurs at a specific concentration which is 
the reciprocal of the intrinsic viscosity of the solution. The intrinsic viscosity, thus, is an indication 
of the hydrodynamic interaction between the polymer and the solvent.  
The rate of solvent evaporation is critical in the film formation process for polymeric solutions: if 
a solvent evaporates too slowly, the substrates become over- wetted and, in extreme cases, begin 
to dissolve. In contrast, if a solvent evaporates too quickly, the polymer-containing droplets may 
dry before either impinging on the substrate surface (spray drying) or spreading on the surface 
(orange peel effect).  
Solvent evaporation is dependent on temperature, atmospheric pressure, air movement and, in 
the case of water, relative humidity. Most of these variables can be adjusted by manipulating 
processing conditions [11]. In film coating processes, several surface tensions are involved, as 
shown in figure 7, including liquid–air, solid–liquid and solid–air interfaces. 
 
Figure 7: Overview of the film formation process and surface tensions involved [11]. 
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Spreading of the polymer-containing liquid droplets can be described as surface wetting or 
replacement of a solid–air interface with a solid–liquid interface. The process is dependent on the 
ability of the atomized droplets to wet the substrate (wetting power) and the ability of the 
substrate to be wetted by the droplets. Thus, ‘wetting’ is influenced not only by solutions 
properties but also by the solid substrate characteristics. Three types of wetting are involved in 
film formation from polymeric solution:  
 adhesional, where the liquid–air interface disappears [14];  
 spreading, where a liquid–air interface forms [15];  
 immersional, where there is no change in the liquid–air inter-face [16].  
Variables that influence wetting are related to substrate formulation (such as surface roughness, 
porosity, hydrophobicity), coating formulation (for example viscosity) and processing conditions 
(including droplet momentum, atomizing air pressure, distance between the spray gun and 
substrate and the rate of solvent evaporation). 
Viscosity is a key variable in coating operations involving solutions. As the concentration of the 
polymer is increased, solution viscosity increases. Viscosity is also dependent on the molecular 
weight of the polymer, with higher molecular weight grades exhibiting higher viscosities at a given 
temperature [11]. Higher solution viscosities require more energy to atomize the solution [17]. 
In practical terms, solution viscosity limits the concentration of polymer that can be used in film 
coating operations. In fact, this limitation has generated a great deal of research to develop new 
‘high solids’ polymer coating systems that allow higher polymer concentrations without the 
significant concomitant increase in solution viscosity [15]. Viscosity also influences droplet 
spreading, with more viscous solutions not able to readily spread across the substrate surface 
before solvent evaporation occurs. Since the viscosity of the individual polymer-containing 
droplets increases as the solvent evaporates (i.e. polymer concentration increases), adequate 
initial spreading is critical to obtain a smooth film [11]. 
 
3.2. Film Formation from Aqueous-Based Polymeric Dispersions 
Over the past several decades, modified release film coating technologies have shifted from 
organic-based polymer solutions to aqueous-based dispersed systems. Such aqueous-based 
polymeric dispersions eliminate potential toxicities associated with residual organic solvents in the 
film. In addition, there are significant economic and environmental benefits. In terms of 
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processing, a major advantage of these dispersed polymer systems is that viscosity is independent 
of polymer concentration or the molecular weight of the polymer, since the polymer is present as 
discrete spheres suspended in water. Thus, higher polymer concentrations may be used in coating 
processes. 
Film coating with aqueous-based polymeric dispersions is similar to the process of coating with 
organic solvent-based systems in that the same type of machinery is used. The processing 
parameters, such as spray rate, bed temperature and gun-to-bed distance, however, must be 
adjusted to compensate for the higher latent heat of evaporation of water. While the application 
process is similar, the mechanism of film formation from aqueous-based polymeric dispersions is 
quite different from solutions. 
Figure 8 shows the major steps involved in film formation from an aqueous-based polymeric 
dispersion [11]. 
 
Figure 8: Steps in film formation (i) and film formation mechanism (ii) from aqueous dispersion [10; 11]. 
(i)         (ii)  
 
 
At the top, water droplets created by at the spraying nozzle (A) accelerated toward the surface of 
the dosage form to be coated (e.g., pellet, tablet or capsule). Water droplets contain very small 
polymer particles, which are often in the nanometer size range. Upon water evaporation (the 
temperature during coating is generally increased and the air flow rate elevated), the polymer 
particles approach each other (B) until a dense packing is achieved. Then, under appropriate 
conditions (especially temperature, relative humidity and in the presence of an appropriate 
plasticizer in sufficient quantity) the polymer particles coalesce and fuse together in a continuous 
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aqueous film (C), in which the polymer particles are dispersed [12]. The degree of coalescence is 
dependent on the intensity of capillary forces that are generated upon water evaporation and the 
time exposed to such forces. Complete coalescence of latex particles occurs when the polymeric 
molecules located at the interface between adjacent particles interpenetrate due to viscous flow 
[9]. Simplified, the disappearance of the water between the nanoparticles creates a pressure, 
which drives the particles together. If particles wouldn’t deform and fill voids, a vacuum would be 
created. If the mobility of the macromolecules is sufficient, this will lead to permanent polymer 
particle deformation and polymer–polymer chain inter - diffusion between neighboring particles. 
In ideal cases, a continuous, intensely entangled polymeric network is created and a homogeneous 
polymeric film without defects is formed [12]. Thus, temperature may significantly influence the 
completeness of coalescence because polymer chain mobility often strongly increases with 
temperature [9; 12]. 
As mentioned earlier (paragraph 3.1), polymer solution will form film coating at room 
temperature, whereas dispersed polymer systems exhibit a minimum film forming temperature 
and, thus, its knowledge is critical in developing a coating process as processing temperatures 
must exceed the MFFT to form a film: below MFFT, a polymeric dispersion will form an opaque 
and discontinuous material upon solvent evaporation, whereas a clear continuous film will be 
formed at temperatures above the MFFT. Moreover, drying at temperatures above the MFFT 
provides sufficient capillary force for coalescence to occur: rapid drying rates are generally 
considered desirable, but may have adverse effects on the resulting film [11]. 
For this reason, processing parameters used during coating must be carefully controlled to 
ensure an appropriate balance between the bed temperature of the coating apparatus and the 
rate of water removal, which is critical for the development of capillary forces [9]. A rapid loss of 
water, for example, may not allow for the development of the capillary pressure necessary and 
thus inhibit deformation and coalescence [18]; whereas excess drying can also prevent the 
droplets from spreading across the substrate during the coating process [11].  
Moreover, low spray rates of aqueous polymeric dispersions, especially when combined with 
higher bed temperatures, can result in spray drying, where the solvent evaporates before the 
polymer chains coalesce and brittle films are produced. In contrast, high spray rates can over wet 
the substrate and cause surface dissolution of the product, with a potential for drug/excipient 
migration into the resulting film coat [9]. 
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In addition to temperature, the relative humidity (RH) during this step is decisive, since it affects 
the water evaporation kinetics [12]. High humidity conditions have been shown to facilitate 
coalescence as adequate capillary pressure is attained [19] and also increase polymer chain inter-
diffusion [20]. Moreover, water itself can function as a plasticizing agent to soften the polymer 
spheres and allow for viscous flow and polymer chain interpenetration [11]. 
Low molecular weight plasticizers could be added to the film coating formulations [12] in order 
to soften the polymer spheres and facilitate its coalescence at lower temperatures: plasticizers 
reduce the intermolecular forces between the polymer chains and reduce internal stresses within 
a film [11]. For softening of the polymer spheres in an aqueous dispersion, the plasticizer must 
partition into the polymer phase. For water soluble plasticizers, uptake into the polymer spheres 
has been shown to occur relatively quickly, whereas longer equilibration times are required for 
water insoluble plasticizers [21]. Sufficient mixing time to allow for plasticizer partitioning into the 
polymer phase prior to initiation of coating is critical, as insufficient mixing can lead to non 
homogenous distribution of the plasticizer which could adversely affect the coalescence process 
[11]. The addition of plasticizers to film coating formulations generally results in a lowering of the 
Tg of the polymer, an increase in film flexibility and a decrease in the incidence of cracking [11; 
22]. Moreover, both plasticizer type and plasticizer concentration have a significant impact to 
influence the MFFT of the dispersed coating systems [11; 23].  
Nevertheless, the complete polymer particle coalescence and the formation of a continuous 
homogeneous film are often not yet achieved at the end of the coating process. Film defects, such 
as holes and/or channels, are still present [12]. Moreover, an incomplete or a partial coalesced can 
lead to changes in polymer properties over time and it could be crucial especially for modified 
release systems [11]. Thus, in order to minimize film imperfections and further promote film 
formation, a curing stage is generally applied. The idea is to increase the temperature in order to 
increase the mobility of the polymer chains to facilitate the fusion of the polymer particles The 
efficiency of the curing step is particularly high, if a sufficient amount of plasticizer is present in 
the system and the relative humidity is increased, since water acting as a plasticizer and being 
mandatory for the capillary forces involved in the process [12].  
Curing can be accomplished by placing the coated substrates in an oven set to a specific 
temperature after application of the coating dispersion (static curing) or allowing the product to 
remain moving within the heated coating equipment (dynamic curing) [11; 24]. 
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The other major concern on aqueous dispersion is physical aging. Most polymers used in coating 
formulations are amorphous and are not at thermodynamic equilibrium at temperatures below 
their Tg. Over time, amorphous polymers undergo a slow transformation toward a thermodynamic 
equilibrium. As temperatures are cooled to below the Tg, the free volume of the polymer will 
slowly relax toward a lower free energy state. Although this equilibration process is slow at 
ambient conditions, physical aging may produce significant changes in polymer properties [9]. 
If a polymeric film coating still contains defects and imperfections after the curing process, the 
system might be unstable during long term storage: even at room temperature polymer particle 
coalescence might continue although at a much lower rate than during coating and curing, 
resulting in denser and less permeable films and, thus, decreased drug release rates [12]. 
 
3.2.1. Stability of aqueous polymeric film coatings 
Aqueous polymeric film coatings provide a great potential to accurately control the release rate 
of a drug from a pharmaceutical dosage form, while avoiding the various disadvantages associated 
with the use of organic solvents. However, long term instability of drug release, due to imperfect 
film formation during coating and curing, can be a serious concern. If the coalescence of the 
particles continues during storage, the film permeability can decrease, slowing down drug release. 
Different strategies can be used to effectively avoid this phenomenon, including optimized curing 
conditions, the addition of appropriate additives and the use of specific packaging materials [12]. 
3.2.1.1. Physical aging in pharmaceutical polymers and the effect on solid oral 
dosage form stability 
Physical aging affects all amorphous polymers used in pharmaceutical coating systems. This 
phenomenon has been shown to cause changes in the mechanical, permeability and drug release 
properties of polymeric films due to a densification and decrease in free volume of the polymer as 
it relaxes to an equilibrated thermodynamic state. Aging has been shown to be influenced by a 
number of factors including humidity and temperature during storage as well as excipients in the 
coating formulation. Polymeric coatings should be adequately cured following processing, with 
careful attention given to curing temperature, humidity, and time. Care must be taken to 
investigate the potential for aging effects during the early stages of product development [25].  
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3.2.1.1.1. The origin of physical aging 
Physical aging is characterized by an increase in rigidity, brittleness and density of a polymer film 
[26]. Amorphous materials were not in thermodynamic equilibrium at temperatures below their 
Tg. This unstable state is the result of a material possessing a greater volume, enthalpy and 
entropy than that found in the equilibrium state [25].  
 
Figure 9: Graphical representation of the origin of physical aging. Tg is the glass transition temperature of 
the polymer and Tβ is the temperature of the highest secondary transition [25; 27]. 
 
 
 
The transport mobility of particles or polymer chains in a tightly packed system, as defined by the 
free volume concept, is primarily dependent on the degree of packing and, thus, the “free 
volume” of said system. Once the polymer is cooled to a temperature below its Tg, the free 
volume is greater than it would be at equilibrium and the volume will decrease slowly over time 
[27; 28]. This contraction is accompanied by a decrease in the polymer chain mobility, which leads 
to a densification of the polymer. Changes in both porosity and tortuosity in the film can 
significantly impact drug release [28; 29].  
3.2.1.1.2. The effect of physical aging on diffusion-based drug release 
The diffusion of drug through a thin permeable or semi-permeable membrane can be described 
mathematically by Fick’s first law of diffusion (Eq.1): 
 
ࡽ =  ࡷ·ࡰ·ࡿ·(࡯૚ି࡯૛)·࢚
ࢎ
          Eq. 1 
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where Q = quantity of drug to diffuse through the film over time, t; h = film thickness; S = the 
surface area available for diffusion; C1 = the concentration of drug in the donor compartment; C2 = 
the concentration of drug in the acceptor compartment; D = the diffusion coefficient of the drug 
and K = the partition coefficient of the drug with respect to the membrane separating the donor 
and acceptor compartments. 
The Iyer equation (Eq. 2) shows that physical aging of a thin polymeric film has an effect on the 
diffusion coefficient, D [30]:  
 
ࡰ =  ࡰࢃ·ࢋ
࣎
           Eq. 2 
 
where Dw = diffusion coefficient of the drug in water, e = film’s porosity and τ = tortuosity.  
Drug transport occurs predominantly by diffusion through water-filled pores. It can be seen from 
Eq. 2 that the diffusion coefficient of the drug is a function of both porosity and tortuosity. As a 
film ages and the density increases [26], the decrease in film porosity and increase in tortuosity 
will result in a decrease in drug dissolution rate [29]. 
3.2.1.2. Factors that influence physical aging 
3.2.1.2.1. Plasticizers 
Plasticizers act to reduce the intermolecular attractions between polymer chains, resulting in an 
increase in film flexibility. In addition, plasticizers enhance the formation of thin films from 
aqueous lattices by softening the polymer spheres to allow for viscous flow. The selection of a 
plasticizer is critical when formulating a polymeric coating dispersion. Plasticizing agents must be 
compatible with the polymer. Using a plasticizer that is incompatible with an aqueous polymeric 
dispersion can result in poor film formation and instabilities in drug release during storage [25]. 
The amount of plasticizer in a coating dispersion is also of great importance. Insufficient 
plasticization can result in polymer films that are brittle or that require longer curing times to 
attain stable films [22]. The coalescence of latex particles is also a function of the concentration of 
plasticizer in the formulation, with higher concentrations of plasticizer producing enhanced or 
more complete film formation, as the softened polymer spheres more readily flow together [25].  
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3.2.1.2.2. Curing and storage conditions 
After completion of the coating process, coated dosage forms are often stored at elevated 
temperatures to promote coalescence of the film, a process known as curing [25]. Both curing 
temperature and curing time can significantly affect the drug release rate [31- 33]. Curing of 
coated dosage forms is an important component in film formation from aqueous lattices. The film 
formation process from these aqueous dispersions relies on capillary forces to draw together and 
deform the latex particles and is influenced by temperature and humidity. Water acts as a 
plasticizer and, at high humidity conditions, the higher water content in the polymer film increases 
the mobility of the polymer chains and enhances coalescence of the latex particles. In contrast, the 
amount of water in the polymeric film is reduced in low humidity environments and consequently 
the capillary forces that facilitate film formation may not be adequate for coalescence. Although 
the presence of water can enhance coalescence of polymeric films during curing, high levels of 
humidity during storage can also destabilize the films, leading to changes in the drug release rate 
over time [25].  
Changes in drug release during curing have been reported for high glass transition temperature 
polymers, such as ethylcellulose. Incomplete film formation and further gradual coalescence 
during storage cause instability in the drug release rate.  
For films cast from an organic solution, a significant shift in creep compliance was noted as aging 
progressed, indicating a decrease in free volume of the film and increased densification of the 
polymer structure. These changes were also responsible for a reduction in the water vapor 
permeability coefficient as a function of aging time [25; 34].  
For aqueous-based cellulosic films, a decrease in free volume was also noted as a result of 
further gradual coalescence of the pseudolatex particles [25; 35]. When dosage forms are cured at 
high temperatures, the time required to reach a fully coalesced film decreases in comparison to 
curing at lower temperatures [25; 36]. At temperatures above the Tg of the film, the mobility of 
the polymer chains increases and latex coalescence is accelerated so that films are nearly 
completely coalesced when removed from the coating apparatus [25]. 
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4. FUNCTIONS OF COATINGS 
At least three types of coating for the production of solid dosage forms exist concerning the 
function of the coat. Non-functional coatings are applied to improve the compliance by better 
appearance and distinguish ability, easier intake and swallowing and to protect the dosage form 
against environmental influences. Functional coatings can be used to mask the bad taste or smell 
of a product, to protect the API (active pharmaceutical ingredient) against the acid environment of 
the stomach or the gastric mucosa against an aggressive API. A large part of functional coatings 
lead to prolonged release of the API. Active coatings contain an API in the coat. They are applied 
to realize different fixed dose combinations, to prevent interaction of different drugs or to 
combine different release behavior in one single solid dosage form.  
The thickness and integrity of the coating is of great importance especially for functional 
coatings. A minimum thickness and the absence of cracks in the film are required to ensure gastro 
resistance of a dosage form. Otherwise the API will be (partly) released in the acid gastric fluid and 
degradation of the API or irritation or damage of the stomach mucosa can occur. Sustained release 
coatings build a barrier around the dosage form. The drug is released via diffusion through the 
polymer film or through pores in the film. Beside the diffusion coefficient of the drug in the film, 
the thickness of the film determines the dissolution rate of the drug. In active coating processes, 
the API is applied together with a film forming agent and/or a binder on a core which can be a 
placebo or contain a second API. The amount of API in the film is directly correlated to the film 
thickness when a uniform distribution on the core and a constant density of the film layer are 
achieved [6]. 
 
4.1. Non Functional Coatings or Cosmetic Applications 
Most solid oral dosage form are colored not only to improve their appearance, but also to satisfy 
good manufacturing practices requirements that require products be differentiable at all stages 
during the manufacturing and distribution cycle. Therefore, film coating with pigments is essential 
in many cases to meet production regulations and thus, has vast importance to pharmaceutical 
manufacturing. Also, lustrous surfaces of solid pharmaceutical dosage forms are commonly 
recognize as more applying to the consumer than a dull surface which often elicits an unfavorable 
impression as to the quality of its content. Thus, film coating is widely used to enhance the 
pharmaceutical elegance of dosage forms by increasing surface luster. Some active ingredients or 
35 
 
excipients can cause a dosage form to appear spotted, mottled or unpleasantly colored leading 
the consumer to believe the content have degraded. In these cases, opaque coats are added to 
hide unsightly appearance. 
Brand recognition is also important with regard to the aesthetic appearance of pharmaceutical 
products. Therefore, with regard to the commercialization of pharmaceutical dosage forms, it is 
essential to consider appearance as it is an important factor with regard to consumer opinions and 
awareness. 
4.2. Immediate Release Application 
4.2.1. Film coatings for taste masking and moisture protection 
Taste masking and moisture protection of oral dosage forms contribute significantly to the 
therapeutic effect of pharmaceutical and nutraceutical formulations either by ensuring patient 
compliance or by providing stability through shelf life in order to provide the desired efficacy to 
the end user. Among different types of taste, bitter taste is the most relevant for patient 
acceptance because of the extremely high sensitivity of taste buds on the back of the tongue. 
As hydrolysis is the most common mode of degradation of an active ingredient, moisture 
protection plays a vital role in the stability of the active. Moisture protection can be achieved by 
reducing the initial moisture content of the formulation and inhibiting further moisture seepage 
into the formulation during manufacturing and storage. Optimized oral dosage forms need to 
reliably hinder the release of bitter drug molecules in the mouth or ensure stability of the active 
compound, while also ensuring fast drug release in the stomach to enable early therapeutic onset. 
Besides different formulation concepts, film coating is found to be the most effective and 
commonly used approach for taste masking and moisture protection.  
Film coating can be achieved through the use of water-soluble, cationic, anionic or neutral 
insoluble polymers from different chemical structures. Use of water-soluble polymers often results 
in a compromise of the isolation or moisture protection ability of the film. Use of anionic or 
neutral polymers necessitates thin films in order to ensure quick release in the gastric fluid. 
Cationic polymers provide efficient moisture protection without influencing the release of the 
drug in the gastric fluids. 
Polymers may be sprayed onto various types of cores from dispersions or solutions in organic 
solvents or water. Organic solvents offer the safest option. However, due to environmental 
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concerns, aqueous formulations are often preferred. Efficient drying with coating equipment can 
ensure effective use of aqueous systems without compromises.  
Coating thickness ranging from 0.5 to 50 µm or more, represents the most important influence 
on the desired function besides physicochemical properties of the coating material.  
Insulating excipients with the least affinity to moisture also taste mask and ensure patient 
compliance as well as keeping the moisture uptake to a minimum during storage. Hydrophobic 
plasticizers would enhance the moisture protection ability of the film over the hydrophilic ones. 
Close attention needs to be payed to the quantity of the plasticizer. Pigments used for esthetics 
can be additionally exploited for their ability to physically obstruct the passage of drug or water 
molecules in the coating films. Efficient taste masking and reliable moisture protection of solid oral 
dosage forms can be achieved by film coating implementing the options of pharmaceutical 
polymers and processes, while also overcoming possible interactions with the active compound or 
different excipients. 
4.2.1.1. Need and concepts of taste masking 
The beneficial therapeutic effect of pharmaceuticals is dependent on regular dosing following 
manufacturer advice. The oral self-dosage route is the most common method for the application 
of many drugs. However, patients tend to neglect instructions when they are inconvenient or 
unpleasant. Particularly for oral pharmaceuticals, compliance depends significantly on the taste of 
the dosage form. Thus, masking bitter taste is the key parameter to improve patient compliance as 
well as the therapeutic efficiency of oral pharmaceuticals [38]. Measures to mask the taste of oral 
dosage forms must include efficiency, but also avoid any negative effect of sensory awareness, 
such as mucosa irritation, roughness in the mouth or hindered swallowing. Another important 
aspect is to not negatively affect the bioavailability of the active compound by hindering its release 
or delaying its effect. This can be accomplished by designing a release kinetic which functions over 
an extended time period after ingestion. 
Several concepts of taste masking for pharmaceuticals have been developed and put into 
practise. Molecular concepts include chemical modifications, such as the prodrug approach or salt 
formation using either anions [39] or cations or interaction with ionogenic polymers, such as 
(meth)acrylates (i.e. Eudragit E) [40]. Physical taste masking may be achieved by complexation 
(i.e., inclusionin cyclodextrins), its derivatives (i.e. hydroxypropyl-beta-cyclodextrin). Additionally 
practiced are concepts of binding to ion exchange resins, which have been revealed to be effective 
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taste masking agents. Cross-linked polymers and copolymers of (meth)acrylic acid are available in 
pharmaceutical grades and optimized variations for different classes of drug may be tested. 
Formulation concepts for taste masking include the incorporation of specific flavour enhancers. 
Examples may be sweeteners, amino acids and their phosphate derivatives, natural products 
including fruit juices, aromatic oils, herbs, alkaline earth oxides, hydroxides and spices informs 
such as high concentrated extracts or dried solids, as well as either alcoholic or aqueous solutions. 
Further functional excipients, which improve the organoleptic perception of unpleasant oral 
formulations, are effervescent agents or rheological modifiers, such as gel forming gums. 
The type of taste masking suitable for final formulation is very much influenced by the selected 
manufacturing process. Processes for applying taste masking are melt and liquid extrusion, spray 
or freeze drying to form solid dispersions or agglomerates, coating with lipids or waxes, formation 
of lipid vesicles or multiple emulsions. Coating processes are preferably used for taste masking of 
tablets or mini-tablets. Commonly applied processes include liquid melt or powder coating with 
lipids, waxes and polysaccharides. Compression coating is an unconventional, alternative method 
with limited practical relevance. A modern variation of coating techniques is film coating 
particularly suitable for microencapsulation of small particles to form taste masked multi-unit 
dosage forms. The functional coating is applied by spray processes from organic or aqueous 
solutions or preferably from aqueous solutions or dispersions including natural or synthetic 
polymers. Among these varieties of formulation designs, film coating provides the highest 
efficiency [37]. 
4.2.1.2. Need and concepts of moisture protection 
An active pharmaceutical ingredient in a dosage form needs to be stable until the end of its shelf 
life, in order to ensure its efficacy and safety for the patient. Degradation of the active ingredient 
can occur though hydrolysis, thermal degradation, oxidation, light, microorganisms or any other 
chemical reaction that renders the active ineffective for its intended purpose [41]. In addition, 
moisture is considered to be one of the most important factors influencing the stability of a 
pharmaceutical formulation. Atmospheric humidity is one of the main sources of moisture that 
chemically or physically influences the active ingredient. However, a formulator also needs to 
consider the inherent moisture of some of the excipients, which could be potential contributors of 
water molecules for hydrolysis. Many active ingredients are hygroscopic in nature and need to be 
protected from moisture. Moreover, moisture protection is often needed when the cores are 
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hygroscopic [42], as is the case with many herbal products. For most powders, residual humidity 
modifies their mechanical and rheological properties. Protecting a formulation from hydrolytic 
degradation is also possible through appropriate packaging, however it does not exclude moisture 
from seeping into the container during multiple openings. Protecting the cores with a moisture 
barrier film is found to be more appropriate, since it also eliminates the problem caused by 
multiple openings of the container. Thus, of all the alternatives available, coating the formulations 
is found to be the most appropriate and widely used technique. 
Moisture-protective polymer coatings are often used to prolong the storage stability of water-
sensitive drugs, including many herbal extracts [43; 44]. 
While developing a coating formulation for a moisture sensitive drug, the following strategies 
need to be considered during the entire development process: 
 Designing the dosage form with non-hygroscopic/low water-activity excipients; 
 Formulating the core with the least amount of inherent moisture; 
 Providing the dosage form with a moisture protective coating; 
 Packaging the dosage form with an appropriate moisture-resistant material [37]. 
 
4.2.1.3. Polymers and formulations 
4.2.1.3.1. Polymers [39] 
Moisture protecting and taste masking polymers used in film coating processes are based on 
polysaccharide, polypeptide or vinyl polymer chemistry. Their physicochemical properties vary 
over a wide range, indicating enormous variability and different formulation approaches. 
Traditionally, water-soluble polymers (Table 4) are used for taste masking. However, some of 
them, like polyvinyl alcohol (PVA), are also used for moisture protection. Expected is the 
enablement of fast drug release independent of the dissolution medium, with no negative effect 
on drug release or therapeutic effect. 
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Table 4: Water-soluble polymers used for taste masking and moisture protection by film coating. 
 
 
These polymers include soluble starch derivatives, cellulose ethers and synthetic vinyl polymers 
or hydrophilic block copolymers. Since these polymers do not carry ionic groups, there is only a 
slight risk of chemical interaction with the active drug. However, efficiency of blocking the 
interaction of bitter drug molecules with taste receptors is somewhat limited. Reliable taste 
masking needs coatings up to 10 µm in thickness or more. In addition, long process times will 
reduce the economy of the manufacturing process.  
Films of entero-soluble cationic polymers (Table 5) provide optimized functionality for taste 
masking and moisture protection. Insoluble in water at the neutral pH of saliva, they provide an 
effective barrier against the movement of drug molecules to the surface and water molecules to 
the core, thus providing taste masking and moisture protection.  
 
Table 5: Entero-soluble cationic polymers used for taste masking and moisture protection by film coating. 
 
 
EUDRAGIT® E is a cationic copolymer based on dimethylaminoethyl (meth)acrylate, butyl 
(meth)acrylate and methyl (meth)acrylate with a ratio of 2:1:1. It is available as a micronized 
powder for aqueous dispersion as EUDRAGIT® E PO and in granule form for organic solution 
preparation as EUDRAGIT® E 100. The tertiary amino groups of EUDRAGIT® E polymer types 
become protonated in the acid media of the human stomach and, hence, rapidly dissolve. Thus, 
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fast drug release is secured even if thicker coatings are applied when needed for moisture 
protection. Kollicoat® Smart seal 30D is also a cationic polymer. It is supplied as an aqueous 
polymer dispersion containing methyl (meth)acrylate and dimethylaminoethyl(meth)acrylate co-
polymer stabilized with ∼0.6% macrogol cetostearyl ether and ∼0.8% sodium lauryl sulfate. The 
solids concentration is approximately 30% w/w.  
Anionic polymers (Table 6) include natural polymers such as shellac and alginates, carboxymethyl 
derivatives of cellulose, cellulose acetate derivatives of phthalic acid and butyric acid, and 
specifically optimized (meth)acrylates carrying different amounts of carboxylic groups.  
 
Table 6: Enteric anionic polymers used for taste masking and moisture protection by film coating. 
 
 
These polymers ensure targeted drug release and controlled dissolution of the coating at a 
defined pH. Primarily, the polymers provide enteric functionality and are used for taste masking 
and moisture protection due to their efficiency in blocking drug release in the mouth and seepage 
of moisture until the formulation is swallowed. Furthermore, free carboxylic groups may adversely 
interact with cationic groups of the active compound leading to instability. Isolating sub - coats 
may be necessary to hinder this chemical interaction. 
Cationic or anionic copolymers, particularly the (meth)acrylates, may be partially neutralized, 
leading to improved drug release more independent of pH while maintaining a barrier effect for 
dissolved molecules in saliva. Cationic amino(meth)acrylate copolymer, carrying tertiary amino 
groups, may be neutralized with a combination of mono and dicarboxylic acids, such as malic or 
tartaric acid in order to achieve solubility of the coating in water. While maintaining a significant 
taste masking effect, the instant therapeutic effect is maintained more independently of the 
physiological influences of the human gastro-intestinal tract. 
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Table 7: Insoluble polymers used for taste masking and moisture protection by film coating. 
 
 
The neutral ethyl acrylate and methyl(meth)acrylate dispersions (EUDRAGIT®NE 30 D and 
EUDRAGIT®NM 30 D) provide coatings with medium permeability while the ammonio 
(meth)acrylate copolymers form films of high (Type A) (EUDRAGIT®RL) and low permeability (Type 
B) (EUDRAGIT®RS). Based on the physic chemical characteristics, the type A polymer may be the 
preferred coating polymer, however, mixtures are often applied for optimized functionality. Due 
to insolubility in water and low permeability the polymers can efficiently mask unpleasant taste 
and provide moisture protection, but fast drug release requires thin coatings similar to the anionic 
polymers.  
Ethylcellulose-based formulations (Aquacoat® ECD) also provide moisture protection. 
Improvement in moisture protection is achieved with an increase in film thickness. 
A further alternative of coating formulation design is a combination of different polymers in the 
coating. Preferably, water-soluble and insoluble types of polymers are combined in various ratios. 
As a result, the positive effect of blocking bitter tasting molecules from interacting with receptors 
on the tongue and instant drug release in the stomach can be linked. Publications mention film 
coatings containing ethylcellulose [45] and low substituted hydroxypropyl cellulose or 
hydroxypropyl methyl cellulose [46]. The insoluble polymer of EUDRAGIT® NE 30 D was combined 
with hydroxypropyl cellulose [47] and insoluble EUDRAGIT® RL 30 D dispersion was co-processed 
with water soluble carboxy methyl cellulose sodium in a 9–1 polymer ratio. The resulting coating 
maintained efficient taste masking combined with instant drug release due to rapid disintegration 
of the polymer layer in water independent of pH [48]. Taste masking of acetaminophen particles 
has been achieved by film coating with EUDRAGIT® RL/Blanose (sodium CMC) in a 9–1 
combination [49]. 
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Cationic entero-soluble EUDRAGIT® E 100 may be combined with swellable MCC and water 
soluble HPC or with water insoluble cellulose acetate [50].  
Kollicoat® IR protect is a blend of PVA/PEG graft copolymer and PVA in a 6:4 ratio. The high 
capacity of this polymer mixture to bind insoluble pigments, due to its low viscosity, has shown to 
be useful for providing oxygen and moisture protection to formulations.  
 
4.2.1.3.2. Formulation principles 
Polymers may be applied by spray coating from organic or aqueous solutions. Preferred solvents 
are ethanol, isopropanol or its mixtures with acetone. Safety and toxicological reasons, as well as 
specific product and formulation development, changed coating processes to aqueous fluids 
containing the polymer in dissolved or dispersed form. Polymer dispersion may be prepared by 
emulsion polymerization, solvent evaporation from emulsions or micronized polymer particles. For 
moisture sensitive drugs, there are concerns about moisture penetrating during the coating 
process itself when using aqueous coating formulations. However, the latest coating equipment 
offers better drying techniques, preventing this moisture penetration during the coating 
processes. Thus, based on optimized formulations, aqueous coatings provide equivalent 
functionality to solvent based coatings. 
Cores used for taste masking and moisture protection by film coatings may have many different 
structures and a wide variety of particle sizes. They can range from crystals or particles of a few 
µm, to granules and pellets up to 2 mm, or tablets of different shapes up to 15 mm or more. 
Traditionally, the preferred application process or tablets needing taste masking and moisture 
protection has been by film and spray coating in drums. Based on optimized formulations in terms 
of shape and hardness, the coating process usually involves little risk of complications and offers 
high reproducibility. 
The thickness of the coating film and the composition of the excipients used in the film are 
important factors influencing the movement of water molecules through the film. Increasing the 
film thickness results both in an improvement of the tensile strength of the core [51] and in 
greater amounts of water retained in the film. This could result in larger amounts of moisture 
condensing in the pores, either because of chemisorption or because of the different nature of the 
internal microporous structure of the thick film. In a typical coating process, the particle size of the 
substrates is heterogeneous, and so is the coating film thickness on each substrate. If films of 
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varying thickness retain different amounts of moisture, the process variables should be closely 
controlled to achieve as uniform a coating thickness as possible for satisfactory product 
performance. This is of vital importance for moisture-protective coating applications because the 
residual moisture in the coating film may migrate into the core and interact with the active 
ingredient in an adverse manner during storage [37]. 
The glass transition temperatures of the polymers used for coatings affect the moisture 
protection ability and the stability of the formulation. Polymers in the amorphous state have a 
higher capacity for moisture sorption than in the crystalline state [52]. The up taken water may be 
thought of as “dissolving” into the amorphous structure and acting as a plasticizer [53]. 
Consequently, the glass transition temperature of the polymeric system decreases with increasing 
water content. Thus, water which permeates through a moisture barrier film would also have an 
influence on the Tg of the film and hence on the stability of the film and the formulation. In the 
presence of moisture, glassy-to-rubbery state transition occurred with the polymeric system of 
Opadry® AMB as opposed to EUDRAGIT® E PO, which did not show this transition under the test 
conditions. Hence, the water uptake with the Opadry® AMB films tend to increase with increasing 
temperature, due to the higher mobility of the macromolecules [54]. 
The plasticizer effect is based on molecular interaction with the polymer chains, thus helping to 
open the polymer chains and helping them interact with each other in order to develop more firm 
bonds, which result in coalescence of the film and film formation. Plasticizers are required to 
impart the essential flexibility to the film. This is obtained through a reduction in the glass 
transition temperature of the film, thus reducing its tensile strength [55]. Plasticizer also helps 
with adhering the film to the core surface. Appropriate concentrations of the plasticizer are 
important in determining the moisture protection properties of the final film. Quantities above the 
optimum level result in molecular scale holes in the film, which help water molecules pass through 
the structure, thus reducing the moisture protection property of the film. The effects of the 
presence of different types of plasticizers in polymeric coating formulations have been reported in 
literature [56 - 58]. The nature of the plasticizer drastically influences the moisture-resistance 
ability of the film. Films having a hydrophilic plasticizer are found to permeate moisture more 
rapidly. On the other hand, addition of hydrophobic plasticizers helps to increase lipophilicity and 
thus the moisture resistance of the film [59]. 
In addition to a plasticizer, pigments have an important role to play in moisture resistant film 
coatings. Due to the presence of intermolecular spaces in polymeric films, a complete barrier to 
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the movement of air or vapor is not possible. Insoluble additives are hence used on the coatings in 
order to block these intermolecular spaces [60]. Pigments, being discrete particles, serve as a 
barrier to the diffusion of moisture through the film. The moisture has to bypass these particles, 
thus increasing the passage time, thereby improving the moisture protection ability of the film. 
This, however, depends on the concentration of the pigments, referred to as critical pigment 
volume concentration. Above this level pigment pores are generated, thus facilitating the 
movement of moisture and resulting in poor moisture protection by the film. Pigments added to a 
polymer need to be distributed uniformly in order not to form agglomerates, which would 
interrupt film formation and possibly result in weaker films. Inadequate pigment distribution 
would also adversely affect film adhesion to the surface. Polyhydric material such as film formers 
or plasticizers can form hydrogen bonds with the water molecules, thus reducing the possibility of 
water molecules to reach the core and in turn provide moisture protection [51].  
Aqueous coating processes are normally associated with longer drying times. Non-aqueous 
coatings are largely discouraged due to the hazards associated with the environment and solvent 
handlings. A solvent-free process with micronized powders for film coating of tablets using acrylic 
polymers such as EUDRAGIT® E PO has been developed. The coated tablets, observed using a 
scanning electron microscope, exhibited a continuous and uniform film coating. The results of 
dissolution testing indicated that in pH 6.8 buffer media, film coating resulted in a delay in the 
release of the drug, while no delay was observed in acidic medium. On the basis of these 
behaviors, taste masking, moisture protection and controlled release applications are expected 
from such films [61].  
Lipidic/waxy excipients with low melting points are also sprayed in their molten state to form a 
uniformly continuous film that acts as the rate-controlling membrane for drug release as well as 
for moisture protection. The hydrophobic wax coating presents a barrier for moisture ingress into 
the drug-laden substrate. The most commonly used waxy excipient is glyceryl behenate. With 
glyceryl behenate, there may be binding of water molecules to the electronegative oxygen atom in 
the terminal carboxylic group via hydrogen bonding. Further, as temperature increases and is 
closer to the melting temperature of the wax, the intermolecular distances increase, leading to a 
greater number of carboxylic groups becoming available. Thus the effective moisture content 
(EMC) increases with increasing temperature for glyceryl behenate film [54]. 
As long term storage of oral dosage forms, often under elevated temperatures and high 
humidity, create a high stress on dosage forms during storage, packaging may be necessary 
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additionally to ensure storage stability of the dosage forms during an adequate period of time. 
Thus plastic or metal containers may be used to strengthen moisture protection over a longer 
period of time or plastic foils out of polyethylene, polypropylene or polyester, probably even 
laminated with aluminum [37]. 
 
4.2.2. Improving ease of injestion / swallowing 
Film coated dosage forms have been reported to improve esophageal transit/swallowing over 
the uncoated counterpart. Film coatings can act as barriers to prevent adhesion of the dosage 
form to the esophagus and in this way act as a lubricant to improve the motility of dosage forms 
through the esophagus. Additionally, film coats can prevent disintegration of dosage forms in the 
esophagus that can lead to extensive adhesion of particulates to the esophagus. Films coatings can 
also be applied to cover sharp tablet edges and increase roundness such that the tablet will be 
easier and more comfortable to swallow [62]. 
 
4.2.3. Sub - coats and top - coats 
Immediate release film coats are also used as sub - coats that are applied to substrates prior to 
the addition of functional coatings. Sub - coats are often necessary to improve the adhesion of 
functional coatings. This not only improves continuous film formation but also increases coating 
efficiency by reducing the amount of the coating dispersion that must be applied to achieve the 
desired release profile. Sub - coats are also applied to prevent the partitioning of active from the 
core into the outer coat as this can result in a burst release of drug and can impair film 
functionality.  
Immediate release film coats are also applied on top of functional coats to reduce adhesion of 
substrates caused by the tackiness of soft film coats after spraying. Topcoats can also be utilized to 
improve color or increase the gloss of film coated dosage forms [62]. 
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4.2.4. Coating materials for immediate release application 
4.2.4.1. Water soluble cellulose ethers 
The most commonly used water – soluble cellulose derivatives for film coating applications 
include hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC) and hydroxypropyl methyl 
cellulose (HPMC). The leading commercial brand of HPC is Klucel®, HEC is available under the 
branded names Natrosol® and Cellosize TM. Bulk HPMC is available under a variety of brand names, 
but most notably as Methocel TM which is marketed by the Dow Chemical Company [62]. 
The European Pharmacopoeia (8.7 Ed.) describes hypromellose as a partly O-methylated and O-
2-hydroxypropylated cellulose. It is available in several grades that vary in viscosity and extent of 
substitution. The degree of polymerization may be distinguished by appending a number 
indicative of the apparent viscosity, in mPa*s (cps), of a 2% w/w aqueous solution at 20°C. 
Hypromellose defined in USP 39/ NF 34 specifies the substitution type appending a four-digit 
number to the non-proprietary name: the first two digits refer to the approximate percentage 
content of the methoxy group (OCH3); the second two digits refer to the approximate percentage 
content of the hydroxypropoxy group (OCH2CH(OH)CH3), calculated on a dried basis. 
Pharmacopeial specification for hypromellose are summarized in table 8. Depending upon the 
viscosity grade, concentrations of 2-20% w/w are used for film forming solutions to film-coat 
tablets [63].  
 
Table 8: Pharmacopeial specifications for hypromellose [63]. 
Type 
Methoxy 
content USP 
Methoxy 
content Eur. Ph 
Hydroxypropoxy 
content USP 
Hydroxypropoxy 
content Eur. Ph 
1828 16.5-20.0% 16.5-20.0% 23.0-32.0% 23.0-32.0% 
2208 19.0-24.0% 19.0-24.0% 4.0-12.0% 4.0-12.0% 
2906 27.0-30.0% 27.0-30.0% 4.0-7.5% 4.0-7.5% 
2910 28.0-30% 28.0-30% 7.0-12.0% 7.0-12.0% 
 
The substitution affects the solubility–temperature relationship. Among the three grades 2208, 
2906 and 2910, which have long been commercially available worldwide, 2910 has the best 
solubility in organic solvents and so it has often been used for organic solvent–based coating. Even 
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though aqueous coating has been replacing solvent-based coating and the solubility in organic 
solvents is of less importance, the 2910 grade is still widely used. Substitution grades other than 
2910 are also applicable for aqueous coating, but there are few suitable commercial products of 
those substitution grades having low viscosity [63]. 
The required viscosity of a solution for aqueous film coating is commonly less than 100 mPa*sec. 
The maximum concentrations of 3, 6, and 15 mPa *sec grades, which can be used in film coating, 
are therefore approximately 14%, 7.5%, and 4.5% w/w, respectively. Thus, the maximum 
concentrations available depend on the viscosity grade of HPMC used. Aqueous solutions of HPMC 
gel upon heating. The thermal gelling temperature, which is close to the clouding point, depends 
on the level of substitution and it is also affected by such factors as viscosity, concentration, 
heating rate and the addition of salts. Dramatic increases in viscosity are observed at near 60°C, 
which indicates the occurrence of gelation. Problems might be encountered if the solutions were 
at around this temperature. Preparation temperature of the coating solution should be less than 
40°C for complete dissolution of HPMC particles [64]. Films prepared with this polymer generally 
will need another polymer, or plasticizer, to improve the adhesion to the core surfaces. HPMC 
forms transparent, tough and flexible films from aqueous solutions. The films dissolve completely 
in the gastrointestinal tract at any biological pH and HPMC provides good bioavailability of the 
active ingredients. The mechanical properties of HPMC films vary with viscosity grade. Both tensile 
strength and elongation of HPMC films decreased as the viscosity decreased. These observations 
suggest that the possibility of crack formation in coated films should be taken into consideration 
when an HPMC of lower viscosity grade is used. [64]. Polyethylene glycol (PEG), especially a high 
molecular weight type such as PEG 6000, is a suitable plasticizer. Liquid type PEG such as PEG 400 
is also applicable particularly for peeling and for avoiding logo-bridging. Although a greater effect 
is expected as the content of plasticizer increases, it should preferably be added at the minimum 
effective level (usually 20– 30% w/w with respect to the polymer). Excessive amounts of plasticizer 
may cause tablet tacking, plasticizer bleeding, color depletion or interaction with the active 
ingredients. Propylene glycol is also effective as a plasticizer to some extent, but tends to volatilize 
during the coating process and storage [64].  
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4.2.4.2. Eudragit ® E100 
Aminoalkiyl (meth)acrylate Copolymer EUDRAGIT® E is a cationic copolymer produced by radical 
copolymerization of butyl (meth)acrylate, dimethylaminoethyl (meth)acrylate and methyl 
(meth)acrylate in a ratio 1:2:1 having an average molecular weight of 150.000 Da. The polymer is 
insoluble at pH greater than 5.5, but becomes soluble at pH below 5.5 due to the protonization of 
the dimethylaminoethyl (meth)acrylate groups that results in a dense cationic charge on the 
polymer backbone that increases the hydrophilicity of the molecule. EUDRAGIT® E 100 is insoluble 
in the saliva (pH 6.8 – 7.4) but readily soluble in gastric fluids (pH 1.5) [62].  
4.2.4.3. Kollicoat® IR 
Kollicoat® IR is a polyvinyl alcohol – polyethylene glycol graft copolymer consisting of 75 % 
polyvinyl alcohol units and 25 % PEG units with an average molecular weight of 45.000 Da. 
Kollicoat® IR is freely soluble in aqueous media over the entire range of physiological pH and 
therefore is primarily used for instant release film coating applications. Films produced from 
Kollicoat® IR are clear, have excellent pigment binding capacity and can be easily printed; thus, are 
frequently utilized to improve the appearance of pharmaceutical dosage forms and to create 
brand trademarks. Kollicoat® IR films are extremely flexible showing much greater elongation at 
break than cellulose derivatives and therefore do not require the use of a plasticizer and in some 
cases may be more resistant to cracking or breaking than these more traditional coating 
alternatives [62].  
4.2.4.4. Polyethylene glycol and Povidone 
Polyethylene glycol and povidone (PVP) are readily water – soluble polymers that are used in 
numerous pharmaceutical applications; however, their applications to film coating are limited by 
their hygroscopicity. Thus, films produced from these polymers are typically tacky, making coated 
dosage forms difficult to handle due to their adhesiveness. PEG and PVP are, however, used as 
additives to film coating formulations to stabilize pigments and to increase the gloss of film 
coatings. Low molecular weight PEGs (500 – 600) are also commonly used as plasticizers in 
immediate release film coated formulations [62].  
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4.3. Film Coating for Modified Release Applications 
The evolution in film coating into modifying the release of actives has led to very advanced 
delivery system that have substantially expanded the complexity and capabilities of oral drug 
delivery. The different modes of modified drug delivery and the materials that enable these modes 
of delivery will be discussed in the following sections. 
4.3.1. Film coating for enteric release 
Enteric release refers to drug delivery that circumvents the stomach to release the delivered 
drug in the intestinal tract. Therefore, enteric – coated oral dosage forms remain intact in the 
stomach, releasing negligible amounts of drug, but dissolve rapidly in the intestinal tract. Polymers 
used for enteric film coating therefore resist dissolution in acidic media, yet dissolve readily in 
slightly acidic to neutral pH environments. There are a few reasons that enteric release is 
preferred for certain actives. If the active is irritating to the gastric mucosa, enteric delivery is 
preferred to avoid the discomfort and injury that may be experienced by the patient with an 
immediate release dosage form. If a drug molecule is acid labile or degraded by digestive enzymes 
in the stomach, enteric delivery is essential to maintain its therapeutic activity as all or a portion of 
the dose may be degraded in the stomach thereby reducing bioavailability. Enteric delivery has 
also been demonstrated to improve the absorbance of some poorly water – soluble drugs. Since 
there is vastly more surface area for drug absorption in the small intestine than in the stomach, 
targeting the delivery of the maximum dissolved drug concentrations to the small intestine can 
substantially improve oral absorption.  
There are two types of materials that have been used for enteric coating of pharmaceutical 
dosage forms:  
(i) slowly eroding materials that provide enteric protection only if complete erosion does not 
occur before dosage forms exits the stomach; 
(ii) pH sensate polymers. 
Erosion based enteric systems are highly dependent on gastric conditions and emptying times 
and thus are not reliable. Therefore, pH sensitive polymers are more widely used for enteric 
coating as they provide greater consistency with respect to enteric drug release.  
All pH sensitive polymers used in enteric film coating exhibit enteric functionality as a result of 
free carboxyl groups contained on the polymer backbone. In acidic environments, these free 
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carboxyl groups remain protoned (neutrally charged) and consequently the polymer remains 
hydrophobic and insoluble. As the acidity of the surrounding media is decreased, the free carboxyl 
groups become deprotonated and anionically charged rendering the polymer increasingly more 
hydrophilic up to a critical pH where there polymer becomes freely soluble. The pH at which this 
transition occurs depends on the degree of substitution of free carboxyl groups and the pKa of the 
substituent acid groups on the polymer chain. A greater degree of acidic functional group 
substitution corresponds to greater solubility of the enteric polymer.  
Enteric polymers can be coated from aqueous latexes or from aqueous solutions that are 
produced by solubilizing the polymer via pH neutralization with the addition of an alkali or organic 
base (i.e. ammonia, sodium hydroxide, triethanolamine, ammonium hydrogen carbonate). In the 
most cases acid pretreatment is required to convert the enteric polymer from its salt state back to 
the neutral state to achieve enteric functionality of the polymer.  
The plasticizer requirement is usually less when enteric coats are produced from neutralized 
aqueous solutions versus latex dispersion since the process of particle coalescence to achieve film 
formation is avoided. Plasticizer is only required in sufficient concentrations to improve film 
flexibility to avoid splitting or cracking. When enteric coating is conducted with latex formulations, 
in most cases, curing at elevated temperatures and relative humidity is required to complete film 
formation and ensure gastro – protection of enteric coat [62].  
4.3.1.1. Enteric cellulose derivatives: CAP, HPMCP and HPMCAS 
Cellulose acetate phthalate (CAP), cellulose acetate trivelliate (CAT), cellulose acetate succinate 
(CAS), hydroxypropyl methylcellulose phthalate (HPMCP) and hydroxypropyl methylcellulose 
acetate succinate (HPMCAS) are widely used for enteric coating applications.  
CAP is produced by reacting partial acetate ester of cellulose with phthalic anhydride in the 
presence of a tertiary organic base or a strong acid. The USP specifies that CAP must contain 21.5 – 
26 % acetyl groups and 30 – 36 % on the cellulose backbone as calculated on an anhydrous basis. 
This degree of substitution equates to acylation of about half of the available hydroxyl groups and 
about one quarter esterified with one of the two free carboxyl groups of phthalic anhydride. With 
only one carboxyl group on the phtalic moiety involved in the substitution, the other remains free 
to form salts and thus provides the enteric functionality to the polymer.  
51 
 
CAP shows aqueous solubility around pH 6. Degree of substitution is key to complete film 
dissolution in intestinal fluids. It has been determined that CAP has a threshold of approximately 
20% phthalyl substitution to ensure rapid dissolution at intestinal pH.  
The glassy transition temperature (Tg) of CAP ranges from 160°C to 175°C and therefore the 
addition of plasticizer is required to reduce the Tg of the polymer so as to improve film flexibility 
and robustness and to achieve complete film formation. The formation of a continuous film is 
essential to achieve adequate protection of the dosage form in the gastric environment. 
Therefore, plasticization of enteric polymers, particularly cellulose based-polymers is 
recommended to ensure the formation of a continuous film and to eliminate incidences of 
cracking or splitting of the film. Typically, 25% – 35% plasticizer based on dry polymer weight is 
sufficient. CAP is compatible with most water – soluble and insoluble plasticizers with diethyl 
phthalate (DEP), tributyl citrate (TBC), triethyl citrate (TEC), tributryin and triacetin being the most 
commonly used [62].  
Depending on the degree of phthalyl substitution, HPMCP is soluble in aqueous media in a pH 
range of 5 – 5.5. There are three primary grades of HPMCP: HP 50, HP 55 and HP 55 S. The HP 50 
grade has a 24% nominal phthalyl content and dissolves at pH ≥ 5.0, while the HP 55 and HP 55 S 
grades have a 31% nominal phthalyl content and dissolve at pH ≥ 5.5. HP 55 S has a greater 
molecular weight than the HP 50 grade which results in higher solution viscosity, greater film 
strength and increased resistance to simulated gastric fluid. The HP 55 S grade therefore requires 
less applied coating for enteric functionality and exhibits greater cracking than the HP 55 grade.  
One of the benefits of HPMCP over CAP is that HPMCP is soluble in water/ethanol co solvent 
system which allows for improved drying efficiency and eliminates the need for neutralization to 
produce an aqueous – based solution coating system. Additionally, solutions and film coats 
prepared from HPMCP show great thermal stability compared to CAP and CAT. 
HP 50 and HP 55 have a glass transition temperatures of 137°C and 133°C, respectively, and 
hence plasticizers are required to improve film flexibility and film formation from latex systems. 
Although HPMCP can be applied to substrates without plasticizer from neutralized solutions, the 
addition of plasticizer will reduce film cracking and thus improve resistance. Effective plasticizers 
include: TEC, diacetin, triacetin, diethyl and dibuthyl phthalate, castor oil, acetyl monoglyceride 
and PEGs. The addition of 30 % plasticizer was found to be sufficient for the formation of a 
continuous HPMCP film pseudolatex dispersions and TEC was determined to be a more efficient 
52 
 
plasticizer than DEP. For coating of HPMCP from neutralized aqueous solutions, TEC concentration 
from 2.5 to 5 % w/w have been reported to be sufficient [62]. 
HPMCAS, or hypromellose acetate succinate as it is known in the USP/NF, is derived from HPMC 
by the esterification of free hydroxyl groups on the polymer backbone with acetic anhydride and 
succinic anhydride. HPMCAS was marketed as AQOAT®, a re-dispersible powder form of the 
polymer. HPMCAS is insoluble in acidic media, yet soluble in neutral pH according to the percent 
of acetyl and succinoyl substitution. These three grades are available in both granular and 
micronized powder form. The onset of aqueous solubility of HPMCAS is in a pH range of 5.5 – 6.8 
according to the polymer grade where determining solubility factor is the succinoyl to acetyl group 
substitution.  
The Tg of HPMCAS lies in the range of 120°C – 135°C according to the polymer grade. Since 
HPMCAS is a relatively rigid polymer, plasticization is utilized to improve film flexibility and reduce 
cracking as well as to promote film formation from HPMCAS aqueous dispersion. TEC, triacetin and 
propylene carbonate formed clear, continuous films from HPMCAS dispersion at concentrations in 
the range of 30%  – 50% by weight of HPMCAS [62]. 
The mechanism of film formation in aqueous latex systems has been suggested by several 
researchers. The particles get closer during the drying process and the capillary force makes the 
particles eventually coalesce with each other. It is considered that this theory can be applied for 
the film formation of HPMCAS, but due to its larger particle size compared with other latex 
emulsions, the mechanism can be slightly different [64]. 
A suggested theory of film formation from the aqueous dispersion of HPMCAS is that the 
plasticizer is separated from the water phase during the drying process and it dissolves or gelates 
the particles of HPMCAS. The particles then fuse to each other to form a film. At the beginning of 
drying, particles dispersed in water are observed. As the water evaporates, the particles are pulled 
together and an increase in temperature causes TEC to separate from water. Separated TEC can be 
seen surrounding aggregates of particles. At the end of drying, TEC fuses the polymer and film 
formation is completed [64]. 
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4.3.1.2. (Meth)acrylic acid Copolymers 
(Meth)acrylic acid copolymers are widely used for enteric coating application. There are four 
types of Eudragit® polymers with enteric release capabilities: Eudragit® L 100 – 55 (also marketed 
as Kollicoat MAE 100P), Eudragit® L 100, Eudragit® S 100 and Eudragit® FS 30 D.  
Eudragit® L 100 – 55, or (meth)acrylic acid copolymer type C USP/NF, is an anionic copolymer of 
(meth)acrylic acid and ethyl acrylate having an average molecular weight of approximately 
250.000 Da. The ratio of free carboxyl groups to ester groups is approximately 1:1. The molecular 
structure of Eudragit® L 100 – 55, most importantly the functional group ratio, gives the polymer 
its characteristic pH dependent aqueous solubility profile. The onset of dissolution begins at or 
above pH 5.5 according to the ionization of free carboxyl groups. 
The Tg of Eudragit® L 100 – 55 has been reported to be in the range of 123°C – 129 °C and thus, 
films formed from this polymer require plasticizer to facilitate film formation and to improve the 
mechanical properties of films. With the addition of 10 – 20 % plasticizer, the MFFT of Eudragit® L 
100 – 55 is reduced to about 15°C. TEC is a commonly used plasticizer for Eudragit® L 100 – 55. 
Triacetin and low molecular weight PEGs have also been successfully utilized.  
Eudragit® L 100 – 55, the spray dried form of the coating material, can be easily re-dispersed in 
water to solids contents of 30 – 40 % with the addition of 3 – 5 % of a neutralizing agent such as an 
alkali or organic base. The addition of a neutralizing agent increases the dispersion pH, ideally to a 
pH of about 5, which improves the wetting of latex particles and facilitates the dispersion of 
agglomerates as primary particles in aqueous medium.  
Acryl–Eze® MP, a product of Colorcon, is a complete pre – formulated enteric coating system 
based on (meth)acrylic acid copolymer Type C. Acryl–Eze® MP is a powder mixture of Eudragit® L 
100 – 55 along with neutralizing agents, plasticizers and pigments that is easily redispersed in 
water. This complete coating system eliminates several of the production steps required for the 
preparation of the coating dispersion and thus improves coating efficiency particularly for large 
scale production.  
Eudragit® L 30 D 55 is a polymeric dispersion in water which following the addition of plasticizer, 
other functional additives, and dilution with deionized water is readily for spray application to 
substrate [62]. To achieve more flexible films for coating of particles, EUDRAGIT® L 30 D-55 can be 
mixed with flexible polymers such as EUDRAGIT® NE 30 D or FS 30 D [10]. 
Eudragit® L 100 and Eudragit® S 100 are (meth)acrylic acid copolymer Types A and B, as they are 
respectively titled in USP/NF, are anionic copolymers of (meth)acrylic acid and methyl 
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(meth)acrylate having an average molecular weight of approximately 135.000 Da. The ratio 
(meth)acrylic acid to methyl (meth)acrylate units is approximately 1:1 for Eudragit® L 100 and 1:2 
for Eudragit® S 100. Thus, Eudragit® L 100 has a greater concentration of free carboxyl groups on 
the polymer backbone than Eudragit® S 100. Consequently, the dissolution of Eudragit® L 100 
begins at about pH 6.0 while Eudragit® S 100 begins to dissolve at pH 7. Both polymers provide 
enteric protection to coated substrates: however, with Eudragit® S 100 the onset of drug release is 
further delayed and will occur in the more distil regions of the intestinal tract as compared to 
Eudragit® L 100.  
The Tg of Eudragit® L 100 and Eudragit® S 100 have been reported to be about 160°C and the 
MFFT has been reported to be 85°C. Thus, continuous film formation is problematic at typical 
coating conditions and resulting films are brittle. Therefore, relatively large amounts of plasticizers 
(40 – 50 % based on dry polymer weight) are required to achieve complete film formation and to 
improve film flexibility. Plasticizers such as triacetin, poloxamer and TEC at a concentration of 
about 50% have been demonstrated to produce film coats with sufficient gastric resistance. 
Eudragit® FS 30 D is a 30 % (w/w) aqueous dispersion of a copolymer produced by the 
polymerization of (meth)acrylic, methyl acrylate and methyl (meth)acrylate monomers. The free 
carboxyl to ester group ratio of this polymer is approximately 1:10 and thus this polymer is less 
soluble than the previously discussed Eudragit®. The onset of dissolution for Eudragit® FS 30 D 
with increasing pH occurs above pH 7 [62]. 
 
Table 9: Chemical names and compendial compliance of poly(meth)acrylates used for delayed release 
coatings [10]. 
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4.3.1.3. Polyvinyl acetate phthalate 
Polyvinyl acetate phthalate (PVAP) is the reaction product of phthalic anhydride and partially 
hydrolyzed polyvinyl acetate (PVAc) that contains less than 55.0 % and no more than 62.0 % 
phthalyl groups. The onset of aqueous dissolution of PVAP begins at a pH of about 5.0 allowing for 
enteric release as well as the potential for targeted drug release to the proximal intestine.  
Although the Tg of PVAP is relatively low, plasticizers are typically incorporated for film coating 
applications to facilitate film formation and to reduce splitting or cracking. PVAP is compatible 
with several of the most common plasticizers: glyceril triacetate, TEC, acetyl triethyl citrate, DEP 
and PEG 400. Sureteric® is a complete pre formulated coating system consisting of a powder blend 
of PVAP, plasticizers and other functional ingredients intended for reconstitution in water for rapid 
coating dispersion production [62]. 
 
4.3.2. Film coating for sustained release 
The overall goal in designing sustained release oral dosage form is to provide systemic drug 
concentrations that remain within the therapeutic concentration range for a prolonged time 
period. The primary benefit of sustained release dosage forms is the reduction of the daily regime 
for drug therapies requiring several daily doses. In many cases sustained release delivery systems 
can reduce dosing to a twice or once–daily schedule. By reducing the number of required daily 
dose, the convenience of the drug therapy is improved resulting in better patient compliance and 
often reduced cost. Additionally, a well–designed sustained release dosage form can stabilize 
systemic drug concentrations by providing a constant rate of drug release (and absorption), as 
opposed to the peaks and valleys of systemic drug levels seen with multi–dosing [65 - 67].  
Sustained release polymeric film coating is based upon a generic reservoir device design in which 
the release of the active from a concentrated core is controlled by an encompassing semi–
permeable membrane. The membrane controls the rate of water permeation into the drug core, 
thereby controlling the dissolution and subsequent outward diffusion of the active agent. The 
semi– permeable membrane, in almost all modern oral sustained release coating formulations, is 
primarily composed of a polymer which is insoluble in water over the entire range of 
gastrointestinal tract. Therefore, insoluble cellulose derivatives, insoluble poly(meth)acrylates, as 
well as polyvinyl acetate are the most commonly used polymer for sustained release film coating 
owing to their water–insolubility [62].  
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Membrane permeability is a function of thickness, porosity, tortuosity and composition. 
Therefore, film formation is a substantial determinant of drug release rate through a sustained 
release film coat. Drug release through an insoluble polymeric membrane produced from a latex 
dispersion will decrease with the evolution of film formation owing to decreasing porosity and 
increasing tortuosity of the polymer film. Therefore, a sustained drug release profile that is stable 
with time depends almost entirely on the formation of a complete polymeric film and the static 
nature of that film over time and under various storage conditions. The utilization of appropriate 
plasticizers as well post–treatment of coated substrates is essential to complete and stabilize film 
formation with sustained release polymers. 
4.3.2.1. Ethylcellulose 
Ethylcellulose is one of the most commonly used polymers for sustained release film coating. The 
polymer is insoluble, but permeable in water over the range of gastro-intestinal pH, and thus can 
be utilized to produce semi–permeable membranes that control the rate of drug release from 
coated substrates. Ethylcellulose contains not less than 44.0 % and not more than 51.0 % ethoxy 
groups as calculated based on dry polymer weight. Bulk ethylcellulose is produce by the Dow 
Chemical Company with a Standard ethoxy content of 48.0 – 49.5 %. Ethylcellulose is available in a 
variety molecular weights corresponding to 5% solution viscosities of 3 – 385 cPs [68]. 
Ethylcellulose is soluble in alcohols, chlorinated solvents and natural oils. Therefore, solvent 
coating with ethylcellulose is commonly conducted from ethanolic solutions, while pseudolatex 
system must be used for aqueous film coating [62]. 
Modified-release tablet formulations may also be produced using ethylcellulose as a matrix 
former. Ethylcellulose, dissolved in an organic solvent or solvent mixture, can be used on its own 
to produce water-insoluble films. Higher-viscosity ethylcellulose grades tend to produce stronger 
and more durable films. Ethylcellulose films may be modified to alter their solubility by the 
addition of hypromellose or a plasticizer. Thus, ethylcellulose is compatible with the following 
plasticizers: dibutyl phthalate; diethyl phthalate; dibutyl sebacate; triethyl citrate; tributyl citrate; 
acetylated monoglyceride; acetyl tributyl citrate; triacetin; dimethyl phthalate; benzyl benzoate; 
butyl and glycol esters of fatty acids; refined mineral oils; oleic acid; stearic acid; ethyl alcohol; 
stearyl alcohol; castor oil; corn oil and camphor [68]. 
Although coating with organic polymer solutions is still widespread, aqueous ethylcellulose 
dispersions have been developed to overcome problems associated with organic solvents. 
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Two aqueous ethylcellulose pseudolatexes dispersions are commercially available: Aquacoat® 
manufactured by FMC Biopolymer (Philadelphia, PA, U.S.A.) and Surelease® by Colorcon (West 
Point, PA, U.S.A.) [69]. 
Aquacoat® ECD is produced by an emulsification/solvent evaporation process that utilizes 
sodium lauryl sulfate and cetyl alcohol as colloid stabilizers [62;70]. The Aquacoat® ECD dispersion 
contains approximately 27 % ethylcellulose and 30 % total solids. The dispersion does not contain 
plasticizer and therefore an appropriate plasticizer must be added to the dispersion prior to 
coating. The dispersion is typically diluted to a final solids content in the range of 15 – 20 % w/w 
prior to spray coating. Although, intended to be a pH – independent sustained release coating 
system, the content of sodium lauryl sulfate in the Aquacoat® ECD dispersion has been 
demonstrated to cause reduced drug release rates in acidic media versus media of neutral pH [30; 
62; 71]. 
Surelease® is produced by first melt extruding ethylcellulose with oleic acid and dibutyl sebacate 
(DBS) (or fractioned coconut oil) to form a molten plasticized polymeric blend. This molten blend 
of plasticized ethylcellulose is then introduced into an ammoniated water solution under high 
shear and pressure to disperse small droplets of plasticized ethylcellulose into the water phase. 
Ammonium oleate is produced in situ during this emulsification process to stabilize the colloidal 
ethylcellulose particles. Additional purified water is the added to reduce the final solids content of 
the pseudolatex dispersion to 25 % [30; 72]. Surelease® is supplied as a 25% (w/w) solids 
dispersion, which is recommended to be diluted with water to 15% (w/w) solids before use. 
Before dilution, the container of Surelease is required to be agitated to ensure homogenization of 
solids in the dispersion. Then the dispersion is diluted by adding two parts of purified water to 
three parts of Surelease and stirred with a low shear mixer for approximately 15 min. It is 
advisable to continue gentle agitation throughout the coating process to prevent potential 
sedimentation of solid particles [73]. 
The compositions of various types of Surelease® are summarized in Table 10. The Surelease® 
coating system does not contain an ionic surfactant and therefore does not exhibit the pH 
dependent drug release observed with Aquacoat® ECD [30; 62].  
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Table 10: Composition of Surelease Product Range (Surelease®-E-7-x) [73]. 
 
Surelease® is applied onto drug layered nonpareils, extruded spheres, granules, drug crystals and 
mini-tablets preferably using fluid-bed coating technology. Top spray coating may be used for 
small particulates such as drug crystals; however, a Würster process (bottom spray) is generally 
recommended. Drug release from Surelease® coated multiparticulates is mainly controller by the 
coating film thickness (theoretical weight gain) [73].  
The Tg of bulk ethylcellulose is in the range of 129°C – 133°C and therefore, at ambient 
conditions films of ethylcellulose are substantially brittle. To be used in film coating applications, 
ethylcellulose requires the addition of plasticizer to improve film flexibility and toughness. The Tg 
of dried latex particles of Aquacoat ECD has been reported to be 89°C [62; 74]. The reduced Tg of 
ethylcellulose dried from a pseudolatex is the result of the temporary plasticizing effects of water. 
Although the Tg of ethylcellulose pseudolatex particles is less than that of bulk ethylcellulose, 
additional plasticizer is required to reduce the internal stress of latex particles and facilitates their 
coalescence during film formation [62; 74]. In order to maximize coalescence and prevent spray 
drying, a product bed temperature range of 40 to 42°C is recommended, keeping the atomization 
pressure around 1.5 to 2 bars. Some typical process conditions established with Glatt fluid bed 
coating machines are shown in Table 11 [73]. 
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Table 11: Typical Process Parameters Used for Application of Surelease® to Drug- Layered Pellets for 
Bottom Spray Würster Systems [73]. 
 
 
The majority of extended release (ER) barrier membrane coating systems require a thermal post 
coating treatment (curing) in order to achieve reproducible and storage-stable drug release 
characteristics. For example, FMC literature recommends that multiparticulates coated with 
Aquacoat® ECD are incubated in a tray dryer at 60°C for two hours post coating to promote 
complete coalescence of polymer particles in the film [73]. Surelease® family products are 
optimally plasticized systems and, as a consequence of plasticization of the polymer during 
manufacture, generally Surelease® films do not require a curing step. However, it is advisable to 
test for the occurrence of incomplete polymer coalescence during coating by placing the 
Surelease® - coated products at 50°C to 60°C for 2, 12, 24 hours and comparing the release 
profiles from these units with “uncured” beads. A curing effect may be noted if the elevated 
temperature incubation results in a decrease in the rate of drug release. The need for a curing step 
may be eliminated through optimization of the coating process [73]. 
 
4.3.2.2. Poly(meth)acrylates 
Poly(meth)acrylate latex coating systems are also used for sustained release film coating. The 
different grades include Eudragit® RL 100, Eudragit ® RS 100 and Eudragit ® NE 30 D. The Eudragit® 
RL 100 and RS 100 are available as a fine powder (PO), granules, 12.5 % w/w organic solution and 
as a 30% (w/w) aqueous colloidal dispersion. These system are composed of polymers that are 
water insoluble, but swallable over the range of physiological pH and thus, are idea for sustained 
release film coating application.  
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Eudragit® RL 100 and RS 100, also known as ammonio (meth)acrylate copolymers Types A and B 
USP/NF, respectively are produced by radical copolymerization of ethyl acrylate, metyl 
(meth)acrylate and trimethyl ammonioethyl (meth)acrylate chloride in a 1:2:0.2 ratio (RL 100) and 
1:2:0.1 (RS 100). In aqueous media, the quaternary ammonium groups on the Eudragit® RL 100, 
and RS 100polymers become ionized causing films to swell by ionic repulsion resulting in 
controlled permeation of the surrounding medium. Eudragit® RL 100 has a greater concentration 
of ammonio (meth)acrylate pendant groups and hence, films produced from this polymer are 
substantially more permeable than films produced from Eudragit® RS 100. Blending of these two 
polymers is a common method to achieve intermediate sustained drug release rates [62]. 
Insoluble ionic poly(meth)acrylates EUDRAGIT® RL (highly permeable) and EUDRAGIT® RS 
(slightly permeable) can be mixed in any ratio in either organic or aqueous form to obtain specific 
release patterns [10]. EUDRAGIT® RL contains more quaternary ammonium groups, is more 
hydrophilic and shows a higher permeability. This means that an increased amount of EUDRAGIT® 
RL accelerates the drug release [75]. In addition to the ratio of the polymers, the thickness of the 
film also controls the release profile. Since the polymer with higher permeability dominates the 
release characteristics, amounts of 5 – 10% w/w are recommended for the blends [10]. In 
extended-release formulations, the amount of EUDRAGIT® RS polymer is usually much higher, 
since the EUDRAGIT® RL properties are dominant. A good starting point for new developments is 
10 % w/w EUDRAGIT® RL, which can then be adapted based on the solubility of the drug and the 
targeted release profile [10]. The MFFTs of Eudragit® RL 100 and RS 100 polymers range between 
40°C and 50°C and thus, plasticizer is required to form continuous films at typical coating and 
curing temperatures [62].  
Due to environmental, safety and cost considerations, pharmaceutical manufacturing has been 
moving from organic to aqueous coating systems [10]. Re-dispersed aqueous dispersions of 
EUDRAGIT® L 100-55, L 100 and S 100 necessitate much higher plasticizer amounts (50–70% w/w 
on dry polymer substance) compared to respective organic coatings where no plasticizer is 
necessary. These higher plasticizer volumes lead to faster dissolution speed in the buffer media 
[76]. With polymers such as EUDRAGIT® RL, EUDRAGIT® RS or EUDRAGIT® E, organic coating 
formulations can be easily replaced by an aqueous system. 
All poly(meth)acrylates are available in both systems, except for EUDRAGIT® FS 30D, EUDRAGIT® 
NE 30D and EUDRAGIT® NM 30D, which are only available as aqueous dispersions. In some cases, 
replacing organic with aqueous systems requires formulation adaptions to create bioequivalent 
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release profiles. The difference between the two systems lies in film density and variances in 
formulation excipients and volumes [10].  
Eudragit® NE 30D is a poly (meth)acrylate based coating system used for sustained release film 
coating. Eudragit® NE 30D is a latex dispersion of a neutral polymer produced by emulsion 
polymerization of ethyl acrylate and methyl (meth)acrylate. The ratio of ethyl acrylate to methyl 
(meth)acrylate on the polymer chain is 2:1 and the average molecular weight of the polymer is 
800.000 Da [62]. Eudragit® NE 30D is similar to Eudragit® RL 100 and RS 100 polymers in that it is 
insoluble in aqueous media over the entire range of physiological pH, but is swellable independent 
of media pH. Therefore, Eudragit® NE 30D is used in film coating application as a drug release rate 
– controlling membrane to sustained release of active over the entire length of the 
gastrointestinal tract. With respect to permeability, the Eudragit® NE 30D films are moderately 
permeable producing drug release rates between that of Eudragit® RL 100 and RS 100. The MFFT 
of Eudragit® NE 30D is 5°C and therefore plasticization is not required for formation of continuous 
flexible films [62]. Films produced from this latex dispersion undergo further gradual coalescence. 
Therefore, substrates coated with Eudragit® NE 30D should be treated following the coating 
process to accelerate the formation of a stable film and ensure static drug release profile on 
storage [62]. 
With EUDRAGIT® NM 30 (permeable), all carboxylic groups are esterified so that they have no 
reactive functional groups. Thus, drug release is mainly controlled by the coating thickness. 
Depending on drug solubility, 5 – 20 % of dry polymer substance based on tablet weight is usually 
sufficient to control drug dissolution and release over a period of 6–8 h [10]. 
 
4.3.2.3. Polyvinyl acetate 
Kollicoat® SR 30 D is a sustained release coating dispersion based on PVAc. Kollicoat® SR 30D is a 
30 % (w/w) dispersion of PVAc in water stabilized by povidone (2.7 %) and sodium lauryl sulfate 
(0.3 %) prepared by an emulsification polymerization method [62]. PVAc is insoluble in aqueous 
media and therefore provides sustained release of active agents from coated substrates by 
controlling the rate of media diffusion through the film [62]. Coating levels of Kollicoat® SR 30D 
between 1 and 5 mg/cm2 were sufficient for extended release coatings of multiple unit dosage 
forms depending on the solubility of the active and the targeted release rate. Coatings below 1 
mg/cm2 (approximately thickness10 µm) will result in incomplete coverage of the surface [77]. 
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Kollicoat® SR dispersion has a MFFT of 18°C and therefore can be utilized for film coating without 
the need for plasticization or curing; however plasticization will enhance film formation and 
flexibility. Recommended plasticizer concentration is in the range of 0 -10 % based on the dry 
PVAc weight. TEC has been shown to be an efficient plasticizer reducing the MFFT to 1° C at a 
concentration of 10 %. As a result of the low MFFT, sticking commonly occurs with substrates 
coated with Kollicoat® SR and therefore, anti – tacking agents such as talc should be added to the 
coating dispersion or the coated substrates should be mixed with colloidal silica after coating [62].  
 
 
5. COATING OF PELLETS 
5.1. Multiple-Unit Dosage Forms: The Rationale 
MUPs (Multiple-Unit Particulate Systems) are modified release preparations which consist of a 
number of discrete units (pellets) combined into one dosage form (capsule or disintegrating 
tablet). In pharmaceutical industry, pellets can be defined as small, free-flowing, spherical or semi-
spherical solid units with a narrow size distribution (typically ranging from 0.5 to 1.5 mm) 
manufactured by the agglomeration of fine powders or granules of drug substances and excipients 
using appropriate processing equipments. 
Pellets have numerous therapeutic advantages over traditional single units, such as tablets and 
powder-filled capsules. Indeed, pellets can be divided into desired dose strengths without 
formulation or process changes and can also be blended to deliver incompatible bioactive agents 
simultaneously or particles with different release profiles at the same site or at different sites 
within the GIT. 
When pellets are orally administrated, they disperse freely in the GIT and exhibit a more 
predictable and reproducible gastrointestinal transit reflected in a lower inter and intra subjects 
variability, minimize local irritation of the mucosa by certain irritant APIs because of the small 
quantity of drug available in a single units, reduce the risk of dose dumping, empty gradually from 
the stomach regardless of the feeding state and improve flexibility of dose release performances 
[78].  
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5.2. Manufacturing Techniques 
Pelletization techniques are mainly based on direct pelletization (production of matrix pellets in 
which drug and excipients undergo to direct pelletization) or pelletization by layering. Layering 
processes are probably the most well-controlled and straightforward pelletization techniques that 
have been used over the years. They are classified into three categories: solution layering, 
suspension layering and powder layering. Table 12 summarizes the characteristics of the different 
layering methods. 
Table 12: Different layering methods. 
solution/suspension layering powder layering 
easier to develop (as a spray coating 
process) 
faster process; lower cost 
traditional coating equipments 
pelletization equipment should have 
powder feeder 
formulation of drug solution/dispersion 
formulation of binder solution and of dry 
powder of drug and/or excipients 
higher process temperatures to permit 
solvent removal 
lower process temperatures; suitable for 
thermo labile APIs; lower solvent amount 
applied 
drug compatibility with selected solvent 
more suitable for high drug load; no dilution 
factor 
smooth surface (suitable for further 
polymeric/drug coating) 
a seal coat is suggested/necessary to reduce 
the roughness surface 
 
5.2.1. Pellets by solution/suspension layering 
Solution and suspension layering involve the deposition of successive layers of solutions or 
suspensions of drug substances, respectively, on non-pareil seeds (starter cores) which may be 
inert materials or crystals or granules of the same drug.  
Conventional coating-pans, fluid-bed centrifugal granulators and Wurster coaters could be used 
to manufacture pellets by solution or suspension layering. Indeed, during solution or suspension 
layering, all the components of the formulation are dissolved or suspended in the application 
medium and hence determine solids content and viscosity of the liquid sprayed. As the solution or 
suspension is sprayed onto the product bed, the droplets impinge on starter seeds and spread on 
their surface. This is followed by a drying phase which allow dissolved materials to crystallize and 
form solid bridges between the core and initial layer of the drug substance as well as among the 
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successive layers of drug substances. The process continues until the desired layers of API and 
hence the potency of pellets are achieved. The rate of particle growth is rather slow due to the 
incremental addition of the dissolved or suspended drug. In this process, thought the amount of 
seeds inside the product chamber remains the same, the size of pellets increases as a function of 
time and, as a result, the total mass of the entire system increases.  
 
5.2.2. Pellets by powder layering 
Powder layering involves the deposition of successive layers of dry powder drug and/or 
excipients on preformed nuclei or cores with the help of a binding liquid. During powder layering, 
a binding solution and a finely milled powder are simultaneously added, at a controlled rate, to a 
bed of starter seeds. In the initial stages, the drug particles are bound to the starter inert seeds 
and subsequently to the forming pellets with the help of liquid bridges originated from the 
sprayed binding liquid. These liquid bridges are replaced by solid bridges derived either from a 
binder in the application medium or from any other substance, including the API, that is soluble in 
the binding liquid. Successive layering of drug and binder solution continues until the desired 
pellet size is reached. Throughout the process, it is extremely important to deliver the powder at a 
predetermined rate and in a manner that maintains an equilibrium between the binder liquid 
application rate and the powder delivery rate.  
If the powder delivery rate is not maintained at predetermined levels, over wetting or dust 
generation occurs and neither the quality nor the yield of the product can be maximized. 
6. ADVANCES IN FILM COATING 
Although film coating is fairly well-controlled and widespread in pharmaceutical production 
processes, comprehensive studies, including Quality-by-Design (QbD) and troubleshooting 
investigations, are necessary to cope with the numerous issues that arise during formulations 
developments. Furthermore, according to the latest FDA guidance (ICH Q8) on Process Analytical 
Technologies (PAT) [80], the most appropriate approach for optimizing pharmaceutical production 
involves process understanding.  
Recent development of analytical techniques to monitor the coating process of pharmaceutical 
solid dosage forms such as pellets and tablets are described in literature [6]. The progress from 
off- or at-line measurements to on- or in-line applications is shown for the spectroscopic methods 
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near infrared (NIR) and Raman spectroscopy as well as for terahertz pulsed imaging (TPI) and 
image analysis.  
The common goal of all these methods is to control or at least to monitor the coating process 
and/or to estimate the coating endpoint through timely measurements. Beside the average 
coating thickness of the dosage form, other process and quality parameters have to be monitored 
during a coating process: the coating has to be homogeneously distributed over the surfaces of all 
particles. Intra- and inter-tablet/pellet variations should be as small as possible. Film formation 
from aqueous dispersion or aqueous or organic solutions/suspensions has to be complete. A high 
coating quality regarding surface roughness and homogeneous distribution of pigments and dyes 
can be required. Holes and cracks in the film have to be avoided. Sticking and adhesion between 
the particles and to the container walls have to be minimized. Over-wetting has to be avoided and 
the moisture of the particles has to be monitored at the end of the coating during the drying 
phase. 
The spectroscopic methods NIR [81 - 83] and Raman spectroscopy [84 - 87] seem to be the most 
advanced techniques for the control of the coating process of solid dosage forms. In-line 
measurements in industrial scale pan coaters were successfully applied for both methods to 
monitor the coating thickness on tablets. NIR has the additional advantage to allow the 
simultaneous estimation of the moisture content of the tablets. The determination of the coating 
end point in an industrial process should be possible with these spectroscopic methods. Their 
measuring principle leads to average values of a number of tablets; single tablet in-line 
measurements are not described in literature to date and, thus, coating uniformity could not be 
investigated. A disadvantage is the need to use multivariate data analysis with data pre-treatment 
and construction of PLS models in most cases.  
Terahertz pulsed imaging could be shown to be able to estimate the thickness of individual 
tablets in-line in a drum coater in a proof of concept investigation. This could be used to calculate 
the coating uniformity of a batch. No chemometric calibration model is required, but the 
knowledge of the refraction index is needed [88; 89].  
Image analysis with fast visual digital imaging systems is a promising tool for the on-line 
measurement of size and shape of pellets and therefore for the estimation of coating thickness. 
However, the technique seems to be limited to spherical dosage forms like pellets and the pellets 
have to be diverted from the process for measuring and returned later [90 - 92].  
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7. DRY POWDER COATING 
Dry powder coating is a technique with no need of any solvents or dispersion media. The film 
forming polymer is applied in powdered form to the cores consisting of the active enabling  very 
short process time compared to conventional coating process [93]. Dry powder coating can be 
performed using different technological approaches which include liquid assisted, or thermal 
adhesion or electrostatic coating [94]. 
The thermal adhesion (melt coating) process requires the application of low melting point 
materials and is performed in a fluid bed coater with the aid of heating systems for atomized air to 
provide a molten spray plume. Unlike conventional fluid bed coating which uses heated gas to 
remove solvent, inlet air will enter the system for melt coating at a reduced temperature to 
solidify the molten coating on the substrate. Implementing a similar strategy, liquid assisted 
layering strategies rely on interfacial capillary action of liquid formulation components to aid in 
the adhesion of the coating layer onto the substrate. In this technology, the liquid additive can be 
partially mixed into the feedstock or added as a separate feed stream into the processing zone. 
Based on the process similarity with conventional strategies, existing equipment, specifically fluid 
beds, can easily be modified to support production, although formulations of this type will 
typically require higher levels of plasticizer or tackifying agent. Thus, the choice of excipients will 
be governed by thermal properties of the coating materials to provide sufficient softening at 
moderate temperatures while still providing suitable mechanical properties at room temperature. 
Adhesion, plastic deformation and consolidation will all be critical points to consider during 
formulation design. Longer processing times and additional post processing curing steps may also 
be required.  
Electrostatic modalities differ from the other forms of dry powder coating both in terms of 
excipients as well as manufacturing equipment. For successful coating, the material must be 
conductive to allow for charge differential formation while exhibiting desired film forming 
characteristics. Electrostatic coating equipment creates specific charge fields allowing for the 
coating of complex designs that cannot be achieved with traditional systems.  
 
7.1. Film Formation Mechanisms in Dry Powder Coating 
From a mechanistic perspective, dry powder coating processes consist of the same sequence of 
steps that are employed with conventional solvent based coatings (paragraphs 3.1 and 3.2 ). In all 
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cases, the process begins with the pre-treatment of the coating material. This is followed by the 
application of coating material to the substrate, relying on the adhesive nature of the formulation 
to maintain uniformity of coating during the film formation process. Film formation occurs by a 
process of evaporation, coalescence and sintering which are influenced by process and 
formulation considerations. Pre-treatment of the coating material varies greatly based on the type 
of coating process utilized. For dry powder coating applications, careful consideration of material 
particle size will be essential to ensure appropriate uniformity for the coating. It is generally 
recommended that coating material diameter be less than 1% the size of the coating substrate. 
This allows for acceptable uniformity of the material on the substrate surface, improving adhesion, 
appearance and processing times. During the dry powder coating process, the substrates are often 
heated above the glass transition temperature of the layering materials so that the coating 
materials soften and adhere to the substrate. For conventional film coating, spreading and 
adherence is well defined based on surface free energies and capillary forces where mobility is not 
a limiting interaction. However, powder systems may become limited by mobility, particularly 
when liquid levels are reduced to the point where solid particle deformation becomes rate 
limiting. This introduces a series of constraints related to mechanical and thermal properties of the 
coating formulation. Coalescence and film formation, which are highly dependent on capillary 
forces in conventional coating systems, will also be dependent on these properties. As such, glass 
transition temperature and plastic deformation characteristics of the coating materials are 
paramount to the success of the process and if materials are deficient in these properties then it 
may be necessary to engineer the formulations with the desired characteristics.  
Many pharmaceutical coating materials are amorphous polymers, exhibiting a glass transition 
temperature related to the change from a glass to a super cooled liquid. On transition, which 
occurs at a specific temperature, mobility of the system increases significantly. The greater 
mobility allows for molecular rearrangement and alters the plastic deformation characteristics of 
the materials. The addition of low glass transition materials to the overall composition is a 
common approach in many dry powder coating formulations to improve coalescence and adhesive 
properties. When processing above the glass transition temperature of a coating material, the 
surface is more “liquid-like” and more susceptible to plastic deformation. Depending on the 
difference between glass transition temperature and processing temperature, the viscosity of the 
coating material can be reduced sufficiently to result in the formation of capillary forces which aid 
68 
 
in the adherence of the powder to the surface. Under such conditions, surface energy differentials 
can aid in the spreading of the semi-molten polymer to enhance coating efficiency.  
Dry powder coating applications also rely on mechanical compaction that occurs naturally during 
the process to facilitate adhesion and coalescence. During this process stresses on the coating 
layer result in consolidation of the bed and deformation driven spreading across the interface. For 
elastic materials, the deformation of the material is reversible, leading to poor contact across the 
surface. When coatings exhibit plastic behaviour, the deformation is irreversible and the 
mechanical compaction leads to greater adhesion of the surface layer due to a larger surface area 
for contact between substrate and coating, as well as possible mechanical interlocking of the 
materials.  
Adhesion and spreading behaviour can also be modified through the application of a sub-coat to 
the substrate. To further promote adhesion with the coating layer, the sub coat can actually be 
intentionally selected to be partially molten at the processing temperatures. The molten priming 
layer promotes the adhesion of the powder coating particles by forming liquid bridges with the 
core surface. Since the spreading of the priming layer on the surface of the coating cores is crucial, 
the best sub coating material is selected by measuring the contact angle with water of the core 
surface and those of the primer and of the polymeric material to be layered [94 - 96]. 
 
Figure 10: Schematic representation of film formation in dry powder coating systems [94]. 
 
 
The mechanism of film formation of the powders layered onto the solid cores is schematized in 
Figure 10 and consist of 3 steps: 
(i) coalescence and sintering of the particles of the polymeric materials in a process that 
involves the partial fusion of the polymer; 
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(ii) levelling of the coating material includes densification of the layer with reduction of the 
empty spaces and smoothing of the surface; 
(iii) cooling of the layer and hardening of the coating. 
In conventional coating applications, coalescence is driven by the presence and subsequent 
removal of solvent which creates capillary forces inside the film and lowers the glass transition 
temperature of the polymer. The mechanism for coalescence of dry powder coated films is similar, 
although much more reliant on non-solvent forces to achieve a uniform film.  
 
࢚ =  ࢑ ·ஜ·ࡾ
ࢽ
           Eq. 3 
 
According to equation 3 the time (t) required for two powder particles to coalesce is directly 
related to the viscosity of the powder coating (µ), the radius of the particles R and the surface 
tension of the coating (γ) where k is a constant describing the process [97]. From this equation, it 
is clear that it could maintain low polymer viscosity to promote distribution of the material over 
the surface of the solid in order to yield an acceptable film. For thermoplastic powders, this will 
depend on the molecular weight of the polymers and on the curing temperature. Unlike many 
solvent-based systems, curing of dry powder coated products is nearly ubiquitous for both 
immediate release and controlled release systems to achieve a visually and functionally acceptable 
layer.  
In order to reduce the processing temperature of the powder coating and to shorten the curing 
phases, polymers which show excessively high Tg (> 60°C) are combined with plasticizers able to 
decrease the Tg of the coating powders [95; 96; 98]. Specific amounts of liquid or solid plasticizers 
can be added to the polymeric materials via physical mixture, concurrent addition during 
production or by the preparation of a solid dispersion coating formulation containing plasticizer 
prior to the coating operation. The nature of plasticizer addition will ultimately contribute to the 
type of coating process selected. Each of these approaches provides unique advantages and 
disadvantages, as summarized in Table 13. 
Alternatively, a polymeric solution containing the plasticizer can be spray dried so that a fine pre-
plasticized polymeric powder can be obtained [99]. In general, powders having a particle size 
below 100 µm (dV50) have been demonstrated to be suitable for powder coating. Further 
consideration of the coating to substrate particle size ratio is necessary to ensure appropriate 
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adhesion and visual appearance. Examining the dry powder coating process as a whole, one notes 
a strong dependence on coating and substrate properties, as well as the interaction between the 
interfaces formed during the process. Successful implementation of dry powder coating 
technologies requires engineering of the product and process to carefully achieve the desired 
material attributes of the finished product. 
 
Table 13: Comparison of pre-processing techniques for dry powder coating [94]. 
 
 
7.1.1. Liquid assisted coating 
While conventional coating technologies rely on large volumes of solvent to ensure adhesion and 
the formation of a uniform coating, liquid assisted technologies limit the amount of liquid within 
the formulation. Additionally, this approach will often use a liquid phase excipient intended to 
remain in the drug product which will serve as an adhesive aid while providing some functionality 
for film formation. Since this approach is mechanistically different than conventional film coating 
technologies, theoretical aspects as well as technological considerations must be balanced to 
ensure success. 
The processes were performed using both a centrifugal granulator or fluidized bed for coating 
pellets and a perforated coating pan for coating tablets. A schematic illustration of each apparatus 
is shown in Figure 11. Since these apparatuses are normally employed for solid oral dosage form 
unit operations, slight modifications were necessary. In addition to the liquid atomizers already in-
place, these units were retro-fitted with powder feeders to support in-line addition of the dry 
powder coating. The dosing rate of the powders was monitored and controlled by loss-in-weight 
feeders, with feed streams entering directly into the processing chambers. During processing, 
differential air flows and gravitational forces, in combination with simultaneous addition of the 
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liquid plasticizer ensured adhesion of the powder to the substrate. Elevated temperatures within 
the processing chamber along with mechanical forces resulting from product bed movement 
further facilitated adhesion and film formation during the layering and curing processes.  
 
Figure 11: Schematic illustration of dry coating with: (a) centrifugal granulator [100]; (b1) top spray 
fluidized bed [100]; (b2) rotary fluidized bed [101] and (c) perforated pan tablet coating machine [100]. 
(a) 
 
 
(b1) (b2) 
 
(c) 
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7.1.2. Thermal adhesion 
Operating in the extreme of liquid assisted processes, where the adhesive liquid level is 
minimized, one generally observes a greater dependence on the thermal characteristics of the 
coating powder. In fact, it becomes possible to remove the liquid aid altogether to rely solely on 
thermal adhesion of the coating powder. Due to the complex nature of the thermal adhesion 
mechanism in combination with the requirements for manufacturability and drug product 
stability, these formulations must be engineered to a greater degree than the liquid assisted 
systems. When compared to liquid assisted dry powder coating, thermal adhesion methods have 
received less attention, although they too have traditionally relied on adaptation of existing 
manufacturing equipment to support production. Several of the most common adaptations have 
largely been centered around spheronizers and rotary fluid beds. For these processes, the 
substrate is maintained at a temperature that facilitates softening and spreading of the coating 
powder. This is further aided by mechanical forces of the process which work to compact powders 
on the surface of the substrate. It is also critical that the temperature is maintained below the 
critical threshold for agglomeration of the powder and drug product. Given the narrow operating 
window for processing, it is imperative to maintain a high accuracy of process control during 
manufacture. One technique extensively reported in the literature has been the adaptation of a 
spheronizer to the production of dry powder coated drug product [61; 95; 98]. This process 
involved only solid materials using a laboratory scale spheronizer (Model 120, G.B. Caleva; Dorset, 
UK) with a smooth stainless steel disc. Represented in Figure 12, the edges of the disk (1) were 
tilted at a 45°angle to facilitate the tumbling movement of the tablets and to prevent the loss of 
the coating powders. 
Figure 12: Schematic representation of the laboratory scale spheronizer used for the thermal coating 
process: (1) rotating disk; (2) infrared lamp; (3) powder feeder; (4)temperature probe; (5) coating cores; 
and (6) glass cover. 
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The heat necessary to perform the powder coating was generated by an infrared lamp (2) 
positioned 3 cm above the top of the spheronisation chamber (250 W Infrared Red Heat Bulb, 
General Electric, USA). The temperature of the coating chamber was controlled by adjusting the 
power of the lamp with a variable transformer (TYPE PF 1010, Staco, Inc., Dayton, OH, USA). The 
temperature of the coating bed (5) was constantly monitored with a digital thermo probe (4). The 
powders were distributed at a constant rate on the top of the rotating coating bed using a single 
screw powder feeder (3). To prevent the heat loss during the process the spheronizer chamber 
was closed by a glass cover (6) [61]. 
The temperature control was the most critical parameter during the powder coating. Due to the 
small scale of the equipment and to the low amount of cores involved, coating trials that 
employed forced hot air as the heating source were unsuccessful. With this technique poor quality 
coatings having reduced yields resulted. Curing of the powdered drug products  was performed in 
either the spheronizer or in a static oven on Teflon® plates. This application is of critical 
importance because most of the formulations used will not have sufficient time to coalesce. It is 
also theoretically possible to incorporate pressure cycles to the powder to mimic the effects of 
mechanical agitation in the bed [61].  
Dry powder coating formulations are engineered to provide the necessary thermal 
characteristics. Compositionally, this is achieved through the incorporation of polymer, plasticizer, 
opacifier, colorant and anti-sticking agent. Unlike traditional formulations, higher levels of 
plasticizers are required to ensure adhesion and film formation. A pre-plasticization process for 
the controlled release polymer ethyl-cellulose could be adapted.  
Anti-sticking agents are also a necessity in coating formulations to prevent adhesion during 
processing. Even though the amount of anti-sticking agent inside the powder coating formulation 
has never been extensively investigated, the presence of 10% of talc in the powder coating blends 
has been considered successful by researchers in the field for preventing the agglomeration of the 
powder particles during storage and during the distribution of the powders on the cores [61; 94].  
The colorants, together with opacifiers, are materials that are commonly used in all formulations 
intended for film coating for their esthetic contribution to the final product. The colours enhance 
the image of the product making it easier for market promotion and identification of the product 
both by the patient and during packaging operations. At the same time the use of dyes in the 
coating layer can help to improve the stability of the active ingredient by protecting it from light 
degradation. For aqueous film coating, water-insoluble colorants (pigments and lacquers) are 
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preferred over soluble dyes due to the fact that during the drying step the solvent tends to 
migrate to the surface bringing the soluble dye molecules with it. In the dry powder coating, since 
no liquids are involved and the process does not include a drying phase, no migration of the 
colorant is expected. The level of plasticizer becomes a critical aspect of successful formulation 
that strongly impacts performance [94]. 
7.1.3. Electrostatic coating 
Electrostatic powder coatings are commonly used in the metal finishing industry and involves the 
deposition of charged coating powder onto a grounded substrate [102]. While this technique has 
seen the lowest level of publication for any of the dry powder techniques, it has also been shown 
to be the most advanced in terms of commercial application. Application of the technology within 
the pharmaceutical industry has demonstrated that more intricate patterns can be formed on the 
coating for brand identification purposes while also providing comparable production outputs to 
larger commercial units. Requiring specialized equipment, Phoqus Pharmaceuticals, Ltd. 
developed an electrostatic powder coating process for tablets [103]. In this system they utilized a 
custom engineered coating apparatus to coat both sides of the tablet cores separately. Infrared 
radiation was applied for a short amount of time to facilitate film formation of Eudragit® RS 
coatings. The technology known as LeQtracoat® exploited the electro-static attraction between 
oppositely charged materials to promote the adhesion of the coating powders onto the surface of 
tablets (Figure 13). 
 
Figure 13: Schematic diagram of the electrostatic dry powder coating process [94]. 
 
 
With the same principle as the ink toner deposition in electro-photography (photocopying), the 
tablets were coated individually one side at a time in special manufacturing plants with capacity 
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up to 250,000 units/h. With this technique, the coating material was directed with such precision 
that 3D images could be created. Final curing leading to film formation could also be achieved 
within the same apparatus, allowing for similar performance to conventional coating operations.  
Qiao et al. developed a powder coating process that combined electrostatic powder coating 
technology with a traditional liquid pan coating technique for the powder coating of tablets [104]. 
The pan coater was equipped with a liquid spray nozzle (an electrostatic spray gun) and a powder 
feeder. Ibuprofen was used a model drug for the study. The polymers Opadry® AMB (polyvinyl 
alcohol based coating blend) and Eudragit® E PO were evaluated. The coating process consisted of 
the following steps: pre-heating, plasticizer spraying, feeding of the charged particles into the 
coating bed and curing at elevated temperature. In addition to lowering the glass transition 
temperature, the plasticizer layer promoted powder adhesion by capillary forces and reduction of 
the electrical resistivity of the core tablets. The polymer particles were negatively charged using an 
electrostatic spray gun and followed the direction of the electrical field between tip of the spray 
gun and grounded coating pan. The repulsive forces between the polymer particles promoted the 
dispersion of the coating powder. The coating level was dependent on the charging voltage used 
to spray the coating powder.  
By achieving a charge on the powder it was possible to coat a drug product using this electrostatic 
– liquid assisted hybrid methodology. Such combinations of technologies provide benefits for 
more effective film formation and may also represent the next steps for applying this technology 
more broadly throughout the industry.  
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9. AIM OF THE RESEARCH PROJECT 
 
The whole doctoral research project focused on the study of different technologies for film 
coating of pellets using ethylcellulose (Surelease ®) as barrier-membrane coating polymer.  
In particular, the research carried out during the first and the half part of second year of the PhD 
provided a comprehensive study of the coating process of guaifenesin (GFN)-loaded pellets in 
order to understand the variables affecting the drug migration through the barrier-membrane film 
coating and thus the stability over time of the final dosage form. The analysed process comprised 
the drug layering followed by the conventional aqueous film coating technique in a Wurster fluid 
bed. The effect of curing conditions, drug loading and coating level and of the drug-layering 
solution on the technological properties of pellets was fully evaluated.  
In the last part of the second year and during the third year, an innovative dry powder coating 
technology was developed to apply the functional ethylcellulose based coating upon pellets 
avoiding the use of solvents (neither organic solvents nor water). In particular, the study was 
designed along three steps: i) preparation of free films to study the film formation process and to 
achieve the minimum film forming temperature of the coating formula; ii) Powder coating process 
of unloaded pellets; iii) Powder coating of drug-loaded pellets. 
The results of this research have then been divided in two parts: PART I) development of suitable 
coating formulations analyzing different combination of polymer, plasticizer, co-plasticizer and 
other adjuvants, characterization of the free films and their assessment through curing and 
storage; finally development of the manufacturing process upon placebo pellets; PART II) 
evaluation of the best coating formula during the dry powder coating of unloaded pellets and then 
manufacturing and characterization of drug-loaded pellets. 
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10. CASE STUDY 1: Ethylcellulose film coating of guaifenesin-loaded 
pellets: A comprehensive evaluation of the manufacturing process to 
prevent drug migration. 
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10.1. INTRODUCTION 
Ethylcellulose is an insoluble polymer used in film coating which offers a great potential to 
accurately control drug release from pharmaceutical oral solid dosage forms [1; 2]. Water-
insoluble polymeric film coatings can either be applied from organic polymer solutions or from 
aqueous polymer dispersions [2]. Functional aqueous polymer coatings are of steadily increasing 
importance while avoiding the well known concerns related to the use of organic solvents [2; 3]; 
moreover higher solids content in aqueous coating formulations can be used, due to lower 
viscosities and decreased sticking tendencies, considerably reducing processing time [2]. However, 
a challenging task of aqueous polymer dispersions is to achieve an efficient polymer particle 
coalescence during the coating process, fundamental to obtaining stable drug release profiles. 
When coalescence is not complete at the beginning, polymer particle fusion can continue during 
storage, affecting film coating structures and, thus, the stability of the release patterns [3 - 5]. This 
is the reason why a thermal post-coating treatment, known as a curing-step, is generally required 
to achieve complete film formation and prevent or stabilize physical aging on diffusion based-drug 
release [3; 6]. 
One of the major remaining challenges associated with a potential imperfect film formation 
during coating and curing is to provide the long-term stability of aqueous polymeric controlled 
release film coatings. Several excellent reviews have provided an overview on the current state of 
the art in this field, covering different types of polymer coatings and drugs, and exhaustively 
identify different strategies to effectively overcome the stability hurdle [2; 6]. These include 
different coating levels, the use of appropriate plasticizers, the addition of immiscible hydrophilic 
excipients or high glass transition temperature of polymeric materials and finally the optimization 
of curing and storage conditions. 
A further problem which negatively affects the stability of aqueous polymeric coatings is the 
phenomenon of migration of several APIs through the barrier membrane coating layer. It has been 
reported [7 - 10] that this phenomenon occurred regardless of the polymer used (Eudragit® NE 
30D, Eudragit® L 100-55 or Acryl-EZE®, ethylcellulose both as Aquacoat® and Surelease®). In 
particular, water soluble drugs are subjected to significant migration when coated with aqueous 
systems and in the case of diltiazem hydrochloride, the amorphous drug migrated and 
recrystallized in the film coating [7]. A highly soluble drug, such as isosorbide 5 mononitrate, 
migrated to the surface of the coating exhibiting crystallization followed by sublimation [8]. In 
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addition to drug-polymer affinity, when drugs with low melting point such as ibuprofen or 
guaifenesin were used, the high temperature involved in the curing step accelerated the migration 
process [9]. Such behaviour is responsible of unstable drug release profiles from pellets or tablets 
upon storage. This phenomenon was controlled by applying either a double layer coating [8] or a 
seal-coating with a polymer having a low affinity for the drug thus avoiding the contact of the drug 
and ethylcellulose membrane [9] or by modifying the curing time and/or temperature according to 
the formulation variables [10]. 
The influence of several variables involved in the whole manufacturing process of pellets has not 
deeply investigate and the influence of the drug layer underneath the barrier membrane film 
coating has not yet been studied. The aim of this work was to investigate the formulation factors 
and the process parameters that influence drug migration through the ethylcellulose film and the 
strategies to hinder or inhibit this phenomenon. Guaifenesin (GFN), a highly water soluble drug 
(BCS Class I) was used as model drug. It also has a melting point very close to coating process 
conditions. Therefore, it has the potential to migrate through the barrier membrane and crystallize 
in or on the film surface. In particular, pellets were prepared by drug layering and then film 
coating in a Würster fluidized bed coater, analysing both formulation variables (drug loading, 
coating level, polymer type in the binding solution) and process-related parameters (different 
curing conditions) that might influence process efficiency, GFN content uniformity, film properties, 
drug migration process and pellet stability upon storage. 
10.2. MATERIALS AND METHODS 
10.2.1. Materials 
Guaifenesin (USP/Eur. Ph. Grade, Rhodia, France, batch n° FGG0529902), Sugar spheres (Suglets® 
25-30 mesh size, 600-710 µm diameter, composed of sucrose and starch), Hypromellose 
(Methocel E5, E10, E15 LV, Hydroxypropylmethylcellulose, HPMC, 2910 USP grade) and Surelease® 
Ethylcellulose Aqueous dispersion (type B NF, grade E-7-19040) were kindly supplied by Colorcon 
Ltd (Dartford, Kent, UK). Sodium alginate from brown algae (medium viscosity), chitosan FG90 high 
purity (≥93% w/w, 100 kDa) and methylcellulose (low viscosity) were purchased from Fluka (Sigma 
Aldrich, Milan, Italy). Phosphate buffer pH 6.8 was prepared as reported in Eur. Ph. 8.7 Ed; all 
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components were from Sigma-Aldrich and Milli-RX20 water (Millipore, Molsheim, France) was 
used throughout. 
 
10.2.2. Methods 
10.2.2.1. Preparation of drug loaded pellets 
Drug loaded multiparticulate pellets were prepared by solution layering, involving the deposition 
of the GFN onto starting non Suglet® seeds in a Mini-Glatt fluidized bed (Glatt GmbH, Binzen, 
Germany) equipped with a Wurster column (bottom spray assessment). Three different batches 
were prepared: batches L1 and L2 with HPMC (Methocel E5) and batch L3 with sodium alginate as 
drug layering binders. 
For batches L1 and L2, GFN was loaded at two different theoretical concentrations (4.5% and 
20% w/w, respectively) on batches of 200 g of Suglets®. The aqueous layering solution was 
prepared adding 10% or 20% w/w of GFN to a 5% w/w HPMC E5 solution. For batch L3, the 20% 
w/w of GFN was added to a 2% w/w sodium alginate aqueous solution. The liquid temperature 
was set at 50°C during the preparation of the all the layering solutions to ensure complete GFN 
solubilisation. 
Drug layering conditions within the fluid bed equipment were: inlet air temperature 60.0±0.5°C; 
product temperature 40.0±0.5 °C; fluidization air flow 21-38 Nm3/h; atomizing air pressure 
1.45±0.50 bar and a spray rate 1.12±0.03 g/min. 
The yield, the theoretical drug loading and the process efficiency expressed as the Relative 
Standard Deviation of the weight applied (RSDW) on a mean of three layering experiments [11; 12] 
were calculated using the following equations: 
 
Yield% = ࢃࡸࡼ
ࢃࡿ
∗ ૚૙૙          Eq.4 
Theoretical drug loading = ࢃࡳࡲࡺࢃࡸࡿ
ࢃࡿା ࢃࡼା ࢃࡳࡲࡺ  ∗ ૚૙૙     Eq. 5 
RSD w % = 
ඥ(ࡿࡰ ࢃࡸࡼ)૛ି (ࡿࡰ ࢃࡿ)૛
ࢃࡸࡼି ࢃࡿ ∗ ૚૙૙       Eq. 6 
where: WLP= mean weight of loaded pellets; WS = mean weight of Suglets; WGFN= GFN weight; WLS 
= weight of layering solution; WP= polymer weight and SD= standard deviation. 
90 
 
The composition of the different batches and the process related parameters are summarized in 
Table 15 (p. 95). 
 
10.2.2.2. Viscosity measurements of the layering solutions 
Several polymers with different viscosity and at various concentrations were examined in the 
layering solution: HPMC E5, E15, E50, sodium alginate, methylcellulose and chitosan. 
The viscosity determination was performed on binder solutions, before and after the GFN 
solubilization at 50°C. Briefly, 10 ml of each layering solution was placed in the small sample 
adapter of the rheometer (Visco Star R, Fungilab SA, Barcelona, Spain), which was previously 
heated to the temperature set for the layering. 
 
10.2.2.3. Coating of GFN loaded pellets 
Drug-loaded pellets with theoretical drug loading of 4.5% and 20% w/w were coated in a Mini-
Glatt fluidized bed (Glatt GMbH, Binzen, Germany) equipped with a Wurster column in bottom 
spray assembly using Surelease®. Briefly, Surelease® is an aqueous ethylcellulose dispersion at 
25% w/w solids (composed of ethylcellulose 20 cps, medium chain triglycerides and oleic acid) [13] 
which was diluted to 15% w/w dispersion by adding distilled water before use. Then the aqueous 
dispersion was sprayed onto GFN loaded pellets and different thicknesses equivalent to 
theoretical weight gains of 12% (batches C1 and C2) and 20% w/w (batch C3) for Methocel E5 and 
17% w/w in the case of sodium alginate (batch C4) were achieved. The batch size for each 
experiment was 200 g and the process conditions were: inlet air temperature 60±0.5°C; product 
temperature 40.0±0.5 °C; fluidization air flow 20-38 Nm3/h; atomizing air pressure 1.22-1.55 bar 
and spray rate 1.4±0.5 g/min. Weight gain (WG %), total yield (%), coating efficiency (RSDW %) 
expressed as the Relative Standard Deviation of the weight applied (RSDW) on a mean of three 
coating experiments and coating loss (%) were calculated as follows: 
 
WG % = ࢃ࡯ࡼିࢃࡸࡼ
ࢃࡸࡼ
∗ ૚૙૙         Eq. 7 
Yield% =ࢃ࡯ࡼ
ࢃࡸࡼ
∗ ૚૙૙          Eq. 8 
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RSD W % = 
ඥ(ࡿࡰ ࢃ࡯ࡼ)૛ି (ࡿࡰ ࢃࡸࡼ)૛
ࢃ࡯ࡼି ࢃࡸࡼ ∗ ૚૙૙        Eq. 9 
Coating loss% =  ࢃܜܐ–ࢃܚ
ࢃܜܐ
∗ ૚૙૙        Eq. 10 
where: WLP= mean weight of loaded pellets (equivalent to uncoated pellets), WCP = mean weight 
of coated pellets, Wth = weight of solids to be applied and Wr = weight of solids applied. 
The composition of the different batches and the process related parameters are summarized in 
Table 15. 
 
10.2.2.4. Curing operations 
After coating, pellets were defluidized for 15 minutes and subsequently a post-coating thermal 
treatment was performed both under static conditions in an air forced oven (at 40°C and 60°C for 
2 and 24 hours) and under dynamic performances using either a solid wall pan coater (GS Coating 
System HT, Bologna, Italy) at 60°C for 2 hours (pan speed 16 rpm, in air T= 78°C; out air T= 54°C) or 
inside the fluid bed equipment (at 40°C and 60°C for 2 hours). Different curing conditions are 
summarized in Table 14. 
All pellets were stored in polyethylene closed bottles at 25°C/ 60% RH and used for pellets 
characterization.  
 
Table 14: Different conditions of curing process. 
Batches Type Equipment Time (hours) 
Temperature 
(°C) 
2 24 40 60 
C1 
dynamic 
Fluid bed X  X X 
solid wall pan X X X X 
static air forced oven X   X 
C2 
dynamic fluid bed X  X  
static air forced oven X  X  
C3 dynamic fluid bed X  X  
C4 dynamic fluid bed X  X  
 
10.2.2.5. Determination of drug content 
The determination of GFN content of each batch was performed off-line throughout the whole 
manufacturing process. Briefly, 50 mg of each sample has been accurately weighed, ground to a 
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fine powder using pestle and mortar and dissolved in 50 mL of phosphate buffer pH 6.8. The 
system was heated up at 50°C and shaken for 15 minutes. Finally, the solution was filtered and the 
drug content has been spectrophotometrically assayed at 273 nm (Unicam Heλios β 
Thermoscientific, Milan, Italy).  
The analytical method was validated in terms of linearity, sensitivity expressed as limit of 
detection (LOD) and limit of quantification (LOQ) and finally repeatability. The correlation 
coefficient (r2) was 0.99991 (range of concentration 5.5-110 µg/ml); the LOD was 0.151 (µg/ml) 
and the LOQ was 0.458 (µg/ml). For the repeatability study three absorption measures for three 
samples with different well- known concentrations (11; 77; 110 µg/ml) had been collected and the 
answer factor was found to calculate the coefficient of variation (CV%). 
CV % had a value smaller than 0.3% for each level of concentration, demonstrating the 
repeatability of measurements. The results of the drug content are expressed as a mean of at least 
three determinations ± standard deviation (SD). The % relative standard deviation of drug content 
(RSDC) was calculated using the following equation:  
 
RSDC % = 
ࡿࡰ
࢓ࢋࢇ࢔ࡳࡲࡺࢉ࢕࢔࢚ࢋ࢔࢚
∗ ૚૙૙        Eq. 11 
 
10.2.2.6. In vitro drug release studies 
In vitro dissolution tests of pellets was performed using USP II dissolution apparatus (ERWEKA 
DT800) rotating at 50 rpm in 500 ml phosphate buffer pH 6.8 and at a temperature of 37 ± 0.5°C. 
Each sample contained about 25-30 mg of GFN. The studies ran over a period of 3 hours (batch 1) 
and 8 hours (batches 2-4) during which 3 ml aliquots of the release medium were collected at 
specific time intervals and replaced with an equal volume of fresh medium. The samples were 
filtered (0.45 µm) and assayed for guaifenesin spectrophotometrically at λ=273 nm. The mean of 
at least six determinations has been used to determine the API release for each formulation. 
Comparison between drug release profiles from pellets were carried out using both the similarity 
factor f2 and the difference factor f1. The difference factor is proportional to the average 
difference between the two profiles, whereas the similarity factor [14] is a logarithmic reciprocal 
square-root transformation of the sum of squared error and is a measurement of the closeness in 
percentage of dissolution between two release profiles.  
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ࢌ૚ =  ൜∑ |ࡾ࢚ି ࢀ࢚|࢔࢚స૚∑ ࡾ࢚࢔࢚స૚ ൠ ∗ ૚૙૙         Eq. 12 
ࢌ૛ = ૞૙ ∗ ܔܗ܏ ൜૚ + ቂ૚࢔ ∗ ∑ (ࡾ࢚ −  ࢀ࢚)૛࢔࢚ୀ૚ ቃି૙.૞ ∗  ૚૙૙ൠ    Eq. 13 
 
where n is the sampling number, Rt and Tt are the cumulative percent dissolved of the reference 
and the test products at each time point t. In dissolution profile comparisons, in order to assure 
performance similarity of the two products, it is important to know how close the two dissolution 
curves are to each other and also to have a measure which is sensitive to large differences at any 
particular time point. For f2 and f1 calculation, sampling number lower than 85% of drug released 
have been considered. The similarity factor fits the result between 0 and 100. Two drug release 
profiles are similar if the f2 is greater than or equal to 50 and f1 values are less than or equal to 15. 
 
10.2.2.7. Pellets morphological analysis 
Scanning electron microscopy (SEM) was used both to evaluate the surface morphology of 
pellets in terms of coating uniformity and to investigate the possible GFN migration and re-
crystallization processes on pellets surface. Samples were fixed on the sample holder with a 
double sided adhesive tape, sputter coated with Au/Pd under an argon atmosphere performed 
using a vacuum evaporator (Edwards, Crawley UK) and examined by means of a scanning electron 
microscope SEM (Philips XL30) operating at an accelerating voltage of 20 kV. 
 
10.2.2.8. Thermal analysis 
Hot stage microscopy (HSM) studies were performed using a hot stage apparatus (Mettler 
Toledo Spa, Novate Milanese Italy) mounted on a Nikon Eclipse 400 optical microscope connected 
to a Nikon Digital Net camera DN 100 for images acquisition. A small amount of sample was placed 
on a glass slide, equilibrated at 25°C for 1 minute and then heated at 10°C/min in the temperature 
range of 25°C to 180°C. The changes of samples were monitored via optical microscope at a 
magnification of 40X.  
DSC thermograms were performed on samples obtained throughout the whole manufacturing 
process (layering, coating and curing) of both uncured and cured pellets using a differential 
scanning calorimeter Perkin-Helmer DSC 6 (Perkin-Elmer, Beaconsfield, UK) equipped with Pyris 
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Software. The instrument was calibrated with indium and lead for temperature, and with indium 
for the measurement of the enthalpy. Samples of 10-15 mg were sealed in an aluminium pan and 
heated from 25°C to 180°C at a scanning rate of 10°C/min under a nitrogen flow rate of 20 ml/min. 
For comparison, the same procedure was followed for the raw materials. Each analysis was carried 
out in duplicate experiments.  
10.2.2.9. X-ray powder diffraction (XRD) analysis 
Raw GFN and GFN re- crystallized after 24 h from its melting were studied by X-ray powder 
diffraction technique using a X’Pert PRO (PAN-analytical, Almelo, NL) diffractometer with CuKα 
radiation (λ= 1.5418 Å) mono- chromatized by a secondary flat graphite crystal. The voltage was 
40 kV and the current 40 mA. The scanning angle ranged from 3 to 40° of 2Ѳ, steps were of 0.016° 
of 2Ѳ and the counting time was of 100s/step.  
 
10.2.2.10. Long term storage stability 
To assess long term storage stability, uncured and cured pellets were stored at 25°C/ 60±0.5% 
relative humidity (R.H.) in PE closed bottles. Drug release from pellets was measured after 3 
months (batch C1) and 6 months (batches C2-C4) of storage. Day 0 corresponded to the day after 
the preparation of layered and coated pellets.  
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10.3. RESULTS AND DISCUSSION 
10.3.1. Evaluation of Drug Layering and Film Coating Processes 
The process parameters related to layering and coating are summarized in Table 15 . 
Table 15: Composition of the batches and results of drug layering and barrier membrane film coating 
processes. 
Process related 
parameters Drug LAYERING PROCESS 
 Batch L1 Batches L2 Batch L3 
Binder solution Methocel E5 LV (5% w/w) 
Methocel E5 LV 
(5% w/w) 
Sodium Alginate MV  
(2% w/w) 
Yield % 98.5 96.0 96.4 
RSDW % 5.36 4.08 n.a.* 
GFN (±SD) % 
RSDC % 
4.65(±0.09) 
1.94 
19.5(±0.22) 
1.14 
19.20(±0.08) 
0.42 
Process related 
parameters Barrier Membrane COATING PROCESS 
 Batch C1 Batch C2 Batch C3 Batch C4 
WG % 13.36 12.60 20.50 17.80 
Yield % 98.4 95.0 94.0 93.3 
RSDW % n.a* 4.12 3.51 n.a* 
Coating loss % 1.04 4.50 3.12 4.85 
GFN (±SD) % 
RSDC % 
4.10(±0.25) 
6.1 
17.3(±0.35) 
2.02 
15.5(±0.23) 
1.48 
16.3(±0.78) 
4.85 
 
The results of the drug layering process of batch L1 show a very good yield and a good layering  
efficiency: the mass variability based on RSDW calculation was 5.36%, indicating a good 
reproducibility of the process. In relation to the drug content of this batch (4.65±0.09%), the value 
of RSDC is high (1.94%). In fact, to assure the quality of dosage units, the drug content of each unit 
in a batch should be distributed in a narrow range around the label strength. Generally, RSD values 
can vary depending on the drug concentration and a low RSD ensures a small distribution of the 
values around the labeled value [15 - 17]. 
Increasing the drug loading to the theoretical value of 20% (batch L2), the layering efficiency 
slightly increased, as the RSDW reduced from 5.36 % of batch L1 to 4.08 % for batch L2. 
Furthermore, the GFN content results show values close to the theoretical one and the RSDC of the 
drug content dropped up to 1.14%, highlighting a good drug loading uniformity. Replacing HPMC 
with sodium alginate in the layering solution, pellets (batch L3) exhibited a very good content 
uniformity (RSDC=0.42%). Comparing the RSD of the real GFN content of the three batches (L1-L3), 
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the best drug uniformity was obtained by using sodium alginate in the layering solution. 
Presumably, the higher viscosity of this polymer minimized the variation in the distribution of the 
applied drug to the Suglet® cores.  
With regards to drug dissolution of pure drug and of drug layered pellets (graph not shown), raw 
guaifenesin is freely soluble in aqueous media (BCS class I) and it was completely dissolved within 
5 min. The initial 85% of the drug loaded was dissolved within three minutes from L1 pellets and 
the complete drug dissolution occurred within 30 minutes. It was noticed that the dissolution 
profiles performed immediately after the production of L1 pellets were different from those 
obtained the day after (day 0). In particular, at day 0 the dissolution profiles were slightly higher, 
suggesting a quick crystallization of GFN on the surface of the HPMC layer. In order to obtain 
comparable data, all the dissolution profiles of the layered pellets were performed the day after 
(day 0) their production. As expected, the drug release from layered pellets with higher GFN 
content (batch L2) increased and the 93 % of the drug dissolving after three minutes. The 
dissolution profile of L3 pellets is superimposed to that of batch L2, indicating that the change of 
the binder (hypromellose or sodium alginate) did not affect the GFN dissolution behaviour.  
The next step was focused on the Surelease® coating process of drug layered pellets (L1-L3) with 
four batches of film coated pellets at two different theoretical coating levels (12 and 20% weight 
gain) (C1-C4). The real drug content of batch C1 decreased to 4.10±0.25% due to the applied 
weight gain (13.36%) and the RSDC value was 6.1%. Anyhow, the yield of the coated batch was 
high. Batch L2 was coated applying the two coating levels and the weight gain was 12.60% for 
batch C2 and 20.50% for batch C3. The maximum variation of the GFN content (RSDc) dropped up 
to 2.02% and 1.48% for batch C2 and C3, respectively, achieving a very good content uniformity. 
Likewise the coating efficiency values showed great uniformity of the coating layer with RSDW of 
4.12% for batch C2 and 3.51% for batch C3, indicating very low coating losses during the coating 
process (Table 15). Finally, when batch L3 was coated, the real GFN content of batch C4 was 16.3 
±0.78 %, the RSDC % was less than 5% and the yield remained high. 
The results showed that changes in the formulation, such as the increase of GFN concentration in 
the hypromellose-based layering solution (L1 vs L2) and of the Surelease® coating level (C2 vs C3) 
did not affect the overall weight variation. In fact, the RSDW results demonstrated the repeatability 
and robustness of both the technological procedures (drug layering and functional coating) 
performed in the fluid bed. Considering the drug content uniformity (RSDC), the lower the GFN 
loading, the higher was the variability. Therefore, both the drug layering (using hypromellose or 
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sodium alginate as binders) and the Surelease coating processes were conducted in a reproducible 
and well-controlled manner and uniformity of dosage units was obtained.  
 
10.3.2. Influence of Curing Process on GFN Release from Pellets 
After film coating of pellets with Surelease, the drug release from pellets (batch C1) significantly 
decreased and the 80% of the drug was dissolved within 3 hours (Figure 14), indicating that the 
ethylcellulose based coating significantly controlled the GFN release rate.  
As previously reported, one of the main challenge associated with functional aqueous 
ethylcellulose-based coating is to achieve complete polymer particle coalescence during the 
coating process and provide stable drug release profiles over time [3, 4]. Since a complete polymer 
particle coalescence is difficult to be assured during the coating process, a curing step is usually 
recommended. Several critical parameters of curing, such as relative humidity (RH), temperature 
and time, may have significant effects on drug release properties and need to be investigated, 
according to the chemical stability of drugs and/or excipients involved [2, 6]. Thus, the 
optimization of curing conditions is very important to ensure the long term stability of samples. 
The post-coating drying step is traditionally carried out under static conditions, requiring the 
transfer of samples in an air forced oven. Nevertheless, performing curing operations directly 
inside the coating equipment under dynamic conditions could be advantageous [4]. The influence 
of different curing conditions on the first batch of pellets (Table 14) was studied and the effect of 
the curing step on the stability of pellets was evaluated through the analysis of their release 
profiles and of their thermal behaviour.  
Analysing the dissolution data of batch C1, no significant differences of the release profiles 
between the uncured and the cured pellets at 40°C in the fluid bed equipment were observed 
(Figure14), both before storage (t0) (f2=86.06±3.41; f1=5.78±3.22) and at t90 (f2=76.95±1.71; 
f1=4.86±0.43), indicating the stability of the ethylcellulose-based Surelease coating of both 
untreated/ treated samples. 
 
 
 
 
98 
 
Figure 14: Influence of curing conditions on the dissolution profiles of C1 pellets at day 0 and after 90 days 
of storage: 40°C in fluid bed. 
 
 
The pellets were then analysed by means of DSC throughout the whole pharmaceutical 
manufacturing process (layering, coating and curing) to detect possible drug solid state 
modification.  
Figure 15a shows the DSC curves of raw drug and layered pellets. GFN is a low melting drug and 
displayed a sharp endothermic peak at 84.84 ± 0.29°C (Tonset= 81.59 ± 1.14°C). The integration of 
the melting endotherm yielded an enthalpy of fusion equal to 183.68 ± 0.61 J/g, in agreement with 
the data reported in literature for the racemic form of the drug [18].Looking inside to the solid 
state of GFN in the layered pellets, GFN exhibited a shift of the endothermic peak to 78.38 ± 
0.23°C, due to the dilution effect in presence of hypromellose (5% w/w). In addition, it was noticed 
the appearance of a new endothermic peak at 71.26 ± 0.24°C (Tonset= 69.52 ± 0.59°C). This peak 
appeared also during the analysis of GFN re- crystallized after 24 h (Figure 15a). 
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Figure 15: DSC curves as a function of storage time of (a): raw GFN, GFN recrystallized from the HPMC 
solution, L1 pellets; (b) uncured and cured C1 pellets. Curing was performed in fluid bed at 40°C for 2 hours. 
(a) 
 
(b)  
 
 
This thermal event was also visualized by the HSM analysis (Table 16): during the temperature 
scan, re- crystallized GFN started its fusion at about 68°C, presumably corresponding to a 
modification of its original form, and completely melted at about 85°C. 
 
 
 
 
100 
 
Table16: HSM images of raw GFN and re- crystallyzed GFN taken after 24 hours from its melting 
(magnification 10x). 
Temperatures 40°C 68°C 85°C 
GFN 
  
recrystallized 
GFN 
   
 
In order to better elucidate this behaviour, XRD analysis was performed and the diffractograms 
of raw GFN and of re- crystallized GFN (assessed after 24 hours) are shown in Figure 16. 
 
Figure 16: XRD diffraction spectra of raw GFN and of re- crystallized GFN taken after 24 hours from its 
melting. 
 
 
The diffraction pattern of raw GFN exactly matched with the GFN racemic form [18; 19]. 
Analysing the pattern of re- crystallized GFN, all the drug reflections were detectable and any shift 
or broadening of the reflections were visualized, indicating that no polymorphic change happened.  
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On the other hand, a dramatic reduction of the intensity of the two main reflections at 12° and 
13.4° (2Ѳ) was observed. Presumably, amorphous GFN was formed during the drug layering phase 
(confirmed by the higher dissolution profiles of fresh L1 pellets) and its re- crystallization occurred 
quickly, starting with the formation of nuclei in a nanocrystal phase which then grew into crystals. 
The change in the crystal habit and the size reduction reflected on the decrease of the melting 
temperature, in agreement with previous thermal analysis results (DSC and HSM). An interesting 
review [20] gives evidence of this phenomenon and could be a reasonable explanation of the GFN 
behaviour upon pellets. Analyzing the stored samples (L1, t90), the left shoulder of the main peak 
at 66.11 ± 0.47°C was still present and the splitting of the main melting endotherm became better 
visualized on the right side of Figure 15a. The first peak was at 76.4 ± 0.01°C due to the melting of 
racemic GFN and the second one at 80.08 ± 0.22°C, probably due to the presence of a small 
amount of the (S) – enantiomer of GFN. In fact, it has been reported in literature [18] that (S)-
guaifenesin exhibits a higher melting point with respect to the commercialized racemic form.  
This hypothesis was supported by the DSC analysis of GFN re- crystallized by HPMC 5% w/w 
solution layering after six month of storage (Figure 15b). In fact its DSC curve highlights two 
distinguishable thermal events: the first one at 85.78 ± 0.62°C (Tonset= 81.14 ± 1.53°C), according to 
the racemic API raw material melting point, and the second one at 97.46 ± 0.13°C (Tonset= 93.33 ± 
1.89°C), attributable to the (S)- enantiomer of GFN which presents a melting range of 95-97°C [18]. 
These results suggested that GFN re- crystallized on the layered pellets in its original racemic form; 
after 90 days of storage a further form, the (S)- enantiomer, appeared. Since all the GFN physical 
forms are very soluble, no significant differences in the dissolution profiles between drug layered 
pellets were observed, as previously described.  
DSC scans of both uncured and cured t0 C1 samples, as illustrated in Figure 15b, showed only 
one broad endothermic peak ranging from 60°C to 80°C, which comprised two thermal events 
non- distinguishable to each other: the GFN melting peaks and the glass transition of the 
ethylcellulose pseudolatex at about 62.5°C. While the Tg of raw ethylcellulose is about 129 - 
133°C, the presence of medium chain triglycerides and oleic acid as plasticizers in the film, strongly 
decreased the glass transition temperature of the polymer and the resulting Tg of the coating 
formula (Surelease®) is reported to be around 62 °C. After 90 days of storage, the DSC analysis was 
repeated and the splitting of the main melting endotherm appeared in the DSC scans of uncured 
pellets, while it was less pronounced but still present in cured samples. 
102 
 
Therefore it can be summarized that layered pellets with the lower drug loading showed a 
modification of the GFN solid state but it did not affect the release profiles of GFN (Figure 1a) from 
the coated pellets. Finally, the influence of curing in fluid bed at 40°C for 2 h on the dissolution 
profiles of C1 pellets was negligible, also after 90 days of storage. 
After two hours of curing at 40°C in an air forced oven, the release profiles (Figure 17) of uncured 
vs cured pellets were similar both at t0 (f2=59.81±2.83; f1=10.06±1.94) and t90 (f2=55.39±0.21; 
384 f1=14.52±0.92). Looking inside to the stored cured samples, a higher burst effect was clearly 
observed and the data were more variable with respect to the uncured ones. In fact, after 90 days 
of storage, a great decrease of f2 values was noticed: f2 value calculated between the uncured 
pellets (t0 and t90) was 75.5 ±2.36 (f1=4.97±0.65), while f2 value calculated between cured ones 
(t0 and t90) was 58.85±3.02 (f1=14.62±0.71). 
 
Figure 17: Influence of curing conditions on the dissolution profiles of C1 pellets at day 0 and after 90 days 
of storage: 40°C in oven. 
 
 
When pellets were cured for two hours at 60°C, it was impossible to perform a post coating 
thermal treatment in fluid bed, as samples stuck and softened along with pellets de-fluidization, 
due to the similar Tg of the polymer/plasticizers blend (around 62°C). Therefore the coating pan 
equipment has been chosen to assess the dynamic curing, owing to its ability to rotate the pellets 
inside the pan. A certain sticking of pellets on the pan wall still occurred without affecting the 
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process. The effect of the curing conditions in the solid wall pan revealed a different behaviour of 
pellets, especially during storage (Figure 18). After 90 days, the release profiles of cured pellets 
showed a significant burst effect within 15 minutes and an increase in API released. According to 
the similarity factor values, the release profiles of cured vs uncured pellets were similar at t0 
(f2=66.49±1.48) and significantly different (f2 =27.56±1.47) after 90 days. Furthermore, the 
release profiles of cured samples at t0 vs t90 were significantly different (f2=29.93±2.04). 
This phenomenon could be attributed to the complete solubilisation of the drug into the coating 
layer as a function of both process temperature and low GFN concentration of C1 pellets. As 
described in the literature [19; 21], GFN has a plasticizing effect on several polymers and, when 
the process temperature is high, the formation of API crystals on pellets surface occurs. Siepmann 
et al [2; 9; 10] also reported that the GFN triggered migration through Aquacoat® coatings resulted 
in a drug re-crystallization on film surface upon storage. Therefore, a dynamic curing step at 60°C 
affected the API crystallization rate upon pellets surface, accelerating the formation of nuclei 
which then grew into crystals.  
 
Figure 18: Influence of curing conditions on the dissolution profiles of C1 pellets at day 0 and after 90 days 
of storage: 60°C in pan coater. 
 
 
 
Similarly, when the curing is performed under static conditions at 60°C (Figure 19), the release 
profiles of uncured and cured samples were similar at t0 (f2=57.36±0.21). 
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Figure 19: Influence of curing conditions on the dissolution profiles of C1 pellets at day 0 and after 90 days 
of storage: 60°C in oven. 
 
 
 
After 90 days of storage the release profiles of cured t0 vs cured t90 were borderline not 
significantly different (f2=50.25±3.98; f1=10.56±2.07) at the end of dissolution test, but 
significantly different (f2=41.23±4.02; f1=24.31±3.97) after the first hour of dissolution, where the 
50% of the drug loaded was already released. The faster GFN release after the thermal treatment 
in oven at 60°C is less pronounced than in the coating pan at 60°C, which may be due to the lower 
thermal exchange of the static curing system. 
The results reveal that the dynamic curing performance was better in terms of stability of drug 
release profiles. Dynamic curing in fluid bed at a suitable temperature (40°C) did not show a 
significant effect on long term stability of pellets coated with aqueous ethylcellulose dispersion 
(Surelease®). Therefore it can be stated that using this formulation (C1: 4.65% GFN layered and 
13.36% Surelease® coating level) together with the described process parameters (dynamic curing 
for 2 h at 40°C), the applied coating layer was stable and a further phase of curing for stabilizing 
the film coating may be unnecessary, at least for the examined time.  
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10.3.3. Influence of GFN Loading and Coating Level on the Properties of 
Controlled Released Pellets 
Once the best curing conditions for the GFN-loaded pellets established, the next step was to 
investigate the influence of increasing the GFN loading form 4.5% w/w to 20% w/w onto the sugar 
spheres on the pellets’ properties. Batch L2 with a theoretical GFN loading of 20% w/w was 
produced and two different coating levels were applied to obtain a theoretical weight gain (WG) of 
12% (batch C2) and 20% w/w (batch C3), respectively. The results of the effective weight gain and 
drug loading are reported in Table 15 (p. 95). 
The dissolution profiles of C2 pellets are shown in Figure 20. 
 
Figure 20: Influence of GFN loading on dissolution profiles; comparison between batch C1 and C2 (both 
uncured and cured pellets) at t0. Curing was performed in fluid bed for both batches at 40°C for 2 hours. 
 
 
 
Increasing the theoretical drug loading, the GFN release from ethylcellulose coated pellets is still 
controlled by diffusion across the film coating. No significant differences on the release profiles 
between the cured and uncured pellets were observed for both t0 (f2= 81.79±4.0) and t180 (f2= 
74.09±4.53). However, an appreciable burst effect within the first hour of dissolution of both 
stored samples (uncured and cured) was clearly observed. As previously reported, this effect could 
be attributed to the GFN partial solubilisation into the polymeric coating and to the GFN 
displacement outward the polymeric film thickness and its surface re- crystallization.  
0
10
20
30
40
50
60
70
80
90
0 30 60 90 120 150 180
%
GF
N
re
le
as
ed
TIME (min)
C1 uncured day 0 C1 uncured day 180
C1 cured day 0 C1 cured day 180
C2 uncured day 0 C2 uncured day 180
C2 cured day 0 C2 cured day 180
106 
 
This phenomenon appeared to be closely related to the drug concentration in the HPMC layering 
solution. In fact, comparing the release profiles of cured pellets of batch C1 and batch C2 (Figure 
20) having approximatively the same coating level (13.36% vs 12.60%, respectively), it can clearly 
be seen that, after 6 months of storage, the extent of burst effect increased in the pellets with 
higher drug loading. This is in agreement with Bruce et al. [21], who reported that the 
supersaturation of the drug in the studied systems was the driving force for its re- crystallization. 
In this case the higher GFN concentration in the HPMC layering solution caused its re- 
crystallization on L2, as clearly shown in Table 5, triggering the migration process through the 
Surelease barrier membrane layer of C2 pellets. Nevertheless, C2 stored samples overall exhibited 
more controlled release profiles and a lower burst effect (as absolute value) than those of batch 
C1 (Figure 20). Therefore, this behavior suggests that drug re- crystallization occurred anyway, but 
the increase in drug loading mitigated the burst effect and better controlled the drug release 
profiles.  
Increasing the coating level from 12.6% w/w (batch C2) to 20.5% w/w (batch C3), the percentage 
of GFN released within 8 hours from both uncured and cured C3 pellets is less than 65% with 
respect to the 80% drug released form coated pellets of batch C2 (Figure 21), indicating that the 
higher ethylcellulose coating level mostly controlled the GFN release rate. 
 
Figure 21: Influence of coating level on GFN dissolution profile: comparison between batch C2 and C3 (both 
uncured and cured pellets) at t0. Curing was performed in fluid bed for both batches at 40°C for 2 hours. 
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In fact f2 values calculated between C2 and C3 was 43.95±2.35 and 50.28±0.14 (f1=22.82±1.28) 
for uncured and cured samples, respectively, indicating a significant difference between the two 
batches. Furthermore, the drug release from batch C3 was characterized by a less pronounced 
burst effect followed by a linear portion, indicating a region of constant drug release. 
Comparing C2 and C3 uncured pellets at day 0 and after 30 days of storage (25°C/60% RH) 
(graphs not shown), it was noticed that the release profiles of pellets with the lower weight gain 
(batch C2)were significantly different (f2=47.93±0.3; f1=27.93±0.83), while the release profiles of 
pellets with the higher weight gain (batch C3) were similar (f2=70.74±5.12; f1=10.81±3.73). The 
SEM images reported in Table 17 serve as an explanation for the release patterns obtained after 1 
month of storage. 
At day 0, uncured C2 pellets showed a great GFN crystallization extent indicating the migration of 
GFN outside the coating layer. Moreover, drug crystals on pellet surface (t0) exhibited a needle-
like structure with respect to a rod-like morphology [18] of GFN raw crystals. After 30 days of 
storage at 25°C/60 RH (Table 5), C2 uncured pellets exhibit a further increase of GFN migration 
throughout the coating thickness: GFN crystals grew across to the pellets surface and a rapid burst 
effect within the first hour of dissolution was clearly observed. 
Moreover, no clear differences on the surfaces were observed between C2 uncured pellets and 
those cured either in the fluid bed or in the oven (Table 17). Increasing the weight gain (batch C3), 
the GFN migration throughout the coating level slowed, but it wasn’t completely prevented or 
avoided (Table 17). In fact, pictures of both uncured and cured C3 pellets shows several GFN 
crystals out of the coating level already at day 0, even if in a less pronounced manner than C2 
pellets. The image of C3 cured pellets after 30 days clearly depicts the GFN crystals that migrated 
out of the film layer.  
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Table 17: SEM pictures of raw materials, layered pellets (L2) and coated pellets (batches C2 and 
C3) taken at the day 0 and after 30 days of storage at different magnifications. 
GFN raw Suglet raw Layered pellet (batch L2) 
 50 µm (236X)  50 µm (109x)  50 µm (154x)  5 µm (2500x)   
Uncured pellets (batch C2) 
t0 t0 t0 t30 
5 µm (1000x)      50 µm (122x) 50 µm (487x) 5 µm (1000x)   
Cured pellets (batch C2) 
In fluid bed                        t0                                          t30 In oven     t0             t30 
 5 µm (1000x)     5 µm (1000x)    5 µm (1000x)    5 µm (2500x)     
Uncured pellets (batch C3) 
t0 t0 t0 t30 
 50 µm (300x )     50 µm (142x)      10 µm (500x)    5 µm (1000x)     
Cured pellets (batch C3) 
In Fluid bed                        t0          t0                                            t30                                            t30 
 5 µm (1000x)     10 µm (500x)   5 µm (1000)x    5 µm (2000x)     
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After 180 days of storage (Figure 22), the release profile of batch C3 uncured pellets decreased 
but remained similar to that of same pellets at day 0.  
 
Figure 22. Influence of coating level on GFN dissolution profile: comparison between batch C2 and C3 (both 
uncured and cured pellets) after 180 days of storage at 25°C/60% RH. Curing was performed in fluid bed for 
both batches at 40°C for 2 hours. 
.  
 
This fact was confirmed by the decreasing of the f2 values: from 70.74±5.12 at t30 to 56.28± 1.76 
at t180. Analyzing the stability of cured samples, the release profiles were similar both at t0 and 
t180 both for batch C2 (f2=59.94±1.75; f1=13.14±0.95) and batch C3 (f2=62.37±1.13; 
f1=12.38±0.88), indicating the better stability of the ethylcellulose-based coating of cured samples 
with respect to the untreated ones. 
Considering the solid state of the drug, the DSC scans of both uncured and cured C2 pellets at 
day 0 (Figure 23a) were similar to DSC curves of batch C1 (Figure 15b). 
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Figure 23: DSC curves of uncured and cured pellets of batches C2 and C3 at (a) day o and (b) after 180 days 
of storage at 25°C/60% RH. 
(a) 
 
(b) 
 
 
After 180 days of storage at 25°C/60% RH (Figure 23b), the splitting of the main endotherm, 
clearly observed in C1 pellets with a lower API content, likewise appeared in both uncured and 
cured C2 pellets. This result indicated that pellets with higher drug content and the same weight 
gain had the same behaviour upon storage. Increasing the weight gain, DSC curves of batch C3 at 
day 0 were similar to those of batch C2 exhibiting only one broad endothermic peak (Figure 
23a).After 6 months of storage (Figure 23b), only the thermogram of C3 uncured pellets exhibited 
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the splitting of the GFN main melting peak, displaying the second peak at higher temperature 
(Tpeak=80.83±0.11°C). Conversely, this thermal event did not appear in the DSC trace of batch C3 
cured pellets, suggesting that increasing the coating level might prevent the GFN solid state 
modification. 
In conclusion, the film properties were strongly affected by the chemical –physical interaction 
between GFN and ethylcellulose and, increasing the drug content, a post-coating thermal 
treatment was absolutely required to stabilize the crystalline state of GFN and consequently the 
film effectiveness. Increasing the coating level, the API migration upon pellet surface was limited 
or delayed but it was impossible to prevent or completely avoid. 
 
10.3.4. Effect of the Layering Solution on the properties of Controlled 
Released Pellets 
In order to limit or to minimize the GFN migration process throughout the film and to reduce its 
re-crystallization on pellets surface, it was decided to investigate various polymers with different 
rheological properties and to evaluate the role of the polymer used in the layering process in 
controlling the GFN diffusion into the coating layer. 
The viscosity values obtained are summarized in Table 18. Methocel E5 exhibited a very low 
viscosity even after the addition of the drug (10 and 20% w/w). Increasing the HPMC molecular 
weight (Methocel E15 and E50), the viscosity of the layering solution increased till 50 cps and cps, 
respectively. The addition of GFN led to a viscosity decrease, especially for Methocel E50.  
 
Table 18: Composition of the drug layering solutions used in the viscosity studies and their relative 
viscosity values – This shows the viscosity of the binders and drug binder solutions (measured at 20 rpm 
and 50°C); * not detectable using the TR8 spindle. 
 
Polymer Polymer (%, w/w) 
Viscosity 
(mPa s) 
GFN (%, w/w) added 
to the polymer sol. 
Viscosity 
(mPa s) 
Methocel E5 5 n. d. * 
10 n. d. * 
20 20 
Methocel E15 5 50 
10 n. d. * 
20 50 
Methocel E50 5 280 
10 n. d. * 
20 130 
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Methylcellulose 
(MC) 
0.5 n. d. * 
20 
n. d. * 
1 50 80 
Chitosan 
1 40 
20 
30 
2 180 120 
3 650 430 
Sodium 
alginate 
1 40 
20 
40 
2 450 430 
3 2300 2210 
 
Figure 24 clearly shows the shear thinning behaviour, thus it is possible to hypothesize that GFN 
caused a complete disentanglement of the polymer chains by the reduction of intermolecular 
attractions between polymer chains, acting as plasticizer. Since all Methocel E (5, 15 and 50) 
underwent a strong decrease of viscosity in the presence of the drug, different polysaccharides 
were investigated in order to identify one that did not drastically affect its viscosity in the 
presence of the drug. Methylcellulose was tested only at 0.5% and 1% w/w, because at higher 
concentrations (2% w/w) the viscosity was too high for the nozzle atomization. Its viscosity 
increased with GFN but the values were similar to those obtained with Methocel E solutions. 
Figure 24: Viscosity curves (from left to right and return) of different: Methocel E50 (5% w/w) solutions. 
 
 
Pure chitosan displayed higher viscosity than Methocel and after the addition of GFN, viscosity 
values decreased with increasing the polymer concentration, especially at 3% w/w (Figure 
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25).Sodium Alginate exhibited the highest viscosity values and in presence of GFN very slight 
changes in its thixotropic behavior were observed (Figure 26). 
Specifically, the polymer solution of 1% w/w was slightly viscous, while the 3% w/w polymer 
solution with and without GFN was too viscous to ensure a correct and optimal atomization. At the 
concentration of 2% w/w, no viscosity changes in the presence of the drug were observed at 20 
rpm (420 cps), allowing its atomization.  
Moreover, unlike the chitosan, which requires the addition of acetic acid at a concentration 1% 
w/V to dissolve, the solubilisation of sodium alginate is only time dependent. This ensures a 
greater process simplicity, as it is not necessary to remove the organic solvent during drying. 
Therefore, sodium alginate at a concentration of 2% w/w was selected as a binder for the drug 
preparation of the layering solution.  
 
Figure 25: Viscosity curves (from left to right and return) of different chitosan (1-3% w/w) solutions before 
and after the addition of GFN. 
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Figure 26: Viscosity curves (from left to right and return) of different Na Alginate (1-3% w/w) solutions 
before and after the addition of GFN. 
 
 
 
As reported for Methocel E5, the sodium alginate layering solution was heated at 50°C to obtain 
the complete GFN solubilization. Fluid bed sodium alginate layered pellets were then produced 
(L3) and coated to obtain batch C4. Pellets were then analyzed by means of DSC (Figure 27). 
Contrary to hypromellose, sodium alginate is a crystalline polymer exhibiting a malting peak at 
146.58±0.29°C. For both L3 and C4 pellets (t0), the only detected thermal event was a sharp 
endothermic peak around 81°C - 82°C very close to the GFN main melting peak (84.84±0.29°C). 
After six months of storage, the thermograms of L3 pellets and uncured and cured samples 
remained unchanged and depicted only a sharp main melting peak at about 80°C.  
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Figure 27: DSC curves of layered pellets with sodium alginate (L3) and of batch C4 uncured and cured 
pellets at day o and after 180 days of storage at 25°C/60% RH. 
 
 
SEM images (Table 19) highlighted a smoother layered samples surface than the HPMC-based 
ones (Table 17) and no GFN crystals grew during storage (30 days). This behaviour suggest that the 
drug supersaturation is not the main driving force of GFN crystallization and the affinity between 
the drug and the binder layering polymer played an important role. It can be thus hypothesized 
that GFN formed a stable solid dispersion with sodium alginate, which inhibit GFN re- 
crystallization on the layered pellets. After Surelease® film coating, alginate-based pellets 
displayed a weight gain of 17.8% and a drug content of 16.3±0.88% w/w (Table 15). 
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Table 19: SEM pictures of layered pellets (L3) and coated pellets (batch C4) after 30 days of storage, at 
different magnifications. 
Layered pellets (batch L3) Cotaed pellets (batch C4) 
Uncured Cured 
 
 
 
 
 
 
 
 
 
 
Figure 28 shows the dissolution profiles C4 pellets upon storage. Uncured pellets released 50% of 
the GFN within 3 hours with respect to the six hours required by uncured pellets of batch C3 
(f2=45.18±1.7), indicating a faster dissolution rate due to the sodium alginate. After curing, the 
pellets (C4) showed a very similar release profile, as confirmed by the f2 results 
(f2uncured/cured=72.28±1.94). According to SEM images (Table 19), GFN did not migrate through 
the film coating after 30 days storage of both uncured/cured samples. After 180 days of storage, 
the release profiles of both untreated/treated samples remained unchanged with respect to the 
initial (day 0) dissolution profiles, even without thermal treatment (f2= 66.04±0.56, f1=10.56±0.14 
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for the uncured; f2= 75.49±1.98, f1= 6.79±1.59 for cured pellets), which was necessary to stabilise 
pellets layered with hypromellose. 
 
Figure 28: Dissolution profiles of C4 uncured/cured pellets at day o and after 180 days of storage at 
25°C/60% RH. 
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10.4. CONCLUSIONS 
The paper provided a comprehensive study of the coating process of guaifenesin-loaded pellets 
in order to understand the variables affecting the drug migration and thus the stability of the final 
dosage form. This study showed that the optimization of a manufacturing process is very 
complicated and despite the well-known and established available technologies, it is extremely 
important during the development of a formulation to thoroughly analyze the whole process and 
its variables. Surprisingly, the results indicated that the drug layering phase was the critical step of 
the whole manufacturing process. The polymer used in the drug layering solution influenced the 
GFN crystallization on the layered pellets becoming the main driving force in the Surelease-based 
film instability. When HPMC is used as a binder in the layering solution, at low drug concentration 
the film stability was ensured even without curing, while at high GFN content a post coating 
thermal treatment may be required regardless of the coating level applied. Replacing HPMC with 
sodium alginate, the migration of the drug was negligible; in addition the curing step was not 
necessary to achieve stable release profiles of pellets upon storage. 
Changing the model drug with another active pharmaceutical ingredient, even of the same BCS 
Class, will not necessarily lead to the same conclusions and it will be necessary to repeat the whole 
evaluation process. 
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Most of the data reported in this chapter has been recently published in the European Journal of 
Pharmaceutics and Biopharmaceutics.   
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11. CASE STUDY 2: A novel dry powder coating of pellets using 
ethylcellulose. Part I: An investigation into the formulation of free-films 
and on process manufacturing. 
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11.1. INTRODUCTION 
 
Conventional technologies for the application of film coatings onto pharmaceutical dosage forms 
involve the atomization of polymeric systems as solution or suspension in volatile organic solvents 
and/or aqueous vehicles. While the use of organic solvents is generally faster with simplified film 
formation processes because of the dissolved nature of the polymer, the use of aqueous systems 
remains the preferred manufacturing approach due to the absence of solvent toxicity, increased 
process safety and lower manufacturing costs [1]. 
Even in light of the benefits of aqueous systems, there are several cases where aqueous systems 
are inappropriate and organic solvent coatings may be necessary. This is particularly true when the 
pharmaceutical ingredient is sensitive to water and organic solvents are used to prevent this issue. 
In addition to degradation of the active ingredient, migration of water with aqueous systems may 
occur during the coating processor during storage thus compromising the quality of the finished 
product. The need to avoid aqueous and organic solvents may be particularly critical if the drug 
product is formulated as an amorphous solid dispersion. Moreover, from a process standpoint, 
aqueous coatings require both a substantial amount of water, as well as energy to evaporate the 
water during manufacturing. While thermal energies to drive evaporation of solvents may be 
lower, the need for environmentally friendly and safe solvent recovery significantly increases costs 
around solvent operations. Overall, this leads to longer processing times and greater overhead 
costs for conventional film coating operations [2].  
In the last decade, dry powder coating of pharmaceuticals has been recognized to be an 
environmentally-friendly and a promising coating technology to overcome the well-known 
disadvantages associated with organic and aqueous coating systems. Driven by a combination of 
cost considerations and functionality, a range of dry powder coating technologies have been 
developed in both academic and industrial settings. Actually, dry powder coating technology for 
pharmaceutical applications has gained increasing attention over the last decade and the first 
review of this process has been published last year in a special issue of IJP, entitled “Progress in 
film coating” [3]. 
Dry powder coating technologies can be generally classified into three major types based on the 
layer formation process: thermal adhesion (melt coating), liquid assisted and electrostatic [1]. In 
addition to specific manufacturing processes that must be implemented to achieve the desired 
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product attributes, many of these techniques also require the use of novel excipients and specific 
formulations to provide acceptable manufacturability [4]. 
Ethylcellulose is one of the most commonly used polymers for sustained release film coating. 
Considering ethylcellulose as film forming polymer in a dry powder coating process, its high glass 
transition temperature (Tg) could represent an obstacle for the process execution.  
Several studies investigated the dry powder coating of pellets with ethylcellulose in a fluidized 
bed coater [5; 6]. A smaller polymer particle size promoted particle film formation. In general, 
pellets coated with polymer powders required higher coating levels to obtain similar drug release 
patterns as pellets coated with organic polymer solutions and aqueous polymer dispersions [5]. 
High plasticizer concentrations (40%) of tributyl citrate (TBC) and a thermal after-treatment 
(curing) were necessary for the coalescence of the polymer particles and good film formation. 
Although ethylcellulose-coated pellets had an uneven surface, extended drug release could be 
obtained with coating level of 15% [6]. Alternatively, to reduce the coating temperature and the 
random deposition of the polymer particles on the core surface, pre-plasticized ethylcellulose with 
20% w/w of MCT was investigated [7]. Hot-melt extrusion/cryogenic grinding and spray drying two 
commercially available plasticized aqueous colloidal ethylcellulose dispersions were used for that 
purpose.  
Smikalla et al., (2011) analyzed several liquid additives (isopropyl myristate, 
cocoylcaprylocaprate, triacetin, octyldodecanol, triethylcitrate, PEG 400 and glycerol) (30-50% 
w/w rel. to the dry polymer) to lower the Tg of ethylcellulose and to enhance the adhesion of the 
powder to the cores inside a fluid bed with a rotor insert. Curing at 80°C for three days and 
isopropyl myristate resulted in the highest coating efficiency [8]. 
In this study a different approach of dry powder coating process was developed for the 
application of functional ethylcellulose based-coating upon pellets. In particular, a novel approach 
based on a combination of both liquid assisted and thermal adhesion technology within a high-
shear rotogranulator was developed and both the formulation and the process-related parameters 
were fully investigated. To this purpose, plastic deformation of ethylcellulose in combination with 
several plasticizers and film formation ability were considered critical points for formulation 
design and process carrying out. Therefore the impact of type and amount of polymers, 
plasticizers and other suitable excipients on the formation and stability of free film were studied.  
The experimental design has been divided in two parts. In the first one, the research focused on 
the film formation process through the preparation of free-films. Formulation variables as polymer 
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particle size, plasticizing activity and minimum film formation temperature were considered. The 
best coating formula on the basis of the minimum film forming temperature and film stability 
were then investigated upon placebo pellets using the novel dry powder coating process. Once the 
feasibility of the process was ascertained, in the second part of the research the process 
manufacturing was optimized using placebo pellets and then applied onto drug-loaded pellets. 
 
11.2. Materials and Methods 
11.2.1. Materials 
Ethocel® Standard E7, E10 and E20 FP (fine particle, with mean dimension of the particles of 9.7 
µm) and Sugar spheres (Suglets® 14/16 mesh size, 1180-1400 µm diameter, composed of sucrose 
and starch (batch n° DT 405540) were kindly donated by Colorcon Ltd (Dartford, Kent, UK). 
The used plasticizers belong to two different categories: saturated fatty acids: oleic acid (OA, 
Carlo Erba, batch n° 3185E100); lauric acid (LA, Sigma-Aldrich, batch n° MKBQ4605V) and myristic 
acid (MA, Fluka) and medium-chain triglycerides: Dynasan 114 (Sasol, batch n° 402156), 
glycerylmonostearate (GMS, Sigma-Aldrich), Myvatex (Prabo srl, Cremona, Italy)and Myverol 
(Prabo srl, Cremona, Italy). 
Kollidon-vinyl acetate copolymer (KVA 64, batch n° 61611468E0) was gently donated by BASF. 
Talc was supplied by ACEF SpA (Piacenza, Italy). 
 
11.2.2. Methods 
11.2.2.1. Preformulation study: screening of polymer and plasticizers 
At the beginning, a pre-formulation study based on binary physical mixtures was carried out 
through DSC measurements. The thermal properties of raw Ethocel® and of the samples were 
characterized using a differential scanning calorimeter Perkin-Helmer DSC 6 (Perkin-Elmer, 
Beaconsfield, UK) equipped with Pyris Software. Samples, weighting 8-12 mg, were sealed in an 
aluminium pan and heated from 25°C to 180°C at a scanning rate of 10°C/min under a nitrogen 
flow rate of 20 ml/min. Each analysis was carried out in duplicate experiments. The mean glass 
transition temperature (Tg) was then calculated. 
The analysed samples were raw ethylcellulose and powder mixtures containing several types of 
low melting plasticizers at different concentrations to evaluate their efficiency in lowering the Tg 
125 
 
of the coating blend. In particular, three types of ethylcellulose, which essentially differed in 
molecular weight and viscosity degree, were used (E7, E10 and E20). The screening of the 
plasticizer was conducted preparing 10 physical mixtures with Ethocel E7 and all plasticizers listed 
above in different percentage ratios. The composition of each physical mixture is reported in Table 
20. 
 
Table 20: Binary physical mixtures based on Ethocel E7 and several type of low melting plasticizers at 
different concentrations. 
Polymer 
(% w/w) Plasticizer (% w/w) 
Physical 
mixture 
Ethocel E7 LA MA Dynasan 114 GMS Myvatex Myverol Ratio (% w/w) 
90 10 X X X X X 90:10 
80 20 X X X X X 80:20 
70 30 X X X X X 70:30 
90 X 10 X X X X 90:10 
80 X 20 X X X X 80:20 
70 X 30 X X X X 70:30 
90 X X 10 X X X 90:10 
90 X X X 10 X X 90:10 
90 X X X X 10 X 90:10 
90 X X X X X 10 90:10 
 
The best plasticizer of Ethocel E7 was then used with the other types of Ethocel (E10 and E20). 
Table 21 lists the composition of the binary physical mixtures containing lauric acid (LA) and 
Ethocel E10 and E20. 
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Table 21: Binary physical mixtures based on Ethocel E10 or E20 and LA at different concentrations. 
Polymer (%w/w) Plasticizer (%w/w) Physical mixture 
Ethocel E10 Lauric acid ratio (% w/w) 
90 10 90:10 
80 20 80:20 
70 30 70:30 
Ethocel E20 Lauric acid ratio (% w/w) 
90 10 90:10 
80 20 80:20 
70 30 70:30 
 
Ternary physical mixture based on Ethocel E10, LA and OA were then prepared and their 
compositions are listed in Table 22. 
 
Table 22: Ternary physical mixture based on Ethocel E10, LA and OA at different concentrations.  
Polymer (% w/w) Plasticizer (% w/w) Physical mixture 
Ethocel E10 LA OA Ratio ( % w/w) 
85 
10 
5 85:10:5 
80 10 80:10:10 
70 20 70:10:20 
75 
20 
5 75:20:5 
70 10 70:20:10 
60 20 60:20:20 
65 
30 
5 65:30:5 
60 10 60:30:10 
50 20 50:30:20 
 
Finally, Kollidon vinyl acetate (KVA 64) was added to the binary physical mixture at a fixed 
concentration of2.5% w/w (Table23) in order to prevent, slow down or inhibit a possible surface 
re-crystallization of the main plasticizer (LA). 
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Table 23: Ternary physical mixture based on Ethocel E10, LA and KVA 64 at different concentrations. 
Polymer (%w/w) Plasticizer (% w/w) Adjuvant (%w/w) physical mixture 
Ethocel E10 LA KVA 64 ratio( % w/w) 
87.5 10 
2.5 
87.5:10:2.5 
77.5 20 77.5:20:2.5 
67.5 30 67.5:30:2.5 
 
 
11.2.2.2. Free Films preparation 
Forty six free films based on ethylcellulose Ethocel® Standard 10 FP (9.7 µm), lauric acid (main 
solid plasticizer), oleic acid (second liquid plasticizer acting as adhesion enhancer) and KVA 64 
(lauric acid re-crystallization inhibitor) in different percentages were prepared and characterized. 
Moreover, free films based on ethylcellulose: lauric acid: oleic acid (70:20:10 %, w/w) containing 
2% and 5% w/w of talc extra-formulation were realized in order to verify the influence of the anti- 
sticking agent on film formation.  
Briefly, the free films were obtained by tableting the physical coating blend (ethylcellulose plus 
plasticizers) in an alternative press machine (EKO, Korsh) equipped with flat faced punches 
(diameter: 25 mm). Firstly, the determination of the minimum polymer- softening temperature 
was carried out on a heating balance (Top Rey, Alessandrini) equipped with a metal plate with a 
variable temperature gradient (50 - 105°C) and the degree of the film formation was determined 
by observing the appearance of transparency of the free film. Afterwards, the free films were 
cured in a static oven (Friocell, MMM Med Center) at the MFFT for at least three hours to 
complete the polymer particle coalescence. Finally the stability of uncured/cured films was 
evaluated (T= 25°C; RH= 60% and t= 1 year). 
The free films were classified according to the percentage w/w of the main solid plasticizer lauric 
acid, (independent variable of the pre-formulation study) and their compositions are reported in 
Table 24. 
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Table 24: Free films compositions. 
Ethocel Plasticizers (% w/w) Adjuvants 
KVA 64 (% w/w) 
Free – Film 
ratio (% w/w) type % (w/w) LA OA 
E7 90 10 - - 90:10 
E10 
90 
10 
- 
- 
90:10 
85 5 85:10:5 
80 10 80:10:10 
E20 90 10 - - 90:10 
E7 77.5 15 7.5 - 77.5:15:7.5 75 10 75:15:10 
E7 75 15 7.5 2.5 75:15:7.5:2.5 
72.5 10 72.5:15:10:2.5 
E7 80 20 - - 80:20 
E10 
80 
20 
- 
- 
80:20 
75 5 75:20:5 
72.5 7.5 72.5:20:7.5 
70 10 70:20:10 
65 15 65:20:15 
60 20 60:20:20 
50 30 50:20:30 
E10 
72.5 
20 
5 
2.5 
72.5:20:5:2.5 
70 7.5 70:20:7.5:2.5 
67.5 10 67.5:20:10:2.5 
E10 
70 
20 
5 
5 
70:20:5:5 
67.5 7.5 67.5:20:7.5:5 
65 10 65:20:10:5 
60 15 60:20:15:5 
55 20 55:20:20:5 
45 30 45:20:30:5 
E10 77.5 20 - 2.5 77.5:20:2.5 
E20 80 20 - - 80:20 
E10 
70 
25 
5 
- 
70:25:5 
67.5 7.5 67.5:25:7.5 
65 10 65:25:10 
E10 
67.5 
25 
5 
2.5 
85:10:5 
65 7.5 65:25:7.5:2.5 
62.5 10 62.5:25:10:2.5 
E10 
65 
25 
5 
5 
65:25:5:5 
62.5 7.5 62.5:25:7.5:5 
60 10 60:25:10:5 
E7 70 30 - - 70:30 
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E10 
70 
30 
- 
- 
70:30 
65 5 65:30:5 
62.5 7.5 62.5:30:7.5 
60 10 60:30:10 
E10 
62.5 
30 
5 
2,5 
62.5:30:5:2.5 
60 7.5 60:30:7.5:2.5 
57.5 10 57.5:30:10:2.5 
E10 
60 
30 
5 
5 
60:30:5:5 
55 10 55:30:10:5 
E20 70 30 - - 70:30 
 
11.2.2.3. Development of dry powder coating process on placebo pellets 
Dry powder coating process was performed in a laboratory scale high shear mixer granulator 
(Roto Lab Zanchetta IMA) and preliminary trials were conducted to optimize the equipment 
configuration on the basis of the selected pellets size and friability. In particular, dry powder 
coating process consisted of three phases (Figure 29): 1) pre-heating of the sugar spheres at 
minimum film forming temperature of the formulation with tilting of the bawl of the Rotolab; 2) 
powdering: addition of the components of the coating formula (the mode and the order of 
addition varied through the trials and were finally optimized) and 3) curing: half batch of each trial 
was cured at minimum film forming temperature (MFFT) for 24 hours in an air forced oven; the 
uncured pellets were immediately stored at room temperature in PE closed bottles. A batch size of 
150 g sugar spheres (1180-1400 µm) was processed in each run of coating.  
Figure 29: The outline of dry coating process [9]. 
 
 
Moreover, formulation variables (particle size of the plasticizer, addition of the anti-sticking 
agent) and process related parameters (jacket temperature, impeller rotation speed, excipients’ 
addition mode and order inside the granulation chamber, tilting on/off) were fully investigated. 
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Since ethylcellulose was employed as FP (lower than 9.7 µm) and the second plasticizer (oleic 
acid) is liquid at room temperature, the influence of three different particle size of the main 
plasticizer (lauric acid) on the whole process was evaluated: <500 µm, <150 µm and <100 µm. 
Then, the influence of the impeller speed on both pellet crushing at the beginning of the coating 
process and on the extent of coated pellets sticking at the end of the film coating process was 
evaluated. Thus, three different rotation speeds, namely 120, 150 and 180 rpm, were assessed in 
order to identify the optimal rotation speed able to minimize pellets fractiousness and, thus 
reducing the coating loss. Subsequently, in order to evaluate and standardize the addition mode of 
the coating excipients, impeller speed, polymer particle size and addition order of the excipients 
into the chamber were first kept unchanged. Thus, ethylcellulose was directly transferred into the 
chamber as fine powder and distributed onto the cores when the impeller was rotating at 120 
rpm.  
Contrarily, lauric acid was introduced into the bowl of the high shear granulator in three different 
modes: (i) as micronized powder; (ii) atomized at 3.5 bar by a compressed air gun inserted into the 
lid of the granulation chamber; (iii) molten and poured in the bowl of the high shear granulator 
together with the second liquid plasticizer, oleic acid, through the lid of the chamber.  
Similarly to lauric acid, oleic acid was added in two different modes: (i) sprayed into the bowl of 
the high shear granulator through a second liquid spray gun at 1.5 bar inserted into the lid of the 
granulation chamber; (ii) molten and poured in the bowl of the high shear granulator together 
with molten lauric acid through the lid of the chamber.  
Talc was added extra- formulation in percentages equal to 2.5% or 5% w/w with respected to the 
theoretical amount of solid applied to reduce pellets aggregation and adhesion on the coating 
chamber. 
Since the maximum working temperature allowed inside the granulation chamber was 80°C and 
higher values were not feasible inside the bowl of the high shear granulator, the lead coating 
formulations should have required an equal MFFT value or lower values. The formulation based on 
the E10FP:LA:OA weight ratio of 70:20:10 exhibited a MFFT equal to 80°C and thus, was 
preliminarily selected as a model coating formulation in order to fully investigated the formulation 
variables and process related parameters listed above. Table 25 lists the details of the different 
mode of addition of the excipients in the first trials. 
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Table 25: Different mode of addition of the excipients. 
Trials 
Formulation variables and process parameters 
Ethocel E10 Lauric Acid Oleic Acid Talc 
 (% w/w) added as (% w/w) µm added as (% w/w) added as (% w/w) 
I 70 fine powder 20 < 500 powder 10 molten X 
II 70 fine powder 20 < 500 molten 10 molten X 
III 70 fine powder 20 < 150 powder 10 nebulised X 
IV 
70 fine powder 20 < 100 atomized 10 nebulised 
X 
V 2,5 
VI 5 
 
Oleic acid was then coloured with lipophilic dye, Red Sudan III, to visually evaluate the uniformity 
of oleic acid distribution on the moving pellets. Four trials were performed while maintaining 
unchanged the formulation variables and process related parameters previously optimized. The 
selected coating formulation (E10:LA:OA w/w equal to 60:20:20) contained an higher amount of 
oleic acid allowing an easier evaluation of its distribution around the Suglets®: in the first trial, 
according to the desired theoretical weight gain, all the amount of ethylcellulose accurately 
weighed was transferred into the granulation chamber during the pre-heating phase and 
intimately distributed onto the pellets to be coated. When the pellets reached the MFFT, 
plasticizers were sequentially introduced inside the bowl: firstly, oleic acid was sprayed through a 
liquid spray gun at 1.5 bar followed by the atomization of lauric acid at 3.5 bar by a compressed air 
gun inserted into the lid of the granulation chamber. 
Alternatively, only the first half of the entire amount of ethylcellulose required for the coating 
process was intimately distributed onto the pellets in the bowl of the chamber during the pre-
heating phase. When the product reached the MFFT, the oleic acid was continuously sprayed at 
1.5 bar followed by the gradually addition to the second half of ethylcellulose required for the 
coating process. Finally lauric acid is atomized at 3.5 bar by a compressed air gun.  
During the third trial, placebo pellets were pre-heated to the expected MFFT of the coating 
formulation in absence of plasticizers and ethylcellulose. Reached the MFFT, oleic acid was 
continuously sprayed at 1.5 bar onto the cores to be coated in order to allow a greater adhesion 
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around Suglets® of the total amount of ethylcellulose necessary to achieve the desired weight 
gain. Afterwards, lauric acid was continuously atomized at 3.5 bar through a compressed air gun.  
Similarly, in the latest trial, placebo pellets were pre-heated to the expected MFFT of the coating 
formulation in absence of plasticizers and ethylcellulose. Once reached the working temperature 
required by the coating formula, the oleic acid was continuously sprayed at 1.5 bar onto the cores 
to be coated, whereas ethylcellulose and lauric acid were alternatively introduced into the 
granulation chamber.  
Figure 30 shows the details of the two spray guns used for the plasticizers atomization: the one 
for the liquid OA and the other for the milled LA. 
 
Figure 30: Details of the two spray guns used for the plasticizers atomization. 
 
 
Weight gain (WG %), total yield (%), coating loss (%), pellets aggregation (%), coating efficiency 
(cRSDW %) were calculated using equations (14-17).  
 
WG % = ࢃ࡯ࡼିࢃࡸࡼ
ࢃࡸࡼ
∗ ૚૙૙         Eq. 14 
Yield % = ࢃࡸࡼ
ࢃࡿ
∗  ૚૙૙         Eq. 15 
Coating loss % = ࢃ࢚ࢎ–ࢃ࢘
ࢃ࢚ࢎ
∗ ૚૙૙        Eq. 16 
RSDw% = 
ඥ(ࡿࡰࢃ࡯ࡼ)૛ି(ࡿࡰࢃࡿ)૛
ࢃ࡯ࡼିࢃࡿ
∗ ૚૙૙       Eq. 17 
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where: WS= mean weight of placebo pellets (equivalent to uncoated pellets), WCP = mean weight 
of coated pellets, Wth = weight of solids to be applied and Wr = weight of solids applied. 
In particular,  cRSD W % was expressed as the Relative Standard Deviation of the weight applied 
(RSDW) on a mean of at least six measurements on 50 pellets within the same coating experiment. 
The pellets aggregation was determined by calculating the percentage of coated pellets that did 
not pass through a 2000 m sieve with respect to the collected amount of pellets at the end of the 
process, since single coated pellets had dimension lower than 2000 m.  
 
11.2.2.4. Morphological analysis 
Free films and coated placebo pellets were observed using a an optical microscope (Nikon SNZ 
2T) connected through a camera (Panasonic GP KR 222) to an image acquisition system (CV 9000, 
FKV S.r.l. BG, Italy). 
 
11.2.2.5. Long term storage stability of free films and pellets 
To assess long term storage stability, uncured and cured pellets were stored at 25°C/ 60 ± 0.5% 
relative humidity (R.H.) in PE closed bottles. Drug release from pellets was measured after 1 year 
of storage. Day 0 corresponded to the day after the preparation of layered and coated pellets.  
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11.3. RESULTS 
11.3.1. Screening of Polymers and Plasticizers 
As extended release coating polymer three types of ethylcellulose with different molecular 
weight and viscosity grade were evaluated. DSC curve of pure ETHOCEL E7, E10 and E20 raw 
materials are reported in Figure 31, whereas their glassy transition temperature values were 
137.24 (± 0.51)°C, 131.07 (± 0.59)°C and 127.08 (± 0.67)°C, respectively. 
 
Figure 31: DSC scans of pure ETHOCEL E7, E10 and E20 raw materials. 
 
 
 
Based on the results, ethylcellulose raw material exhibits a high glass transition temperature and 
forms weak and brittle films [8]. These characteristics require the use of plasticizers to lower the 
minimum film forming temperature (MFFT) and to improve the film properties. In dry powder 
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coating, plasticizers are of particular importance, as, besides the enhancement of film formation 
by lowering the Tg, they improve the adhesion of coating material to the core pellets by forming 
liquid bridges. Moreover, due to the fact that no water was used, which could act as temporary 
plasticizer, a sufficient plasticizing activity of the used additives is necessary. Therefore, DSC 
measurements of both plasticized and pure ethylcellulose were conducted with commonly used 
plasticizers of various concentration to evaluate their efficiency in lowering the Tg of 
ethylcellulose. 
Binary physical mixtures based on Ethocel E7 and low melting fatty acids, lauric (LA) and myristic 
(MA) acid, Dynasan 114, glyceryl monostearate (GMS), Myvatex and Myverol at different 
concentrations (10%, 20% and 30% w/w based on the dry polymer weight) were prepared and 
characterized by means of DSC in order to lower the Tg of the coating blend and, thus, to reach 
the working temperature allowed by the high shear rotogranulator, which works at a maximum 
temperature of80°C. The results are listed in Table 26. 
 
Table 26: Tg (°C) ± SD of binary physical mixtures based on Ethocel E7 and low melting fatty acids at 
different concentrations. 
Polymer 
(% w/w) Plasticizer (% w/w) Physical mixture 
Ethocel E7 LA MA Dynasan 114 GMS Myvatex Myverol Ratio (% w/w) Tg (°C) ± SD 
90 10 X X X X X 90:10 102.01 ± 2.31 
80 20 X X X X X 80:20 98.84 ± 2.85 
70 30 X X X X X 70:30 84.73 ± 0.43 
90 X 10 X X X X 90:10 111.69 ± 0.21 
80 X 20 X X X X 80:20 110.7 ± 0.78 
70 X 30 X X X X 70:30 100.22 ± 1.91 
90 X X 10 X X X 90:10 120.97 ± 0.30 
90 X X X 10 X X 90:10 131.61 ± 0.37 
90 X X X X 10 X 90:10 125.22 ± 2.96 
90 X X X X X 10 90:10 131.21 ± 0.14 
 
As expected, the minimum polymer softening temperature (MST) decreased as the plasticizer 
concentration increased. The efficiency of the plasticizer to lower the MST was in order: lauric 
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acid> myristic acid> Dynasan 114> Myvatex> Myverol> GSM. Therefore, the lowest melting fatty 
acid, lauric acid, was chosen as mains solid plasticizer for further pre-formulation studies. Thus, 
several weight ratio between lauric acid and two ethylcellulose with different viscosity grade were 
evaluated. The experimental results are shown in Table 27, the glassy transition temperature 
values of all type of Ethocel decreased as the lauric acid concentration increased. 
 
Table 27: Tg (°C) ± SD of binary physical mixtures based on LA and Ethocel E10 or E20 at different 
concentrations. 
Ethocel (%w/w) Plasticizer (%w/w) Physical mixture 
E10 Lauric acid ratio (% w/w) Tg (°C) ± SD 
90 10 90:10 111.12 ± 0.22 
80 20 80:20 100.09 ± 0.53 
70 30 70:30 85.69 ± 0.98 
E20 Lauric acid ratio (% w/w) Tg (°C) ± SD 
90 10 90:10 107.9 ± 0.61 
80 20 80:20 102.83 ± 0.70 
70 30 70:30 99.04 ± 0.44 
 
DSC scans of both pure and plasticized (20% lauric acid based on dry polymer weight) 
ethylcellulose are compared in Figure 32. 
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Figure 32: DSC scans of both pure ETHOCEL E10 and of the physical mixture based on E10:LA/80:20. 
 
Tg values assessed throughout the DSC measurements plotted as a function of the percentage of 
lauric acid (based on the dry polymer weight) added to the coating formulation are reported in 
Figure 33. Ethocel E10 exhibits a more linear trend (r2 = 0.986) with respected to the other 
cellulosic polymer evaluated. 
 
Figure 33: Tg values plotted as a function of the percentage of lauric acid (based on the dry polymer 
weight). 
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Nevertheless, the Tg measured was still too high and the desired working temperature hadn’t 
reached. Therefore, a second liquid plasticizer, oleic acid, was added to the powder coating blend 
in order to further lower the Tg of ethylcellulose. Oleic acid was selected as suitable excipient, 
since its salt form (ammonium oleate) commonly acts as a plasticizer in aqueous based 
ethylcellulose dispersions of (i.e. Surealese®). To this purpose, 9 physical mixtures containing both 
lauric and oleic acid were prepared. The obtained glassy transition temperature are listed in Table 
28. The experimental results revealed that the powder coating blend based on at least 20% w/w of 
lauric acid and 10% w/w of oleic acid reached the target Tg value. 
 
Table 28: Tg (°C) ± SD of ternary physical mixtures based on Ethocel E10: LA: OA at different concentrations.  
 
Polymer (% w/w) Plasticizer (% w/w) Physical mixture 
Ethocel E10 LA OA Ratio (% w/w) Tg (°C) ± SD 
85 
10 
5 85:10:5 107.33 ± 0.36 
80 10 80:10:10 93.42 ± 0.89 
70 20 70:10:20 85.56 ± 0.25 
75 20 5 75:20:5 93.2 ± 0.28 
70 
20 
10 70:20:10 78.07 ± 0.72 
60 20 60:20:20 72.06 ± 0.76 
65 
30 
5 65:30:5 83.04 ± 0.11 
60 10 60:30:10 66.66 ± 0.14 
50 20 50:30:20 60.04 ± 0.17 
 
Figure 34 compares the DSC measurements of the physical mixture based on Ethocel: LA: OA/ 70: 
20: 10 with respected to the pure polymer and the same physical mixture (Figure 32, p. 137) 
without the liquid plasticizer. The DSC scan of the ternary mixture exhibited the lower Tg with 
respected to the binary one. 
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Figure 34: DSC scans of: pure ETHOCEL E10; binary physical mixture based on E10:LA/80:20; ternary 
physical mixture based on E10:LA:OA/70:20:10. 
 
In Figure 35, Tg values assessed throughout the DSC measurements were plotted as a function of 
the percentage of LA (based on the dry polymer weight) added to the coating formulation (10 – 
30% w/w) in presence of 5%, 10% and 20% w/w of OA.  
 
Figure 35: Tg values plotted as a function of the percentage of LA (10 – 30%) in presence of OA (5 -20%). 
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It can be noticed that, the main solid plasticizer, LA, and the second liquid one, OA, had a 
synergistic effect in lowering Tg of the polymer. Indeed, the physical mixture containing the 30% 
w/w only of LA exhibited a Tg value equal to 85.69 (± 0.98)°C. This valuedecreasedto78.07 (± 
0.72)°C in the physical mixtures based on LA:OA/2:1 weight ratio maintaining, thereby, the total 
amount of plasticizer closed to 30% w/w and reaching the target Tg value.  
Afterwards, the influence of KVA 64as adjuvant to prevent the surface re-crystallization of lauric 
acid on the glassy transition temperature of the plasticized ethylcellulose was evaluated. The Tg 
values assessed by means of DSC measurements are listed in Table 29 and they were plotted as a 
function of the percentage of LA (based on the dry polymer weight) added to the coating 
formulation (10 – 30% w/w). The graph obtained is depicted in Figure 36. KVA 64 didn’t affected 
the glassy transition temperature of the plasticized ethylcellulose. 
 
Table 29: Tg (°C) ± SD of ternary physical mixtures based on Ethocel E10: LA: KVA 64 at different 
concentrations. 
Ethocel (%w/w) Plasticizer (% w/w) Adjuvant (%w/w) physical mixture 
E10 LA KVA 64 ratio( % w/w) Tg (°C) ± SD 
87.5 10 
2.5 
87.5:10:2.5 113.96 ± 0.65 
77.5 20 77.5:20:2.5 103.75 ± 0.31 
67.5 30 67.5:30:2.5 89.98 ± 0.54 
 
Figure 36: Tg values plotted as a function of the percentage of LA (10 – 30% w/w) in absence and presence 
of a fixed concentration of KVA 64 (2.5 % w/w). 
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11.3.2. Free Films Characterization 
In order to better understand the film formation process and to achieve the minimum film 
forming temperature (MFFT) of each coating blend, free film were prepared and analysed.The free 
films based on ethylcellulose as hydrophobic coating agent have been classified into 5 groups 
(Table 30) according to the amount of the main solid plasticizer, LA, added to the coating 
formulation (10/15/20/25/30 % w/w). Oleic acid was the second liquid plasticizer acting as 
adhesion enhancer. The experiments considered also the addition of Kollidon –vinyl acetate 
copolymer (KVA 64). The degree of the film formation was determined by observing the 
appearance of transparency of the free film.  
Table 30: MFFT of the free films. 
Ethocel Plasticizers (% w/w) Adjuvants 
KVA 64 (% w/w) 
Free – Film 
ratio (% w/w) MFFT (°C) type % (w/w) LA OA 
E7 90 10 - - 90:10 - 
E10 
90 
10 
- 
- 
90:10 - 
85 5 85:10:5 100 
80 10 80:10:10 90 
E20 90 10 - - 90:10 - 
E7 
77.5 
15 
7.5 
- 
77.5:15:7.5 
85 
75 10 75:15:10 
E7 
75 
15 
7.5 
2.5 
75:15:7.5:2.5 
85 
72.5 10 72.5:15:10:2.5 
E7 80 20 - - 80:20 100 
E10 
80 
20 
- 
- 
80:20 100 
75 5 75:20:5 90 
72.5 7.5 72.5:20:7.5 80 
70 10 70:20:10 80 
65 15 65:20:15 75 
60 20 60:20:20 70 
50 30 50:20:30 50 
E10 
72.5 
20 
5 
2.5 
72.5:20:5:2.5 90 
70 7.5 70:20:7.5:2.5 80 
67.5 10 67.5:20:10:2.5 80 
E10 
70 
20 
5 
5 
70:20:5:5 90 
67.5 7.5 67.5:20:7.5:5 
80 65 10 65:20:10:5 
60 15 60:20:15:5 
55 20 55:20:20:5 70 
45 30 45:20:30:5 50 
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E10 77.5 20 - 2.5 77.5:20:2.5 100 
E20 80 20 - - 80:20 100 
E10 
70 
25 
5 
- 
70:25:5 
80 67.5 7.5 67.5:25:7.5 
65 10 65:25:10 
E10 
67.5 
25 
5 
2.5 
85:10:5 
80 65 7.5 65:25:7.5:2.5 
62.5 10 62.5:25:10:2.5 
E10 
65 
25 
5 
5 
65:25:5:5 
80 62.5 7.5 62.5:25:7.5:5 
60 10 60:25:10:5 
E7 70 30 - - 70:30 90 
E10 
70 
30 
- 
- 
70:30 90 
65 5 65:30:5 
80 62.5 7.5 62.5:30:7.5 
60 10 60:30:10 
E10 
62.5 
30 
5 
2.5 
62.5:30:5:2.5 
80 60 7.5 60:30:7.5:2.5 
57.5 10 57.5:30:10:2.5 
E10 
60 
30 
5 
5 
60:30:5:5 
80 
55 10 55:30:10:5 
E20 70 30 - - 70:30 90 
 
All the films based on both 10% w/w and 15% w/w of lauric acid did not achieve the Tg target 
value as about 80°C closed to the working temperature allowed by the high shear granulator. All 
the films with 20% of LA and more than 7.5 % w/w of OA reached the Tg target value between 
50°C and 80°C and the presence of KVA form 2.5% w/w to 5% w/w to prevent the lauric acid 
surface re- crystallization didn’t avoid the film formation. 
With regards to the stability, cured and uncured free - films based on at least 1.33:1 weight ratio 
of LA:OA (i.e. 20% LA and 15% OA) resulted stable for one year (Tables 30 and 31) and no re-
crystallization of low melting fatty acid occurred, even in absence of KVA 64 (Figure 37a). 
Moreover, cured free films based on 2:1 ratio of LA:OA (i.e. 20% LA and 10% OA) resulted stable 
for one year only in presence of 5 % KVA 64. Contrarily, LA re- crystallized throughout the surfaces 
of both 10 cured and uncured free films based on 2:1 ratio of LA:OA when the coating blend did 
not contained KVA 64.  
All the films containing the 25% w/w of lauric acid reached the expected Tg target value as about 
80°C (Table 30), but after only 3 months of storage they didn’t appear stable: lauric acid re- 
crystallized with or without KVA 64 on the surface of both cured and uncured free films (Tables 31 
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and 32). In fact, the free films analyzed by means of DSC measurements both at t0 and t 1 year 
(Figure 37b) revealed a sharp endothermic peak at 45.08 ± 0.35°C, temperature value very closed 
to the LA main melting peak, after one year of storage (25°C/60 RH). As previously disclosed, the 
free films with 30% w/w of lauric acid achieved the Tg target value but the amount of oleic acid 
and KVA used was too low to completely avoid or minimize the lauric acid re- crystallization at 
room temperature immediately after the film formation (Tables 31 and 32). This thermal behavior 
was clearly highlighted throughout the DSC measurements depicted in Figure 37c. 
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Table 31: Stability of free – films after 3, 6 months and 1 year of storage at 25°C/60% RH. 
 
Coating formulations Stability (25°C / 60% RH) 
LA 
% (w/w) 
E10:LA:OA:KVA 64 
weight ratio  
3 months 6 months 1 year 
uncured cured Uncured cured uncured cured 
20 
72.5:20:7.5:0 V V X V X X 
70:20:10:0 V V X V X X 
65:20:15:0 V V V V V V 
60:20:20:0 V V V V V V 
50:20:30:0 V V V V V V 
70:20:7.5:2.5 V V V V X X 
67.5:20:10:2.5 V V V V X X 
67.5:20:7.5:5 V V V V X X 
65:20:10:5 V V X V X V 
60:20:15:5 V V V V X X 
55:20:20:5 V V V V V V 
45:20:30:5 V V V V V V 
25 
70:25:5:0 X X X X X X 
67.5:25:7.5:0 X X X X X X 
65:25:10:0 X X X X X X 
67.5:25:5:2.5 X V * X X X X 
65:25:7.5:2.5 X V * X X X X 
62.5:25:10:2.5 X X X X X X 
65:25:5:5 X V * X X X X 
62.5:25:7.5:5 X V * X X X X 
60:25:10:5 X X X X X X 
30 
65:30:5:0 X X X X X X 
62.5:30:7.5:0 X X X X X X 
60:30:10:0 X X X X X X 
62.5:30:5:2.5 X X X X X X 
60:30:7.5:2.5 X X X X X X 
57.5:30:10:2.5 X X X X X X 
60:30:5:5 X X X X X X 
55:30:10:5 X X X X X X 
  
145 
 
Table 32: Pictures of free films upon storage. 
Coating 
formulations Stability (25°C / 60% RH) 
E10:LA:OA:KVA 64  day 0 1 year 
weight ratio uncured cured uncured Cured 
70:20:10:0 
60:20:20:0 
65:20:10:5 
55:20:20:5 
62.5:25:10:2.5 
60:25:10:5 
55:30:10:5 
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Figure 37: DSC scan of free films upon storage containing: a) 20% ; b) 25% and c) 30% w/w of LA. 
a) 
 
b)  
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Therefore it can be stated that the optimal concentration of the solid plasticizer was 20% w/w. 
Formulations with lower concentration of lauric acid showed Tg of the polymer greater than 80°C, 
too high to be able to be maintained in the course of a coating process. At LA concentration higher 
than 20%, some extent of re- crystallization occurred: lauric acid molecules tend to diffuse out of 
the polymer of ethyl cellulose chains, forming crystals on the film surface, as clearly shown by the 
picture reported in Table 32. 
Oleic acid, the liquid plasticizer, was important for the formation of the film concurring with 
lauric acid to a significant lowering of the MFFT. Oleic acid percentages ranging between 7.5% and 
10% w/w decreased the MFFT to 80°C. To achieve lower temperature values without increase the 
solid plasticizer, it was necessary to increase the concentration of oleic acid up to values between 
15% (MFFT= 75°C) and 20% w/w (MFFT= 70°C). In the presence of 30% of oleic acid, the film was 
formed at 50 °C but was extremely soft and poorly applicable to the dry powder coating process. 
The optimum concentration of oleic acid was thus between 10% and 20% w/w. 
The curing phase was important to ensure the formation of a homogeneous and stable film over 
time, as well as to improve the appearance. 
As regards the adjuvant, KVA 64 did not alter the fundamental properties of the film (although it 
slightly increased the rigidity) and acted as a stabilizer decreasing the extent of re- crystallization 
of the solid plasticizer; however it was not decisive for the stability of the film. Generally it was 
preferable to use the KVA in concentrations up to 2.5% w/w, but if used in the presence of oleic 
acid, it was possible to use up to 5% w/w.  
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11.3.3. Dry Powder Coating Process on Placebo Pellets 
Dry powder coating process was performed in a laboratory scale high shear mixer granulator 
(Roto Lab Zanchetta IMA) and preliminary trials were conducted to optimize the equipment 
configuration and setting it for a layering/coating process. Then preliminary tests were performed 
to optimize the formulation parameters (i. e., particle size of LA) and standardize the process 
parameters involved (i.e. mode of addition of the excipients and their order). 
 
11.3.3.1. Excipients’ addition manner inside the equipment 
The formulation based on ethylcellulose E10 FP:LA:OA/70:20:10 exhibited a MFFT equal to 80°C 
and thus, was preliminarily selected as a model coating formulation in order to fully investigated 
the process related parameters. Six experiments were assessed and a batch size of 150 pellets 
(1180 – 1400 µm) was coated in each process in order to apply a theoretical weight gain equal to 
15% w/w. In each run of coating, ethylcellulose was firstly transferred into the granulation 
chamber as micronized powder lower than 9.7 µm and distributed onto the cores when the 
impeller was rotating at the fixed rotating speed closed to 120 rpm. Afterwards, both lauric and 
oleic acid has been introduced into the bowl of the high shear granulator in different ways 
summarized in Table 25 (p. 131; paragraph 11.2.2.3). 
(I) lauric acid was added as micronized powder lower than 500 µm whereas oleic acid was 
poured into the granulation chamber; 
(II) lauric acid was molten and poured in the bowl of the high shear granulator together with 
the second liquid plasticizer oleic acid through the lid of the chamber; 
(III) lauric acid was inserted as micronized powder lower than 150 µm whereas oleic acid was 
sprayed into the bowl of the high shear granulator through a liquid spray gun at 1.5 bar inserted 
into the lid of the granulation chamber; 
(IV) lauric acid was micronized in a fine powder lower than 100 µm and, afterwards, was 
atomized at 3.5 bar by a compressed air gun inserted into the lid of the granulation chamber, 
whereas oleic acid was sprayed into the bowl of the high shear granulator through a second liquid 
spray gun at 1.5 bar inserted into the lid of the granulation chamber. 
The anti-sticking properties of talc was also studied in order to optimize the coating efficiency. 
Thereby, the ability of talc to reduce pellets aggregation to each other and to minimize their 
adhesion both on the wall of the granulation chamber as well as on the impeller during the coating 
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process was evaluated. Talc, in percentages equal to 2.5% (V) or 5% w/w (VI) with respected to 
the amount of solid applied, was transferred into the granulation chamber together with the 
ethylcellulose and homogeneously distributed onto the cores before the film formation during the 
pre-heating phase of the dry powder coating process. 
The particle size of the powders involved in the coating process was a critical key formulation 
parameter leading to a successfully powder adhesion and improving the film properties; thereby 
micronized ethylcellulose powders lower than 9.7 µm and atomized lauric acid particles lower 
than 100 µm were necessary to assure both the adhesion around the Suglets® and the uniformity 
of the final film. 
Based on the obtained resultsusing this formulation, the optimized process was structured as 
follows: placebo pellets were pre-heated to the selected temperature of 80°C, since it is the MFFT 
of the model coating formulation. During the powdering phase, Ethocel® E10 fine powder (< 9.7 
µm) was alternatively transferred into the granulation chamber and distributed onto the cores 
using an impeller speed at 120 rpm, meanwhile the main solid plasticizer lauric acid (particle size < 
100 µm) was atomized inside the bowl through a compressed air spray gun at 3.5 bar inserted into 
the lid of the granulation chamber. Afterward, the second liquid plasticizer oleic acid was sprayed 
through a second spray gun at 1.5 bar to promote both polymer particle adhesion and coalescence 
and, thus, the formation of the film layer around the Suglets®. Talc, in percentages equal to 5% 
w/w with respected to the theoretical amount of solid applied, was added to coated cores at the 
end of the coating process, when the film formation has been already occurred, in order to 
minimize the percentage of aggregation of pellets during the curing step in oven at the MFFT.  
Coated pellets were further cured for 24 hours in a static oven at 80°C and weight gain (wg %), 
total yield (%), coating efficiency (RSDW %) expressed as the Relative Standard Deviation of the 
weight applied (RSDW) on a mean of at least three coating experiments, coating loss (%) and 
percentage of aggregation/sticking calculated are shown in Table 33. 
The results demonstrate the impact of the spreading behaviour of plasticizers and consequently 
their influence on the coating efficiency of the process: in agreement with the cRSDw % results 
reported in Table 33, the atomization of both the main solid plasticizer lauric acid and the second 
liquid adhesion enhancer oleic acid at 3.5 bar and 1.5 bar respectively (trials IV and VI) is 
suggested in order to maximize the coating efficiency. The experimental weight gains applied were 
closed to the theoretical ones, total yields were higher than 80% (ranging from 83.59 % to 88.47 
%) and cLoss decreased from 32.21% - 36.01% (trials I - II) to 11.53 % (trial VI).  
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The optimized dry powder coating process (trials IV and VI) was reproducible with relative 
standard deviation intra batches (cRSDw%) ranging from 3.32% to 5.39% for cured coated pellets 
whereas the cRSDw% values for the untreated samples varied within 5.35 % and 7.63 %. Thus, the 
post coating thermal treatment at the MFFT of the coating formulation was successful for lowering 
the cRSDw% values than the USP reference value closed to 6.25% and resulting in a better coating 
uniformity.  
Furthermore, talc in percentages equal to 5% w/w optimized the percentage of sticking without 
significantly affecting the cRSDw% both reducing pellets aggregation to each other and minimizing 
their adhesion on the wall of the granulation chamber as well as on the impeller during the coating 
process. Thereby, the % of aggregation of pellets lowered from 34.04 % (trial II) – 28.97 % (trial IV) 
without talc to 6.79 % (trial VI) having 5% w/w of talc. 
 
Table 33: Dry powder coating process related parameters and c RSD w % intra batch values. 
trial Dry Powder Coating Process Related Parameters C RSD w % INTRA BATCH 
n° Yield cLoss WG (th.) % WG (s) % Pellets aggregation (%) cured (24h) uncured 
I 67.79 32.21 15 10.17 23.36 6.60 11.91 
II 63.99 36.01 15 9.60 34.04 n.a 9.23 
III 87.56 12.44 15 13.14 31.46 4.88 6.33 
IV 86.57 13.43 15 12.99 28.97 3.32 5.35 
V 83.59 16.41 15 12.54 13.42 5.39 7.63 
VI 88.47 11.53 15 13.27 6.79 3.64 7.21 
 
 
11.3.3.2. Excipients’ addition order inside the granulation chamber 
In order to investigate the impact of the order of addition of the excipients inside the working 
chamber on the reproducibility of the dry powder coating process, oleic acid has been colored 
with a lipophilic dye, Red Sudan III to visually evaluate the oleic acid distribution uniformity on the 
pellets. To this purpose, four preliminary trials were carried out using a coating formulation based 
on E10:LA:OA/ 60:20:20 since it exhibits a MFFT equal 70°C and, according to the weight gain 
applied, the greatest amount of oleic acid required allows an easier evaluation of its distribution 
around the Suglets® (Figure 38). Each run of coating has been previously described in paragraph 
11.2.2.3. OA was not intimately distributed onto the pellets if oleic acid was sprayed inside the 
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bowl after the entire amount or the half of ethylcellulose, (trial I – II described in paragraph 
11.2.2.3); thus the coating uniformity wasn’t reached (Figure 38a). Otherwise, during the 
powdering phase, if ethylcellulose and lauric acid weren’t alternatively transferred into the bowl 
of the high shear granulator, the coating was not uniform as well. 
To successfully achieve the coating uniformity (Figure 38b), placebo pellets were pre-heated to 
the MFFT of the coating formulation (70°C) in absence of both plasticizers (lauric and oleic acid) 
and ethylcellulose. Reached the working temperature required by the coating formulation, the 
oleic acid is continuously sprayed at 1.5 bar onto the cores to be coated through a liquid spray gun 
inserted into the lid of the granulation chamber in order to promote the subsequent polymer 
particle adhesion and coalescence and, thus, the formation of the film layer around the Suglets®. 
Afterwards, during the powdering phase, Ethocel® E10 fine powder (< 9.7 µm) was alternatively 
transferred into the granulation chamber and distributed onto the cores using an impeller speed 
at 120 rpm, meanwhile the main solid plasticizer lauric acid (particle size < 100 µm) was atomized 
inside the bowl through a compressed air spray gun at 3.5 bar inserted into the lid of the 
granulation chamber. The powder coated pellets were further cured for 24 hours in a static oven 
at the MMFT of the selected coating formulation. 
 
Figure 38: Oleic acid distribution uniformity evaluation. 
(a) coating uniformity not reached (b) coating uniformity reached 
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11.4. CONCLUSIONS 
 
The results showed that it was possible to carry out the process of dry powder coating based on 
ethylcellulose without the use of water or organic solvents inside a rotogranulator, usually proper 
for granulation end pellettization procedures. Physical mixtures of ethylcellulose with suitable 
plasticizers formed transparent and flexible films. Each physical mixture or "coating formula", 
according to its composition showed a different MFFT.  
The most active plasticizers were lauric acid, a low melting lipid, and oleic acid, a liquid fatty acid, 
which, besides having a synergistic effect in lowering the Tg of the polymer, worked by adhesion 
enhancer by “wetting” the cores. The results demonstrate that the optimal amount of lauric acid 
in the mixture was 20% (w/w). The best oleic acid percentages varied vary between 15-20% (w/w). 
Another important parameter was the particle size of the powders, that greatly influenced the 
formation of the film and powders in the micronized form were effective.  
The study on free films considered also the addition of Kollidon –vinyl acetate copolymer (KVA 
64) as adjuvant to prevent the re-crystallization of lauric acid, especially when the lauric acid was 
in a concentration higher than 20%. Therefore, the composition of the coating mixture contained a 
relatively high percentage of plasticizer (35-40% w/w based on dry polymer), to allow a lowering 
of the Tg of the polymer from 131° C to a temperature equal to 80°C or less. A temperature range 
of 70-80°C was necessary to enable the process of dry powder coating inside the selected the high 
shear rotogranulator, specifically adapted to this novel process. 
The dry powder coating process was developed onto placebo pellets and the coating trials 
revealed that first pellets must be heated until the MFFT; then OA has to be atomize to enable the 
adhesion of Ethocel and lauric acid, the main polymer plasticizer. The powder were added 
alternately till the end of the process. The third stage of the process was the curing phase, a heat 
treatment able to improve the appearance of the film (transparency and uniformity) as well as the 
formation of a homogeneous and stable film over time. 
In conclusion, a dry powder coating process based on suitably plasticized ethylcellulose was 
developed, highlighting the influence of the manner and order of addition of the excipients inside 
the equipment on the powder distribution and adhesion onto placebo pellets and finally on film 
uniformity. 
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12. CASE STUDY 2: A novel dry powder coating of pellets using 
ethylcellulose. Part II: Process optimization on placebo pellets and on 
drug-loaded pellets. 
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12.1. INTRODUCTION 
 
The first example of a dry coating was realized in 1999 by Obara, as part of a filming process in 
which an enteric coating upon pellets and tablets was applied [1]. The polymer used was 
hypromellose acetate succinate (HPMCAS, Shin-Etsu), while the liquid plasticizer, triethyl citrate 
(TEC), was sprayed at the same time the addition of the polymer. The pellet coating was 
conducted both in a centrifugal granulator and in a fluidized bed, while the tablets were coated in 
perforated coating pan. 
Pearnchob and Bodmeier [2 – 4] reported a series of experiments of liquid assisted coating of 
pellets using a physical mixtures of several polymers (ethylcellulose, Eudragit® RS and shellac), 
employing a fluid bed in the Würster configuration. The tested plasticizers, which include TEC, 
acetyl tributyl citrate (ATC) and acetylated monoglycerides (AMG), were spray-dried in the course 
of the process. For each plasticizer various concentrations, respectively 20%, 30% and 40% on the 
dry weight of the polymer, were investigated and in a second stage they were diluted with an 
aqueous 10% solution of HPMC to limit the pellets agglomeration. 
HPMCAS was also employed as a polymer of dry powder coating by other researchers to produce 
enteric coated pellets and as plasticizer, a liquid mixture consisting of TEC, glycerol triacetate and 
AMG, were employed. The process was conducted in a fluid-bed granulator [5; 6]. 
Cerea et al. (2008) used the same excipients (HPMCAS plasticized by TEC or mixtures of TEC and 
AMG nebulised) for dry coating soft gelatin capsules [7]. 
Examples of dry powder coating based on the principle of thermal adhesion were conducted by 
the same researchers of the University of Milan, which coated tablets using Eudragit® E PO as 
polymer and various solid additives such as glycerol monostearate, PEG 3350 and PVP K-90, pre-
mixed with the polymer inside of a spheronizer, suitably adapted [8]. 
In literature, a further strategy of dry powder coating based on thermal adhesion was reported 
and consisted in the physical mixing of polymer and plasticizer to form single solid component, 
which was then added to the substrate during the process. This technique was applied in 2004 by 
Zheng on theophylline-loaded tablets and a mixture of Eudragit® RS/RL PO (95: 5) pre-plasticized 
with TEC by hot melt extrusion, were used. In this case the atomization phase of the liquid 
component during the process was deleted [9]. 
Finally, Sauer used the same technique of Zheng to film tablets with Eudragit® L 100-55 pre-
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plasticized with a 40% w / w of the TEC. During the process the mixture of solid coating consisting 
of polymer and plasticizer, PEG 3350, used as a solid adhesive agent was added [10]. 
More recently, the dry powder coating technique has been exploited with success in the 
production of muco- adhesive pharmaceutical dosage forms with the aim to increase the oral 
bioavailability of the active ingredient. For instance, Cao et al. [11] obtained muco- adhesive 
pellets of valsartan, using as HPMC and carbomer polymers (CB), the polymer mixture suitable to 
ensure good adhesion to the walls of the gastrointestinal tract. The process of dry coating was 
carried out in a spheronizer and the polymer mixture was added simultaneously to a solution of 
70%ethanol as wetting agent and SiO2 as lubricant.  
In this research a novel dry powder coating process based on both liquid assisted and thermal 
adhesion technology was set up and its development is reported in the Part I of the study. Once 
the process parameters (impeller speed, temperature, method and order of powder layering) and 
the main formulation variables (size and molecular weight of the dry polymer, kind and amount of 
plasticizers and of adjuvant, minimum film forming temperature (MFFT)) were established (Part I), 
in the second part of the research (Part II) the process was optimized on placebo pellets to assess 
the best coating formulation in terms of yield, coating loss, pellets aggregation and relative 
standard deviation (RSD) of the weight. The coating experiments considered also the addition of 
Kollidon – vinyl acetate copolymer (KVA 64) as adjuvant and different weight ratio between 
plasticizers and KVA 64 were studied to prevent the surface re-crystallization of lauric acid upon 
storage. The stability of dry coated pellets was investigate over 1 year. The coating efficiency was 
then assessed on loaded pellets and the extent of drug release over time through the applied 
coating layer was studied. Caffeine (CFN) was selected as BCS class I model drug, being suitable for 
formulating modified release systems. To this aim, the effect of weight gain, drug loading, Suglets® 
particle size, coating formulation and of glidants on the drug release profiles was fully investigated. 
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12.2. MATERIALS AND METHODS 
12.2.1. Materials 
Ethocel® Standard E10 FP (fine particle, with mean dimension of the particles of 9.7 µm), Sugar 
spheres (Suglets® 14/16 mesh size, 1180-1400 µm diameter, composed of sucrose and starch 
(batch n° DT 405540) and hypromellose (Methocel E5, Hydroxypropylmethylcellulose, HPMC, 2910 
USP grade) were kindly donated by Colorcon Ltd (Dartford, Kent, UK). The plasticizers were oleic 
acid (OA, Carlo Erba, batch n° 3185E100) and lauric acid (LA, Sigma-Aldrich, batch n° MKBQ4605V). 
Kollidon-vinyl acetate copolymer (KVA 64, batch n° 61611468E0) and Aerosil® R974 were gently 
donated by BASF. Talc was purchased from ACEF SpA (Piacenza, Italy ). Caffein (CFN) was supplied 
by Sigma-Aldrich. 
 
12.2.2. Methods 
12.2.2.1. Dry powder coating of placebo pellets 
The dry powder coating process was performed in a laboratory scale high shear mixer granulator 
(Roto Lab Zanchetta IMA) and consisted of three phases: pre- heating, powdering and curing. This 
process was developed and set up in the Part I of the research. In this Part II of the work, several 
placebo formulations having different MFFT were investigated keeping fixed the process 
parameters and the addition order of the excipients. The theoretical weight gain was 15% 
(w/w).The analysed placebo formulations (P1-P6) are listed in Table 34. Talc, in percentages equal 
to 5% w/w with respected to the theoretical amount of solid applied, was added in all trials at the 
end of the coating process, before the curing process. Curing at minimum film forming 
temperature (MFFT) for 24 hours in an air forced oven was then performed. 
Weight gain (WG %), total yield (%),coating loss (%), coating efficiency (RSDW %) and pellets 
aggregation (%) were calculated as follows: 
 
WG % = ࢃ࡯ࡼିࢃࡸࡼ
ࢃࡸࡼ
∗ ૚૙૙         Eq. 18 
Yield % = ࢃࡸࡼ
ࢃࡿ
∗  ૚૙૙         Eq. 19 
Coating loss % = ࢃ࢚ࢎ–ࢃ࢘
ࢃ࢚ࢎ
∗ ૚૙૙        Eq. 20 
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RSDw = 
ඥ(ࡿࡰࢃ࡯ࡼ)૛ି(ࡿࡰࢃࡿ)૛
ࢃ࡯ࡼିࢃࡿ
∗ ૚૙૙        Eq. 21 
where: WS= mean weight of placebo(equivalent to uncoated pellets), WCP = mean weight of 
coated pellets, Wth = weight of solids to be applied and Wr = weight of solids applied. 
In particular, cRSDW % was expressed as the Relative Standard Deviation of the weight applied 
(RSDW) on a mean of at least six measurements on 50 pellets within the same coating experiment. 
The pellets aggregation was determined by calculating the percentage of coated pellets that did 
not pass through a 2000 m sieve with respect to the collected amount of pellets at the end of the 
process, since single coated pellets had dimension lower than 2000 m.  
 
Table 34: Dry powder coating on placebo pellets. The theoretical WG was 15% w/w. 
Batch 
E10:LA:OA:KVA 
Weight ratio 
MFFT 
(°C) 
Yield 
% 
cLoss 
% 
WG 
%(exp.) 
Pellets 
aggregation (%) 
C RSDw% intra batch 
cured  uncured 
P1 70:20:10:0 80 88.47 11.53 13.27 6.79 3.64 7.21 
P2 65:20:10:5 80 85.83 14.18 12.87 9.21 5.01 6.88 
P3 65:20:15:0 75 93.91 6.09 14.09 10.11 1.16 4.12 
P4 60:20:20:0 70 89.24 10.76 13.39 16.24 4.76 6.05 
P5 55:20:20:5 70 87.42 12.58 13.14 13.55 5.93 6.96 
P6 55:20:25:0 70 74.78 25.23 11.22 Maximum 8.61 24.09 
 
12.2.2.2. Preparation of drug loaded pellets: CFN solution layering 
Drug loaded multiparticulate pellets were prepared by solution layering, involving the deposition 
of the CFN onto starting non Suglet seeds in a Mini-Glatt fluidized bed (Glatt GmbH, Binzen, 
Germany) equipped with a Wurster column (bottom spray assessment).  
The aqueous layering solution was prepared adding 2% or 4% of CFN to a 5% w/w HPMC E5 
solution. Drug layering conditions within the fluid bed equipment were: inlet air temperature 60 
±0.5°C; product temperature 33.8±0.5 °C; fluidization air flow in the range 18-22 Nm3/h; atomizing 
air pressure 1.43±0.60 bar and a spray rate 1.9 ±0.01 g/min.  
The yield, the theoretical drug loading and the process efficiency expressed as the Relative 
Standard Deviation of the weight applied (RSDW) on a mean of at least seven (2% CFN) or two (4% 
CFN) layering experiments[109; 110] were calculated using the following equations: 
Yield % = ࢃࡸࡼ
ࢃࡿ
∗  ૚૙૙         Eq. 22 
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Theoretical drug loading= ࢃ࡯ࡲࡺࢃࡸࡿ
ࢃࡿା ࢃࡼା ࢃ࡯ࡲࡺ       Eq. 23 
RSDw% = 
ඥ(ࡿࡰࢃࡸࡼ)૛ି  (ࡿࡰࢃࡿ)૛
ࢃࡸࡼିࢃࡿ
∗  ૚૙૙        Eq. 24 
where: WLP= mean weight of loaded pellets; WS= mean weight of Suglets; WCFN= CFN weight; WLS= 
weight of layering solution; WP= polymer weight and SD= standard deviation. 
 
12.2.2.3. Dry Powder coating process on CFN-loaded pellets 
The drug-loaded pellets were then coated using the systematic approach based on both liquid 
assisted and thermal adhesion technology optimized using placebo pellets.  
A batch size of 150 g caffeine loaded pellets (1180 - 1400 µm) was coated. First, the powder 
adhesion onto the sugar beads surface was promoted by the liquid plasticizer oleic acid 
continuously atomized at 1.5 bar by a compressed air gun inserted into the lid of the granulation 
chamber. Afterward, Ethocel® E10 FP was alternatively transferred into the granulation chamber 
and distributed onto the cores using an impeller speed at 120 rpm (the lowest rotation speed 
allowed), meanwhile the main solid plasticizer lauric acid (particle size < 100 µm) was atomized 
inside the bowl through a second spray gun at 3.5 bar to promote the coalescence of the powder 
particles and the formation of the final film layer around the Suglets®.  
The coated pellets were further cured for 24 hours in a static oven at the MMFT of selected 
coating formulations based on two different weight ratio of E10FP:LA:OA: the first one was 
60:20:20 and second one was 65: 20: 15. Moreover, the introduction of talc or Aerosil® R974 
within the coating formulation as adjuvant to avoid agglomeration and sticking of pellets during 
the coating process and curing step. From a practical point of view, the anti-sticking agents were 
added extra-formulation in percentages equal to 2.5% or 5% w/w with respected to the 
theoretical amount of solid applied. Overall eleven different trials at three different theoretical 
weight gain: 10%, 15% and 20%were performed. The analyzed formulations are shown in Table 35. 
Drug loading (CFN%), weight gain (WG %), total yield (%), pellets aggregation (%), coating 
efficiency (cRSDW %) expressed as the Relative Standard Deviation of the weight applied (RSDW) on 
a mean of at least six measurements on 50 pellets within the same coating experiment and 
coating loss (%) were evaluated.  
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WG % = ࢃ࡯ࡼିࢃࡸࡼ
ࢃࡸࡼ
∗ ૚૙૙         Eq. 25 
Yield % = ࢃࡸࡼ
ࢃࡿ
∗  ૚૙૙         Eq. 26 
Coating loss % = ࢃ࢚ࢎ–ࢃ࢘
ࢃ࢚ࢎ
∗ ૚૙૙        Eq. 27 
RSDw% = 
ඥ(ࡿࡰࢃ࡯ࡼ)૛ି(ࡿࡰࢃࡸࡼ)૛
ࢃ࡯ࡼିࢃࡸࡼ
∗ ૚૙૙       Eq. 28 
 
where: WLP= mean weight of loaded pellets (equivalent to uncoated pellets), WCP = mean weight 
of coated pellets, Wth = weight of solids to be applied and Wr = weight of solids applied. 
 
Table 35: Experiments of dry powder coating process of CFN-loaded pellets starting from Suglets® of 1180 - 
1400 m size. 
Batch 
E10:LA:OA 
Weight ratio 
Antisticking agent Th. 
wg.(%, 
w/w) 
Th CFN 
content(%, 
w/w) Type Addition way 
I 60:20:20 - - 10 2 
II 60:20:20 - - 15 2 
III 60:20:20 - - 20 2 
IV 60:20:20 - - 15 4 
V* 60:20:20 - - 15 4 
VI 65:20:15 - - 15 2 
VII 60:20:20 Talc, 5% at the beginning 15 2 
VIII 60:20:20 Talc, 5% at the end 15 2 
IX 60:20:20 Talc, 5% 
throughout the 
whole process 
15 2 
X 60:20:20 Talc, 2.5% 
atomized with 
lauric acid 
15 2 
XI 60:20:20 
Aerosil® R794, 
2.5% 
atomized with 
lauric acid 
15 2 
* different pellets size: 850-1000 m. 
 
12.2.2.4. Determination of drug content 
The determination of CFN content within each batch was performed off-line throughout the 
whole manufacturing process. Briefly, 50 mg of each sample has been accurately weighed, ground 
to a fine powder using pestle and mortar and dissolved in 50 ml of phosphate buffer pH 6.8. The 
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system was shaken for 45 minutes. Finally, the solution was filtered and the drug content has been 
spectrophotometrically assayed at 273 nm (Unicam Heλios β Thermoscientific, Milan, Italy). The 
analytical method was validated in terms of linearity, sensitivity expressed as limit of detection 
(LOD) and limit of quantification (LOQ) and finally repeatability. The correlation coefficient (r2) was 
0.9997 (range of concentration 0.1 – 20 µg/ml); the LOD was 0.029 (μg/ml) and the LOQ was 0.088 
(µg/ml). For the repeatability study three absorption measures for three samples with different 
well- known concentrations (0.5; 5; 20 µg/ml) had been collected and the answer factor was found 
to calculate the coefficient of variation (CV%). CV % had a value smaller than 0.25 for each level of 
concentration, demonstrating the repeatability of measurements.  
The results of the drug content are expressed as a mean of at least three determinations ± 
standard deviation (SD). The % relative standard deviation of drug content (RSDC) was calculated 
using the following equation: 
 
RSD C % = 
ࡿࡰ
࢓ࢋࢇ࢔࡯ࡲࡺࢉ࢕࢔࢚ࢋ࢔࢚
∗ ૚૙૙        Eq. 29 
 
12.2.2.5. In vitro drug release studies 
In vitro dissolution tests of pellets was performed using USP II dissolution apparatus (ERWEKA 
DT800) rotating at 50 rpm in 500 ml phosphate buffer pH 6.8 and at a temperature of 37 ± 0.5°C. 
Each sample contained about 8-10 mg of CFN. The studies ran over a period of 90 minutes during 
which 3 ml aliquots of the release medium were collected at specific time intervals and replaced 
with an equal volume of fresh medium. The samples were filtered (0.45 µm) and assayed for 
caffeine spectrophotometrically at λ=273 nm. The mean of at least six determinations has been 
used to determine the API release for each formulation.  
Comparison between drug release profiles from pellets were carried out using both the similarity 
factor f2 and the difference factor f1. The difference factor is proportional to the average 
difference between the two profiles, whereas the similarity factor [12] is a logarithmic reciprocal 
square-root transformation of the sum of squared error and is a measurement of the closeness in 
percentage of dissolution between two release profiles. 
 
ࢌ૚ =  ൜∑ |ࡾ࢚ିࢀ࢚|࢔࢚స૚∑ ࡾ࢚࢔࢚స૚ ൠ ∗ ૚૙૙         Eq. 30 
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ࢌ૛ = ૞૙ ∗ ࢒࢕ࢍ ൜૚ + ቂ૚࢔ ∗ ∑ (ࡾ࢚ − ࢀ࢚)૛࢔࢚ୀ૚ ቃି૙.૞ ∗ ૚૙૙ൠ     Eq. 31 
 
where n is the sampling number, Rt and Tt are the cumulative percent dissolved of the reference 
and the test products at each time point t.  
In dissolution profile comparisons, especially to assure similarity in product performance, 
regulatory interest is both in knowing how closeness two curves are and to have a measure which 
is more sensitive to large differences at any particular time point. For f2 and f1 values calculation, 
sampling number lower than 85% of drug released have been considered. The similarity factor fits 
the result between 0 and 100. Two drug release profiles are similar if the f2 is greater than or equal 
to 50 and f1 values are less than or equal to 15. 
 
12.2.2.6. Pellets morphological analysis 
During the process optimization, the surface of the coated pellets was observed using an optical 
microscope (Nikon SNZ 2T) connected through a camera (Panasonic GP KR 222) to an image 
acquisition system (CV 9000, FKV S.r.l. BG, Italy). Moreover, scanning electron microscopy (SEM) 
was used both to better evaluate the surface morphology of CFN-loaded pellets. Samples were 
fixed on the sample holder with a double sided adhesive tape, sputter coated with Au/Pd under an 
argon atmosphere performed using a vacuum evaporator (Edwards, Crawley UK) and examined by 
means of a scanning electron microscope SEM (Philips XL30) operating at an accelerating voltage 
of 20 kV. 
 
12.2.2.7. Pellets thermal analysis 
The thermal properties of unloaded and CFN-loaded pellets were characterized using a 
differential scanning calorimeter (DSC) Perkin-Helmer DSC 6 (Perkin-Elmer, Beaconsfield, UK) 
equipped with Pyris Software. Samples, weighting 8-12 mg, were sealed in an aluminium pan and 
heated from 25°C to 180°C at a scanning rate of 10°C/min under a nitrogen flow rate of 20 ml/min. 
Each analysis was carried out in duplicate experiments. The mean glass transition temperature 
(Tg) of the coating formula and the fusion of the drug were then calculated.  
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12.2.2.8. Long term storage stability of pellets 
To assess long term storage stability, uncured and cured pellets were stored at 25°C/ 60 ± 0.5% 
relative humidity (R.H.) in PE closed bottles. Drug release from pellets was measured after 1 year 
of storage. Day 0 corresponded to the day after the preparation of layered and coated pellets.  
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12.3. RESULTS AND DISCUSSION 
12.3.1. Optimization of the Process on Placebo Pellets 
A novel dry powder coating process using ethylcellulose as film forming agent was maximized 
and six different coating formulations were additionally investigated for further coating 
experiments. The composition of the different formulations with respected to the results of the 
coating procedure are listed in Table 34 (p. 158). 
The experimental weight gain applied was closed to the theoretical one for each run of coating. 
All formulations wherein the plasticizers ratio LA:OA was 1:1 or 2:1 displayed total yields higher 
than 85% and ranging from 85.83 % to 93.91 % (P1 – P5). On the contrary,P6 having more OA than 
LA exhibited a total yield closed to 75% and a doubled coating loss % (25.23 %) with respected to 
the previous trials. Therefore a larger amount of the liquid plasticizer could minimize pellets 
fractiousness and promote the coalescence of the powder particles leading to a successful powder 
adhesion around the Suglets® and film uniformity. On the other hand an excessive percentage of 
liquid plasticizer resulted in pellets aggregation (Table 34, p. 158) and further adhesion on the wall 
of the granulation chamber, increasing coating losses and agglomeration, even in presence of 
lubricants. In the last formulation (P6), having the highest OA concentration, the pellets 
aggregation was absolute as reported in Figure 39. 
 
Figure 39: Pellets aggregation inside the granulation chamber. 
 
 
Optical microscopy was then used to evaluate the surface morphology of pellets and the 
captured images are shown in Figures 40 and 41. 
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Figure 40 depicted the surface morphology of a pellet raw material with respected to dry coated 
uncured pellets. Suglets® looked opaque and perfectly spherical whereas uncured coated pellets 
exhibited a more glossy and less regular surface and, thereby, it’s possible to clearly recognize a 
certain powder deposition around the pellets surfaces.  
 
Figure 40: Surface morphology of a pellet raw material with respected to dry coated uncured ones. 
 
 
Moreover, figure 41 compared the surface morphology of cured pellets with respected to the 
untreated ones in order to evaluate the impact of a post coating thermal treatment for 24 hours at 
the MFFT of the coating formulation on both the appearance of the final film.  
 
Figure 41: Surface morphology of cured pellets with respected to the untreated ones. 
 
 
Once the suitable temperature was obtained, during the dry powder coating both plasticizers LA 
and OA interposed between the polymer chains and lowered the Tg of ethylcellulose, thereby 
Dry  coated uncured pellets 
Dry  coated cured pellets 
Suglets raw 
Dry  coated pellets 
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significantly enhancing the mobility of the polymeric system. The greater mobility allowed for 
molecular rearrangement and alters the plastic deformation characteristics of the materials. Based 
on literature [13], the addition of low melting materials or liquid excipients to the overall 
composition is a common approach in many dry powder coating formulations to improve 
coalescence and adhesive properties. When processing above the glass transition temperature of 
a coating material, the surface is more “liquid-like” and more susceptible to plastic deformation.  
Depending on the difference between glass transition temperature and processing temperature, 
the viscosity of the coating material can be reduced sufficiently to result in the formation of 
capillary forces which aid in the adherence and coalescence of the powder to the pellets surface 
promoting of the final film layer around the Suglets®. Nevertheless, a complete particle 
coalescence couldn’t occur at the end of the dry powder coating process and, thus, a post coating 
thermal treatment was absolutely required in order to obtain a continuous film. Indeed, treated 
samples exhibited a more homogeneous and less wrinkled surfaces with respected to the 
untreated pellets (as shown in Figure 41). 
The cRSDw% intra–batch for the optimized process are listed in Table 34 (p. 158). Dry powder 
coating resulted reproducible both for uncured and cured pellets, especially forP3 and P4 coating 
formulations(E10:LA:OA weight ratio at 65:20:15 and 60:20:20, respectively). cRSDw% values were 
less than 6.25 % and ranging from 1.16 % to 4.76 % for treated samples and from 4.12 % to 6.05 % 
for the untreated ones. Therefore the best coating formula were P3 and P4. 
Moreover, the solid state of the pellets, especially of the main solid plasticizer lauric acid, was 
investigated by means of DSC and the stability of cured samples during storage was evaluated. 
After six months of storage (graphs not shown) at 25°C/60 RH any re- crystallization of lauric acid 
occurred for the coating formulations with the plasticizers LA:OA weight ratio of 2:1 (P1 and P2) or 
1:1 (P4 and P5), both for uncured and cured pellets. After one year of storage, only P1 pellets 
showed a clear endotherm associated to LA re-crystallization both for uncured and cured samples. 
These results indicate that curing was not sufficient enough to completely inhibiting the plasticizer 
re- crystallization process and the presence of 5% (w/w) of KVA 64 in P2 was fundamental to 
pellets stability; therefore the 1:1 plasticizers weight ratio (corresponding to a 40% w/w based on 
the dry polymer) resulted the better coating formula. Figure 42 depicted the DSC scans of both 
cured and uncured pellets with respect to the initial DSC trace of P1 pellets. In the case of P3 
sample having a LA:OA weight ratio of 1.33 to 1, both uncured and cured pellets remained stable 
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after 1 year of storage (graph not shown). The percentages of LA re- crystallization are listed in 
Table 36. 
Figure 42: DSC scans of uncured and cured pellets based on P1 coating formulation at day 0 and after 1 
year of storage at 25°C/60 RH. 
 
 
 
 
Table 36: Percentages of LA re– crystallization. 
trial LA/OA RATIO KVA 64 (5% w/w) % LA re – crystallized after 1 year cured samples (24 h) uncured samples 
P1 2:1 X 0.27 4.31 
P2 2:1 V V V 
P3 1.33:1 X V V 
P4 1:1 X V V 
P5 1:1 V V V 
 
Therefore, coated pellets based on 1:1 and 1.33:1 weight ratios of oleic acid and lauric acid 
resulted stable for one year and no re-crystallization of the solid plasticizer occurred, even in 
absence of KVA 64 and were selected for further investigations. 
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12.3.2. Preparation of Drug Loaded Pellets (Drug Layering) 
To assess the coating efficiency, in the next step the caffeine loading onto the starting pellets 
with a solution layering process was performed.CFN concentrations of 2% and 4% (w/w) were 
beneath than the saturation solubility in the 5% (w/w) HPMC solution; while CFN concentration 
higher than 4% (w/w) produced a suspension. 
The results related to drug layering trials are summarized in Table 37and evidenced a very good 
yield and a good layering efficiency: the mass variability based on RSDw calculation was 3.92%, 
indicating a good reproducibility of the process. In relation to the low drug loading ranging from 
1.79 % to 2.32 %, the value of the obtained RSDc is of relevance (≤ 2%). In fact, to assure the 
quality of dosage units, the drug content of each unit in a batch should be distributed in a narrow 
range around the label strength. Generally, RSD values can vary depending on the drug 
concentration and a low RSD ensures a small distribution of the values around the average value 
[14 - 16]. Increasing the drug loading to the theoretical value of 4%, the layering efficiency mildly 
increased, as the RSDw reduced from 3.92 % to 2.84 %. Furthermore, CFN content resulted very 
closed to the theoretical one and the RSDc highlighted a good drug loading uniformity. Thus, 
increasing CFN concentration in the hypromellose – based layering solution did not affect the mass 
variation.  
The RSDw results demonstrated the repeatability and robustness of the technological procedure 
performed in fluid bed. Therefore, the layering process was performed in a reproducible and well 
– controlled manner and the uniformity of dosage units was obtained.  
 
Table 37: Results of drug layering processes. 
Batch Yield (%) powder Loss (%) L RSD w % % CFN (± SD) %RSD C 
L1 89.61 10.39 
3.92 
1.79 (± 0.01) 0.4 
L2 92.53 7.47 1.89 (± 0.03) 1.78 
L3 98.38 1.62 1.90 (± 0.04) 2.00 
L4 94.48 5.52 1.98 (± 0.02) 1.27 
L5 97.66 2.34 2.18 (± 0.03) 1.35 
L6 99.49 0.51 2.18 (± 0.04) 1.96 
L7 99.59 0.41 2.32 (± 0.00) 0.14 
L8 92.26 7.74 2.84 4.07 (± 0.05) 1.22 L9 96.67 3.34 4.06 (± 0.01) 0.36 
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12.3.3. Dry Powder Coating Process on Caffeine Loaded Pellets 
Based on the results of process optimization, the coating blend based on E10FP:LA:OA/60: 20: 20 
(P4) (MFFT closed to 70°C) was selected as model coating formulation and drug loading (CFN%), 
weight gain (WG %), total yield (%),coating loss (%), pellets aggregation (%)and coating efficiency 
(cRSDW %) were calculated and theextent of drug release over time through the applied coating 
thickness was evaluated.For a better assessment of the film effectiveness, formulation P3 (MFFT 
at 75°C) was also applied to CFN-loaded pellets.Overall 11 coating experiments were performed 
and the results of the best coating trials are displayed in Table 38. 
 
Table 38: Results of drug powder coating processes. 
BATCH 
WG 
(%) 
Yield 
(%) 
C Loss 
(%) 
Pellets 
aggregation 
(%) 
% CFN (±SD) 
layering 
% CFN (±SD) 
coating 
RSDC 
% 
c RSD w % intra 
batch 
cured uncured 
I 9.87 98.69 1.31 n. d. 1.79 (± 0.01) 1.61 (± 0.03) 1.86 -- -- 
II 13.97 91.93 8.52 15.48 1.89 (± 0.03) 1.64 (± 0.02) 1.22 4.68 4.68 
III 12.57 62.86 37.14 n. d. 1.98 (± 0.02) 1.73 (± 0.03) 1.73 3.68 3.68 
IV 11.69 78.62 21.38 n. d. 4.07 (± 0.05) 3.59 (± 0.03) 0.84 -- -- 
V 10.87 73.45 26.55 n. d. 4.06 (± 0.01) 3.61 (± 0.02) 0.55 -- -- 
VI 14.54 96.30 3.70 8.40 1.90 (± 0.04) 1.62 (± 0.01) 0.62 1.02 3.98 
VII 13.75 88.20 11.8 6.60 1.89 (± 0.03) 1.63 (± 0.03) 1.84 2.30 7.86 
VIII 14.08 86.55 13.45 16.75 1.90 (± 0.04) 1.63 (± 0.03) 1.84 3.70 4.34 
IX 13.55 83.84 16.16 13.62 2.18 (± 0.03) 1.88 (± 0.02) 1.06 3.64 7.21 
X 13.39 88.39 11.61 12.81 2.18 (± 0.04) 1.95 (± 0.03) 1.54 3.01 3.41 
XI 13.88 86.86 13.14 12.13 2.32 (± 0.00) 1.99 (± 0.03) 1.50 3.32 5.35 
n. d.: not determined 
12.3.3.1.Effect of the weight gain 
In order to verify the extent of drug release over time through the coating thickness, three 
different theoretical weight gains ranging from 10% to 20% w/w (batches I-III) onto 1180 – 1400 
µm CFN-loaded (2% w/w) sugar sphere were applied. Considering the coating level applied, the 
lower weight gain, the higher was the total yield and the lower was the coating loss (batches I and 
II). Contrarily, increasing the coating level (batch III), total yield dramatically decreased from 
98.69% to 62.86% and coating loss significantly increased to 37.14 %. These results suggested that 
a 20% (w/w) powder layering was too high to adhere on the pellets surface and to form the final 
coating. 
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Comparing the parameters related to the dry powder coating process assessed onto placebo 
pellets (batch P4, Table 34, p.158) with those of CFN loaded pellets (batch II), the yields of both 
trials were similar; moreover the cLoss decreased from 10.76% of placebo pellets to 8.52% of CFN 
loaded ones. Considering the coating efficiency, the mass variability based on RSDw calculation 
(intra–batch) was lowered from 6.05% to 4.68% indicating the uniform distribution of the coating 
within the processed batches. After the post–coating thermal treatment, the RSDw mildly reduced 
from 4.76% to 3.68%, confirming the importance of the curing in the dry powder coating 
procedure.  
Moreover, the cRSDw inter–batches values (1.84% and 3.11% for cured and uncured pellets, 
respectively) calculated on a mean of three coating processes, highlighted that the process was 
performed in a well–controlled manner and demonstrated the repeatability and robustness of the 
coating process. In addition, the process resulted more reproducible for the cured pellets than for 
the untreated ones. 
With regards to drug dissolution, raw CFN is freely soluble in aqueous media as belongs to BCS 
class I and after two minutes it was completely dissolved (graph not shown). The 90% of the drug 
loaded was dissolved in 5 minutes form layered pellets and the complete dissolution occurred 
within 30 minutes. Analysing the pellets with the lower weight gain (9.87% w/w), the drug release 
from uncured pellets decreased but the 80% of the drug was dissolved within 60 minutes (Figure 
43). Furthermore, no significant differences of the release profiles between the cured and the 
uncured pellets were observed (f2=60.65±1.79). 
Increasing the coating level from 9.87% to 13.97% w/w (batch II), the percentage of CFN released 
from uncured pellets within the first hour of dissolution was equally closed to 80%, but a 
significant difference between the release profile of cured and uncured pellets was noticed 
(f2=44.19±1.29). In effect, the 50% of the drug loaded was released within 25 minutes, indicating 
that both the curing step and the higher ethylcellulose coating level most modified the CFN 
release rate. 
To the light of the result of the first three trials, the following batches were processed to obtain a 
final WG of 15%.  
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Figure 43: Influence of coating level on CFN dissolution profile: comparison between batch I and II (both 
uncured and cured pellets) at day 0. 
 
 
12.3.3.2. Drug loading 
The real drug content of each batch was lowered according to the weight gain achieved and the 
variation of the API content (RSDC %) evidenced a good drug content uniformity of dosage units. 
According to the solubility of the CFN in the hypromellose based solution, the CFN loading was 
increased from 2.0% w/w to 4% w/wand the theoretical WG of 15% w/w was applied. The 
dissolution profile of 2% CFN layered pellets was superimposed to that of 4% CFN loaded sugar 
spheres. 
Comparing the results of batch II with batch IV (Table 38, p.169), the experimental WG was a little 
bit lower for batch IV; while the maximum variation of the CFN content lowered from 1.22% to 
0.84%, achieving a very good content uniformity. With regards to total yield and coating loss, the 
higher the CFN loading, the lower was the yield and the higher was the coating loss. The filling 
volume of the chamber was similar but batch IV pellets were bigger and the batch size resulted 
lower (150 g for batch II vs 135/139 g for batch IV). Moreover during the process pellets crushed 
more, probably because they were less hard. Moreover, the CFN release throughout the coated 
pellets was still controlled by diffusion through the film thickness (Figure 44). Contrarily to batch II, 
no significant differences on the release profiles between the cured and the uncured pellets of 
batch IV were noticed (f2=66.80 ± 1.87). Comparing the release profiles between the batches, 
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uncured pellets of batch IV exhibited a more controlled release profile with respected to the 
uncured pellets of batch II (f2=51.83; f1=26.48). Conversely, the release profiles of cured pellets of 
both batches were similar (f2=68.03 ± 1.67) although the extent of burst effect (as absolute value) 
in batch II was slightly higher.  
 
Figure 44: Influence of drug loading on CFN dissolution profile: comparison between batch II and IV (both 
uncured and cured pellets) at day 0. 
 
 
 
12.3.3.3. Particle size of Suglets® 
Once stated the influence of both coating level and CFN loading on the properties of modified 
released pellets was investigated, two different particle size of the sugar spheres was then 
studied. Precisely, a theoretical weight gain of 15% w/w onto both 1180 – 1400 µm and 850 – 
1000 µm CFN 4% w/w loaded sugar spheres was applied. The parameters related to the coating 
processes are shown in Table 38 (p. 169).The coated pellets of both batches (IV and V) had 
approximately the same coating level (11.69% vs 10.78%, respectively), indicating a good 
reproducibility of the process. Contrarily to what happened changing the drug loading, the size of 
pellets significantly affected the drug release rate (Figure 45). As expected, the pellets with the 
lower particle size (batch V, 850 – 1000 µm) exhibited a faster release profile (f2=40.53 ± 2.27) 
since the surface area exposed to the dissolution medium was greater than that of the pellets with 
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the higher particle size. Significantly differences of the release profiles between the cured and the 
uncured pellets with the lower dimensions were noticed (f2=49.43; f1=30.41). Nevertheless, the 
ethylcellulose based coating did not significantly controlled the CFN release rate and within 15 
minutes the 50% of the drug loaded was already released.  
 
Figure 45: Influence of drug loading on CFN dissolution profile: comparison between batch IV and V(both 
uncured and cured pellets) at day 0. 
 
 
12.3.3.4. Effect of the coating formulation 
The next step focused on changes in coating formulation in order to evaluate the extent of 
controlled drug release over time through the applied ethylcellulose based coating layer. The 
coating formula E10FP:LA:OA/60:20:20 (batch II) was then compared with the E10FP:LA:OA/ 
65:20:15 (batch VI).The process parameters related to layering and coating are summarized in 
Table 38 (p. 169). Both batches had approximately the same coating level (14.54% vs 13.97%, 
respectively) and the drug uniformity increased increasing the OA amount in the coating 
formulation (the RSDC %, dropped up to 0.62%). Moreover comparing the cRSD w of batches II and 
VI, the value reduced from 4.68% to 1.02%, respectively, indicating a very good coating efficiency 
using both coating formulations. 
Comparing the parameters related to the dry powder coating process assessed onto placebo 
pellets (batch P3, Table 34, p. 158) with those of CFN loaded pellets (batch VI, Table 38, p. 169), 
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the yields of both batches were similar (93.91% vs 96.30% respectively); moreover the cLoss 
decreased from 6.07% of placebo pellets to 3.70% of CFN loaded ones. Considering the coating 
efficiency, the mass variability based on RSDw calculation was lowered from 4.12% to 3.98% for 
uncured pellets demonstrating the repeatability and robustness of the dry powder coating 
processes. After curing the RSDw dropped up to 1%. 
With regards to drug release (Figure 46), significant differences between uncured and cured 
samples of batch VI were clearly observed (f2=45.56 ± 3.14) at day 0, as noticed for the previous 
batches. The release profile of cured pellets of batches II and IV were similar (f2=67.08 ± 2.41), 
suggesting that the two different coating formula did not affect significantly the CFN release 
profile. 
Figure 46: Influence of coating formulation on CFN dissolution profile: comparison between batch II and 
VI (both uncured and cured pellets) at day 0. 
 
Subsequently the two different coating formulation were analyzed during storage: after one 
year, the difference (Figure 47) between the release profiles of uncured and cured pellets of batch 
VI stored at the MFFT (equal to 75°C) was maintained (f2=44.85 ± 0.31). 
Looking inside to the stored uncured samples, an higher burst effect was clearly observed and, 
after one year of storage, significant differences on the release profile between the uncured 
pellets (t0 and t1 year) were observed (f2= 43.27 ± 1.98). Otherwise cured stored samples were 
similar at t1 year (f2= 61.75 ± 0.31) indicating the better stability of cured pellets with respected to 
the uncured ones. 
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Figure 47: Comparison between the release profile of both uncured and cured pellets of batch IV at day 0 
and after one year of storage at 25°C/60 RH. 
 
Figure 48 reports the SEM pictures of uncured (Fig. 48 a) and cured (Fig 48 b) pellets after 1 year 
of storage. Both pellets exhibited a great CFN crystallization extent indicating the migration of the 
drug outside the coating layer determining the rapid burst effect clearly observed in the 
dissolution profiles. Furthermore, Fig 48b shows a minor CFN crystallization onto the coating layer, 
suggesting that curing step was fundamental for film strengthening; the complete film formation 
could thus slowed the CFN migration process through the film thickness but didn’t completely 
avoid it. 
Figure 48: SEM pictures of uncured (a) and cured (b) pellets of batch VI taken after 1 year of storage at 
different magnifications.  
(a) (b) 
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Therefore, this behaviour suggests that drug re- crystallization anyhow occurred but the post-
coating thermal treatment mitigated the burst effect and better controlled the drug release 
profiles. This phenomenon has been fully described in the Case study 1. 
Moreover during storage, DSC measurements were performed, too. DSC scans (Figure 49) of 
indicated that no re-crystallization of the main solid plasticizer, LA, occurred for both cured and 
uncured pellets of batch VI, as previously disclosed (paragraph 12.3.1). Therefore, as observed for 
P3 pellets, the film formed around the cores was stable. 
 
Figure 49: DSC scans of both uncured and cured pellets based on E10: LA:OA/ 65:20:15 coating formulation: 
comparison between P3 (placebo) and batch VI (drug loaded) formulations at day 0 and after 1 year of 
storage at 25°C/60 RH. 
 
 
Considering batch II, significant differences of the release profiles between the uncured and the 
cured pellets were observed at t0 (as previously reported at p. 169, the similarity factor was lower 
than 50, f2=44.19 ± 1.829); whereas analysing the dissolution data of batch II pellets (after one 
year of storage at 25°C/60 RH Figure 50), the release profile of uncured and cured samples were 
similar (f2=71.35 ± 4.29). Moreover the similarity of the dissolution profiles of uncured pellets 
resulted borderline different (day 0 vs1 year of storage: f2=51.76 ± 3.89 and f1 18.71 ± 3.08); while 
the dissolution profiles of cured pellets remained superimposed (f2= 75.6 ± 4.66). 
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These results confirm again the better long term storage stability of cured pellets with respected 
to the uncured ones. As previously reported, one of the main challenge associated with the dry 
powder coating is to achieve both complete powder adhesion and coalescence around Suglets® 
during the coating process leading to a uniform final film. Incomplete film formation and further 
gradual coalescence during storage (uncured pellets t0 vs t1 year) cause instability in the drug 
release rate. Thus, a curing step is recommended to assure the long term stability of samples. 
 
Figure 50: Comparison between the release profile of both uncured and cured pellets of batch II at day 0 
and after one year of storage at 25°C/60 RH. 
 
The batch II pellets were then analysed by means of DSC to verify eventual LA re–crystallization, 
even if placebo pellets having the same coating formulation (P4) did not show any thermal event 
(Figure 42, p.167). DSC scans (graph not shown) of both uncured and cured pellets were 
superimposed both to those of placebo pellets, confirming the stability of this coating formulation. 
Therefore these results showed indicate that the used LA:OA weight ratio (20:20 or 20:15) didn’t 
affect the main solid plasticizer re-crystallization process throughout the pellets surface also after 
1 year of storage. Regarding drug release, both formulations likewise controlled the CFN release 
from cured coated pellets (f2=67.08 ± 2.41 cured II vs VI day 0 and f2=63.45 ± 3.86 cured II vs VI 1 
year), as reported in Figure 51. 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90
%
 C
FN
 re
le
as
ed
Time (min)
UNCURED DAY 0
UNCURED 1 YEAR
CURED DAY 0
CURED 1 YEAR
178 
 
Figure 51: Comparison between release profile of cured pellets of both batch II and VI both at day 0 and 
after 1 year of storage 25°C/ 60 RH. 
 
 
12.3.3.5. Impact of anti- sticking agents on the coating effectiveness 
The percentage of pellets aggregation during trial P4 about was 16% w/w and talc was added in 
an amount equal to 5% w/w extra formulation to prevent aggregation during the curing phase. 
The effect of talc onto to the performance of the dry powder coating was preliminary evaluated in 
trials V and VI (reported in the Part I of this study), which contained talc at 2.5% and 5% w/w, 
respectively, added in blend with the polymer. The percentage of pellets aggregation resulted very 
low and dropped to 13.4% with 2.5% of talc and to 6.8% w/w with the 5% (w/w) of the glidant. 
Here the effect of talc or Aerosil® R974 within the coating blend on the manufacturing of CFN-
loaded pellets and mostly on CFN release was investigated.  
Different trials (batches VII – X) reported in Table 35 (p. 160) were carried out as follow: 
 Talc (5% w/w) was transferred into the granulation chamber together with the 
ethylcellulose and homogeneously distributed onto the cores before the film formation 
during the pre-heating phase of the dry powder coating process (batch VII); 
 Talc (5% w/w)was added to coated cores at the end of the coating process, when the film 
formation has been already occurred, in order to minimize the percentage of aggregation 
of pellets during the curing step in oven at the MFFT (batch VIII); 
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 Talc (1.25% w/w) was transferred into the granulation chamber together with the 
ethylcellulose and homogeneously distributed onto the cores before the film formation 
during the pre-heating phase of the dry powder coating process. Afterwards, further 2.5% 
w/w of talc was atomized with the main solid plasticizer (LA) during the powdering phase; 
whereas the remaining 1.25% w/w was added to coated pellets at the end of the process 
(when the film formation has been already occurred) before the curing step (batch IX); 
 Talc (2.5% w/w) was atomized at 3.5 bar once mixed with the main solid plasticizer 
(LA)during the powdering phase (batch X);  
 Lipophilic Aerosil ® R974 (2.5% w/w) was atomized at 3.5 bar with the main solid plasticizer 
(LA) during the powdering phase (batch XI). 
The parameters related to the coating processes are shown in Table 38 (p. 169). After the coating 
process, the variation of the CFN content (RSDC %) evidenced a good drug content uniformity of 
dosage units for all batches. The results evidenced good yields (ranging from 83% to 89%) and 
weight gains closed to the theoretical ones. Moreover, with respect to batch II, the greater the 
amount of powder to layer, the higher the coating losses. Anyhow the cRSDw intra–batch values 
demonstrated the uniform distribution of the powder upon pellets, especially for the cured ones. 
Regarding the extent of pellets aggregation, the addition of the glidant was helpful (Table 38, 
p.169) and in line with the results obtained on placebo pellets. The better results were obtained 
with batch VII and then with batches X and XI. 
Analysing the dissolution data (Figure 52) of cured pellets, the addition of the anti-sticking agent 
deeply influenced the drug release throughout the coating thickness. With the addition of 5% of 
talc to the coating formula (batch VII) the CFN release profile changed dramatically with respect to 
batch II. To explain this behaviour was hypothesized that talc would form a lubricant layer, that 
interfered with the powder adhesion upon sugar spheres and consequently with the film 
formation. This hypothesis was confirmed by the picture (Figure 53) taken at the end of the 
dissolution of these pellets. The applied coating layer fractured already after 5 min of dissolution 
and detached from the CFN-layered core. On the contrary, the addition of talc at the end of the 
process (batch VIII) resulted in a greater controlled release of CFN than batch VII; however the 
release profiles was significantly different from that of batch II (f2=34.01 ± 1.14), indicating that 
that amount of talc at the end interfered with the completion of the film formation during the 
curing step. The addition of the same amount of talc along the whole process (batch IX) produced 
pellets having the same release profile of pellets from batch II (f2= 64.37 ± 0.48). In this case the 
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CLoss slightly increased with respect to batch II and VIII, but the pellets aggregation decreased, 
suggesting that the atomization of a smaller amount of talc together with the plasticizer could be 
useful.  
Actually, the best dissolution performance was achieved by atomizing talc 2.5% w/w with LA 
(batch X, green line). Furthermore, the CFN release from pellets of batch X was characterized by a 
less pronounced burst effect followed by a linear portion, indicating a region of constant drug 
release (y= 0.589x + 22.98; r2= 0.96). The release profile of cured pellets of batch X vs cured pellets 
batch II were significantly different (f2= 45.73±3.30; f2(D50)=42.41±3.31). Similarly, the release 
profile of cured pellets of batch X vs cured pellets batch XI (containing Aerosil® R974) were 
significantly different (f2=41.54±1.14) and no significant differences of drug release 
(f2=73.48±2.17) were observed with respected to batch II (blue line).  
Figure 54 shows the SEM pictures of cured pellets of batches II and X and XI. These SEM images 
explain the release patters obtained. Cured pellets of batch II (pictures c and e) and XI (picture a) 
exhibited a greater CFN crystallization on pellets surface; hence a similar CFN release profile was 
observed. Contrarily, cured pellets of batch X (pictures b and d) exhibited a lower CFN 
crystallization extent throughout the film thickness and less crystals appeared onto the surface of 
treated samples. Thus, the ethylcellulose based coating layer mostly controlled the CFN release 
rate. 
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Figure 52: Influence of antisticking agents on CFN dissolution profile: comparison between cured pellets 
of batches II and VII – XI at day 0. 
 
 
Figure 53: Pellets of batch VII taken at the end of the dissolution. 
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Figure 53: SEM pictures of cured pellets of batches XI (a); X (b; d) and II (c; e). 
a) batch XI b)batch X c)batch II 
   
d) cross-section batch X e)cross-section batch II 
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12.4. CONCLUSIONS 
 
An innovative dry powder coating technology developed into a rotogranulator was used to apply 
a functional ethylcellulose based coating upon pellets, avoiding the use of organic solvents or 
water. Lauric acid (LA) was the main solid plasticizer of Ethocel® (E10 FP) and oleic acid (OA) was 
the second liquid plasticizer acting as adhesion enhancer. The coating process was optimized 
according to the selected coating formulation (Ethocel E10FP:LA:OA at 60:20:20 weight ratio, 
corresponding to 40% (w/w) on the dry polymer) owing to its minimum film forming temperature 
(70°C) and to its stability during 1 year storage. Despite the processing time was very short 
(maximum 20 min once reached the MFFT), the results indicated that curing was fundamental for 
film completion. The very low values of mass variability based on RSDw calculation (intra–batch) 
revealed the uniform distribution of the coating around the pellets. 
The dry powder coating effectiveness on drug release highlighted that the coating level applied 
modified the CFN release and the optimal WG was 15% w/w. The size of sugar spheres highly 
influenced the dissolution profiles, while negligible changes were observed varying the amount of 
plasticizers from 40% to 35% (w/w) on the dry polymer. The better dissolution performance was 
obtained by atomizing the anti-sticking agent (talc 2.5% w/w) with the main solid plasticizer. 
Finally, the stability over 1 year of storage at RT of cured formulations confirmed that the dry 
powder coating process using ethylcellulose performed in a high-shear mixer granulator was 
successful. 
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13.  FINAL CONSIDERATIONS 
 
Film coating represents one of the major technology used in the pharmaceutical and nowadays 
also in the nutraceutical industries. This research addressed on two different aspects of the 
coating technology linked with the same film forming functional polymer upon pellets.  
The first case study focused on a traditional film coating process and analyzed the problem of 
drug migration throughout the ethylcellulose-based film layer. This behavior was observed for 
numerous soluble drugs seriously affecting the stability of the coated dosage forms during 
storage. The study highlighted that the optimization of a coating manufacturing process is very 
complicated and despite the well-known and established available technologies, it is extremely 
important during the development of a formulation to thoroughly analyze the whole process and 
its variables. The results revealed that variables joined with the drug layering process resulted the 
predominant critical parameters on the whole manufacturing process and they were closely 
related to the chemical-physical characteristic of the drug. The substitution of hypromellose, the 
polymer generally used for constituting the layering solution, significantly decreased the 
phenomenon of drug diffusion and crystallization on the surface of coated pellets. 
The second case study approached to an innovative method of dry powder coating, a 
technological procedure that has been considerably developed over the last decade. The method 
studied in this thesis combined two types of the layering formation process: the liquid assisted and 
the thermal adhesion (melt coating)methods. Unlike conventional fluid bed coating, the used 
equipment, an high shear rotogranulator, was specifically adapted to enable the dry powder 
coating of pellets. The research analyzed in details the film formation process through the 
screening of several coating formula forming free-films to select the better plasticizers/adjuvants 
of ethylcellulose suitable for the adopted technological procedure. The selected coating 
formulation reached the minimum film forming temperature at 70°C, easy to maintain inside the 
equipment. The process optimized first on placebo pellets obtained high yields and low pellets 
aggregation. The same procedure applied on drug-loaded pellets has proven to be effective to 
reproducibly coat pellets with ethylcellulose without solvents. The stability over 1 year of storage 
of both films containing the 35%-40% (w/w) of plasticizers on the dry polymer and of the drug 
release from cured pellets demonstrated that the coating formulation and the manufacturing 
process were successful developed and optimized. 
 
